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Abstract  
 
Post-translational modifications (PTMs) of proteins increase the complexity of the 
proteome, alter protein function, and play important roles in cellular function. Lysine 
acetylation, catalyzed by lysine acetyltransferases, is an important post-translational 
modification of proteins, including histones, transcription factors, and cytoplasmic 
proteins. The modification is reversible; hydrolysis is catalyzed by histone deacetylases 
(HDACs). Lysine deacetylation is important for regulating cellular processes, and aberrant 
deacetylation is implicated in diseases including cancer. HDAC8 is a metal-dependent 
HDAC that is activated by Zn(II) and Fe(II) under in vitro conditions, and altering the metal 
ion identity affects activity. This enzyme is a therapeutic target for cancers, parasitic 
infection, and a developmental disorder; however, therapeutic research is impeded by the 
lack of knowledge regarding HDAC substrate recognition and regulation and by the 
challenge of identifying HDAC substrates and binding partners. My research has focused 
on the substrate specificity, metal dependence, and regulation by phosphorylation of 
HDAC8. I have shown that the sequence specificity of HDAC8 toward peptide substrates 
is dependent on the identity of the catalytic metal ion. Additionally, I have investigated 
regulation of HDAC8 by phosphorylation on residue Ser39, using the S39E mutant as a 
mimetic, demonstrating that this modification significantly alters metal binding properties 
of HDAC8, decreases HDAC8-catalyzed deacetylation of peptides, and alters substrate 
binding. I have shown that HDAC8 exhibits changes in substrate specificity for singly 
acetylated octamers and nucleosome in vitro, compared to peptide substrates 
representing the same sites. Elucidating the mechanisms that regulate HDAC8 substrate 
specificity is important for determining the role of this enzyme in normal and 
pathophysiological processes in the cell. 
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Chapter 1  
HDAC8 substrates: Histones and beyond1,2 
 
Overview 
Post-translational modifications (PTMs) on proteins increase the complexity of the 
proteome, alter protein function, and play important roles in cellular processes. There are 
over 300 post-translational modifications (1). Protein acetylation is one such modification 
which has seen significant growth in research interest over the past twenty years and the 
annual publication rate continues to increase (2). Protein acetylation occurs in two forms: 
N-terminal Nα-acetylation and Nε-acetylation of the amino acid lysine. Lysine acetylation 
is enzymatically reversible. Lysine acetyltransferases (KATs; also known as histone 
acetyltransferases (HATs)) catalyze addition of the acetyl moiety to the amine side chain 
on a lysine residue to form Nε-acetyl-lysine, and as of July 2015 there are more than 3,800 
sites of lysine Nε-acetylation reported in the mammalian proteome (1). Deacetylation, 
hydrolysis of this modification to yield lysine and acetate, is catalyzed by acetyl-lysine 
deacetylase enzymes called histone deacetylases (HDACs). Protein acetylation, and 
therefore deacetylation, is important for regulating cellular processes such as 
transcription, signaling, and cytoskeletal dynamics (3, 4). HDACs are targets for cancer 
therapeutics, but a key limitation of developing these drugs is that the functions of the 18 
HDAC isozymes are poorly understood. Here I discuss the current understanding of 
substrate specificity as it pertains to the best-studied metal-dependent human histone 
deacetylase, HDAC8. In the following chapters I will present my research designed to 
address the gaps in our knowledge of HDAC8 function and regulation, including substrate 
                                            
1 Reproduced in part, with permission from John Wiley and Sons, from Wolfson, N. A.; 
Pitcairn, C. A.; Fierke, C. A., HDAC8 substrates: Histones and beyond. Biopolymers. 
2013;99(2):112-26. 
2 Original text written by Noah A. Wolfson and Carol Ann Pitcairn and updated by Carol 
Ann Pitcairn to reflect relevant recent advances published in the literature. 
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recognition determinants, metal-dependent substrate specificity, and post-translational 
modification. 
 
Introduction of HDACs 
Protein lysine acetylation is a reversible posttranslational modification observed in 
organisms from bacteria to humans (reviewed in 5). The modification affects protein 
properties including protein-protein and protein-DNA interactions, protein stability, and 
enzymatic activity (reviewed in 3, 6). Initially, acetylation was studied as an epigenetic 
marker on histones. Histone acetylation can regulate the accessibility of DNA to the 
transcription machinery, thereby changing the protein expression profiles of cells 
(reviewed in 7). Due to the role of acetylation in transcription and its effects on the 
proteome, it is not surprising that many diseases have been associated with the aberrant 
acetylation of histones (reviewed in 8). In the last twelve years, the focus of the protein 
acetylation field has evolved from a histone-centric model to a proteome-centric model, 
even coining the term “lysine acetylome” (9). This change in mindset has resulted from 
the identification of acetylated lysine residues that affect the function of numerous non-
histone proteins (e.g. 9, 10). Currently, over 3,800 acetylation sites have been 
experimentally identified on mammalian proteins (1) and acetylated proteins are important 
in many cellular processes, including gluconeogenesis and DNA damage repair (9, 10). 
Regulation of the acetylation state of proteins via KATs and HDACs is important since the 
abnormal acetylation state of both histone and non-histone proteins can contribute to the 
development of many disease states (reviewed in 11, 12, 13), and so it follows that there 
are multiple acetyltransferase and deacetylase enzymes.  
Lysine deacetylase isozymes can be broken into four classes based on their 
phylogenetic similarity (14). Class I (HDAC1, 2, 3, and 8), class II (HDAC4, 5, 6, 7, 9, and 
10), and class IV (HDAC11) enzymes catalyze deacetylation using a metal dependent 
mechanism (14, 15), while class III (Sirt1-7) enzymes use an NAD+ cofactor to perform 
deacetylation (16, 17). This dissertation pertains to metal-dependent HDACs. Crystal 
structures have demonstrated that the HDAC deacetylase domain has an arginase-
deacetylase fold, which consists of a multi-strand β-sheet surrounded by α-helices, and 
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in HDACs the active site contains a single divalent metal ion site with His and Asp ligands 
(5, 18, 19). HDAC6 is unique in that it contains two deacetylase domains and a zinc-finger 
domain (reviewed in 20).  
The metal-dependent HDACs are metallohydrolases, and a metal-water is the 
nucleophile in the reaction, which is activated by a general acid-base catalysis 
mechanism (GABC) (reviewed in 19), as described later. Not much is known regarding 
the substrate specificity of the HDAC isozymes, however the loop L2 residue D101 is 
conserved and suggested to confer substrate selectivity, based on structures of HDAC8-
substrate complexes (reviewed in 19). Interestingly, several HDACs have putative non-
deacetylase functions. HDAC3 may be a molecular chaperone for orphan nuclear 
receptor TR2 (reviewed in 21). HDACs 4, 5, and 7 promote protein sumoylation; HDAC4 
and HDAC5 are suggested to have small ubiquitin-like modifier (SUMO) E3 ligase activity, 
and HDAC7 may act as a SUMO E3 ligase as well (22-24). 
Class I HDAC isozymes 1, 2, and 3 are found in protein complexes and play 
important roles in the regulation of transcription.  HDAC1 and HDAC2 are components of 
the Sin3 complex, the repressor element-1 silencing transcription factor (REST) 
corepressor 1 (CoREST) complex, and the nucleosome remodeling deacetylase (NuRD) 
complex, which are involved in transcription regulation (reviewed in 5). HDAC3 forms a 
complex with the nuclear receptor corepressor (N-CoR) and silencing mediator of retinoic 
acid and thyroid hormone receptors (SMRT) (reviewed in 5). HDAC3 also shuttles 
between the nucleus and cytoplasm, is important for mitosis and transcriptional 
regulation, and has both nuclear and cytoplasmic substrates (reviewed in 21). HDAC8, 
which will be discussed in detail below, differs from the other class I enzymes in its lack 
of identified protein complexes. HDAC8 is the shortest human HDAC (377 amino acids), 
while the other HDACs have long N-terminal or C-terminal tails (reviewed in 5). Class I 
HDACs undergo post-translational modifications including phosphorylation and 
acetylation, and these modifications regulate catalytic activity and protein-protein 
interactions (reviewed in 25, 26).  
Class II HDACs are regulated by post-translational modifications and protein-
protein interactions, and several of these isozymes shuttle between the nucleus and 
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cytoplasm. HDAC6 activity is decreased by phosphorylation (reviewed in 21) and 
interaction with invasion inhibitory protein 45 (IIp45) results in a decreased HDAC6 half-
life as well as HDAC6 inhibition (27). HDAC7 plays a role in osteoblast maturation via 
protein-protein interaction with the transcriptional regulator Runx2 (28). HDAC4, HDAC5, 
and HDAC7 shuttle between the nucleus and cytoplasm, which is regulated in several 
ways including a phosphorylation-dependent interaction with 14-3-3 proteins (HDACs 4, 
5, and 7) (29-32) and cysteine oxidation (HDACs 4 and 5) (33-35). Interactions with 
various proteins retain HDAC4 in either the cytoplasm or nucleus, including 14-3-3 
proteins, MEF2C, DNAJB5, and thioredoxin 1 (Trx1), and HDAC4 has both nuclear and 
cytoplasmic substrates, such as the transcription factor p53 and cytoplasmic chaperone 
DNAJB8 (reviewed in 21). HDAC10 is considered a cytoplasmic deacetylase, however 
putative substrates include Hsp70 as well as nuclear, non-histone, proteins (reviewed in 
21). HDAC6 is localized to the cytoplasm, where its substrates include tubulin and Hsp90 
(reviewed in 5, 20, 21), however there is also evidence of a role for HDAC6 in transcription 
and nuclear localization (reviewed in 20).  
HDACs are involved in many biological processes and are implicated in disease 
states including cancers, neurodegenerative disorders, and heart disease (5). Due to the 
abundance and importance of HDAC substrates, one of the foremost questions in the 
field is the determination of the substrate specificity of HDACs. This area of research 
seeks to identify which of the 18 deacetylases catalyzes deacetylation of each of the 
>3,800 mammalian acetylation sites. This question is complex, because cellular 
conditions and regulatory mechanisms may alter both the catalytic activity and the 
substrate specificity of HDACs. Understanding the substrate selectivity and regulation of 
HDACs will illuminate the disease mechanisms in which they partake and will inform 
development of therapeutics for the treatment of acetylation-related diseases.  
Three pan-HDAC inhibitors (suberoylanilide hydroxamic acid (SAHA), 
Romidepsin, and most recently Belinostat) have been approved by the FDA to treat T-
cell Lymphomas (Figure 1-1), and another inhibitor, panobinostat, is approved to treat 
multiple myeloma (reviewed in 36, 37-41). Natural products have produced many HDAC 
inhibitors (HDACi), including sodium butyrate, trichostatin A (TSA), and romidepsin (42). 
However, most HDAC inhibitors are unselective, class selective, or effective toward a few 
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HDACs, so continued study to increase inhibitor selectivity is important from a therapeutic 
standpoint. Human and parasitic organism HDACs remain the targets of drug design for 
conditions including cancer and parasitic diseases (reviewed in 36, 43). HDACi design 
also continues to provide insight into the structure-function properties of these enzymes, 
such as the flexibility of HDAC8’s substrate and inhibitor binding interface demonstrated 
by inhibitor-bound HDAC8 crystal structures (44). There is a limit to the information 
gleaned from inhibitor design studies, and rational drug design necessitates knowledge 
of metal-dependent HDAC isozyme specificity, so substrate recognition and HDAC 
regulation continue to be important areas of research. 
Mechanistically and structurally, HDAC8 is the best studied of the HDAC 
homologues. Furthermore, HDAC8 is proposed to recognize a number of non-histone 
substrates (e.g. 45, 46, 47) and is therefore a good model for developing techniques to 
elucidate HDAC substrate specificity. The HDAC8 isozyme is also implicated in disease 
states, as described later. In this review we discuss the current view of HDAC8 regulation, 
and compare HDAC8 to other promiscuous enzymes to identify factors that determine 
substrate specificity. 
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Suberoylanilide hydroxamic acid (SAHA)     Belinostat 
 
 
 
 
 
 
                            Romidepsin (FK228)        Trichostatin A (TSA) 
 
 
 
 
 
 
Panobinostat 
 
Figure 1-1: Select HDAC inhibitors 
SAHA, belinostat, and romidepsin, are FDA-approved as treatments of T-cell lymphomas. 
Panobinostat is FDA-approved to treat multiple myeloma. TSA is a hydroxamic acid inhibitor used 
for in vitro and in vivo studies (36).
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Biological importance of HDAC8 
HDAC8 is important to the pathology of several disease states, including cancers 
and developmental disorders. HDAC8 mRNA levels are upregulated in several urothelial 
(bladder) cancer cell lines and cancerous tissue samples (48). HDAC8 is targeted in 
developing treatments for childhood neuroblastoma, as higher HDAC8 mRNA levels have 
been correlated with characteristics of poor disease outcome (49) and HDAC8-specific 
inhibition yields effective antitumor activity in cells and mouse models (50). Clinically 
observed HDAC8 mutations are involved in some cases of the developmental disorder 
Cornelia de Lange syndrome (discussed later), in which patients exhibit facial, skeletal, 
and intellectual abnormalities (47, 51). Additionally, the HDAC8 homolog found in the 
tropical flatworm Schistosoma mansoni (smHDAC8) is an antiparasitic target for 
therapeutics and inhibitors specific for smHDAC8 over hHDAC8 are in development (52).  
HDAC8 knockouts after birth are non-lethal (53), consistent with the ability of 
humans to tolerate pan-HDAC inhibitors as an anti-cancer treatment (54). However, 
protein expression profiles can vary significantly during development and several HDAC 
knockouts are lethal during mammalian embryonic development (11). For example, cells 
lacking HDAC3 die before embryonic day 9.5; deletion of HDAC3 leads to hyperactivity 
of the nuclear receptor PPARα and problems with embryonic gastrulation (55). Similarly, 
HDAC8 expression is crucial to development, as mice lacking this enzyme die soon after 
birth (53). Death is due to brain hemorrhaging caused by developmental defects in the 
mouse skull resulting from problems with neural crest patterning. These skull defects are 
similar to those that occur upon overexpression of the transcription factors Otx2 and Lhx1, 
suggesting that HDAC8 either directly regulates these proteins or affects regulators of 
these proteins (53). The mechanism of HDAC8 regulation of Otx2 and Lhx1 has yet to be 
determined. Furthermore, since HDAC8 knockouts are not lethal after birth (53), it is 
unclear whether HDAC8 no longer regulates these proteins, this regulation still occurs but 
is not vital for viability, or another HDAC compensates for the lack of HDAC8. 
Interestingly, recent reports catalog the features of human patients expressing loss-of-
function HDAC8 mutants. The phenotypes were wide-ranging and included 
brachycephaly, anteverted nostrils, widely spaced teeth, small hands and feet, 
gastrointestinal anomalies, and intellectual disability (51). Some of the observed features 
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overlap with those typical of Cornelia de Lange syndrome (CdLS). The non-CdLS 
phenotypes unique to HDAC8 dysfunction included features linked to skull development, 
which is consistent with the mouse knockout findings (51, 53). 
 
Known HDAC8 substrates 
Upon the discovery of HDAC8 in 2000, it was demonstrated to catalyze 
deacetylation of a number of acetylated histone variants in vitro (56-58). These histone 
substrates included full-length H2A/H2B, H3, and H4 histones, acetylated at non-specific 
lysines (56, 57). Concurrent studies showed that peptide sequences representing the H4 
histone tail with an acetylated lysine at position K16ac were also substrates in vitro (57, 
58). Several studies have used the H4 histone tail sequence as a peptide template to 
investigate the preferred substrate amino acid sequences of HDAC8 (discussed below) 
(59-62). Despite the widespread use of histones as generic HDAC8 substrates, the actual 
role and specificity of HDAC8 in catalyzing deacetylation of histones in vivo remains 
unclear. 
Shortly after HDAC8 was identified, the first acetylated non-histone proteins were 
reported (63, 64), which prompted the search for other possible HDAC substrates. The 
search for new HDAC8 substrates was further broadened to include non-nuclear 
substrates upon the discovery that this enzyme is present in the cytoplasm of smooth 
muscle cells (65, 66). The kcat/KM for HDAC8-catalyzed deacetylation of a coumarin-
conjugated peptide corresponding to the C-terminal region of the p53 transcription factor 
(Figure 1-2) is 2.7-fold greater than for a coumarin-conjugated H4K16ac histone peptide, 
with kcat/KM values of 7,500 M-1s-1 (67) and 2,800 M-1s-1 (68), respectively. Since the 
kcat/KM parameter reflects the relative catalytic efficiency of an enzyme with different 
substrates (reviewed in 69 pp. 111, 116-117), these values suggest that HDAC8 has a 
modest preference for catalyzing deacetylation of p53 over the H4 histone. It is important 
to note that these kcat/KM values for HDAC8 were measured using the commercially 
available Fluor-de-Lys assay (Enzo Life Sciences). This assay uses peptide substrates 
containing a methylcoumarin fluorophore conjugated to the C-terminal side of the acetyl-
lysine residue. After deacetylation, digestion by trypsin cleaves the coumarin fluorophore, 
causing an increase in fluorescence at 460 nm; deacetylation is measured from an 
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increase in the fluorescence signal (70) (Figure 1-2B). While this assay has been a 
valuable tool for studying histone deacetylases, the methylcoumarin fluorophore 
increases the activity of HDAC8 (71) and HDAC8-catalyzed deacetylation of unlabeled 
acetylated p53 and H4 histone peptides is slower than this assay reports (71, 72). 
Furthermore, coumarin-conjugated peptides are unlikely to reflect HDAC substrate 
specificity in the context of full-length proteins. 
 
Figure 1-2: The Fluor-de-Lys® assay (Enzo Life Sciences) 
A. The sequence of two HDAC8 peptide substrates used in the Fluor-de-Lys assay. B. Schematic 
of the Fluor-de-Lys assay and the wavelengths at which the fluorophores are measured. 
Reproduced from (73) with permission from John Wiley and Sons.
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The steady state kinetic parameters for catalysis of the deacetylation of peptides 
can provide insight into both kinetic mechanism and substrate recognition. HDAC8-
catalyzed deacetylation of the p53 and H4 coumarin peptides has a low value of kcat/KM 
(103 – 104 M-1s-1) in comparison to enzymes that function near diffusion-controlled limits 
(106 – 108 M-1s-1) and a high value for KM (320 µM, H4 peptide) (68) compared to other 
HDAC isozymes (~30 µM) (74). These data suggest a simple Michaelis-Menten kinetic 
model whereby substrate binding and dissociation is rapid, and is followed by rate-limiting 
deacetylation. This conclusion is bolstered by the observed enhancement of the kcat value 
for deacetylation of peptides labeled with a more reactive trifluoroacetyl group (75, 76). 
Therefore, substrate specificity is determined by both the affinity of HDAC8 for a peptide 
substrate and the activity of HDAC8 in the enzyme-substrate complex. Assuming that the 
kinetic constants for deacetylation of these peptides mimic the full-length proteins, the 
low kcat/KM and high KM values for HDAC8-catalyzed deacetylation of H4 and p53 
peptides compared to the activity of other HDAC isozymes (67, 74) (68) suggest that 
HDAC8 may not catalyze deacetylation of these sites in vivo. However, it is possible that 
natural, full-length, substrates may be better optimized for efficient deacetylation to allow 
for regulation of these post-translational modifications. In addition to these proposed 
substrates, in vitro kinetic studies combined with cellular assays have yielded several 
promising candidates for in vivo HDAC8 substrates.  
There are a number of factors that must be taken into account when parsing 
whether substrates are acted upon by a given enzyme in vivo. HDAC selectivity is 
minimally described by the relative values of kcat/KM for deacetylation, the relative 
concentrations of the HDAC isozymes, and the concentrations of competing substrates. 
Relative kcat/KM values indicate the substrate preference of an enzyme when 
discriminating among multiple substrates (reviewed in 69 pp. 110-111). The majority of 
enzymes have kcat/KM values of 105-106 M-1s-1 (77). These values are generally slower 
than the diffusion controlled rate constants for substrate binding, which can be as high as 
107-108 M-1s-1 (reviewed in 69 pp. 158-166). Consistent with this, the kcat/KM values for the 
HDAC8 homolog HDAC1 and the homologous enzyme, arginase I, are on the order of 
105 M-1s-1 (74, 78), suggesting that similar values should be achievable for efficient 
HDAC8 substrates. A caveat to drawing conclusions from in vitro kinetic parameters is 
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that some enzymes require an activator, such as a binding partner or covalent 
modification, for optimal activity. Since many HDAC isozymes associate with large protein 
complexes in vivo, it is possible that other proteins in the complex could activate the 
catalytic activity or enhance the substrate affinity to increase the value of kcat/KM in the 
cell. Additionally, HDAC8 may activated by a small molecule in vivo, perhaps via allosteric 
regulation. N-Acylthiourea binds in two locations and has been shown to activate HDAC8, 
in vitro and in cells, by interacting with the active site and an allosteric site (79). 
 
Candidate non-histone HDAC8 substrates 
The identification of HDAC8 substrates is an ongoing topic of investigation. 
Methods such as co-immunoprecipitation, in vitro kinetic measurements, cellular HDAC8 
knockdowns, and proteomic mass spectrometry are employed; and proposed substrates 
include structural maintenance of chromosomes 3 (SMC3), Estrogen-Related Receptor 
α (ERRα), the inv(16) fusion protein, cAMP responsive element-binding protein (CREB), 
AT Rich Interactive Domain 1A (ARID1A), transcription factor p53, and heat shock protein 
Hsp20 (47, 73, 80-83). 
A recently identified HDAC8 substrate is SMC3, a protein subunit of the cohesin 
complex. Human SMC3 is acetylated at K105 and K106 during S phase, and this is 
important for the cohesion of sister chromatids during the cell cycle (80, 84-86). SMC3 
was recently reported to be an HDAC8 substrate in vivo, based on cellular studies, and 
lack of HDAC8-catalyzed deacetylation of SMC3 is implicated in CdLS (47, 80). The 
proposed cellular model requires HDAC8-catalyzed deacetylation of SMC3 for the 
disassembly and regeneration of cohesin following anaphase and the separation of the 
chromosomes (Figure 1-3) (47, 87). Deacetylation of SMC3 releases components such 
as RAD21 protein fragments and allows the reassembly of the cohesin complex (47). 
HDAC8 is also immunopurified with cohesin components SMC3, SMC1A, and STAG2 
(81). In cases where HDAC8 abnormalities contribute to CdLS, it is likely via loss-of-
function mutations or decreased stability of HDAC8, leading to decreased deacetylation 
of SMC3 and disruption of the cohesin complex cycle (47, 51). Knockdown and inhibition 
of HDAC8 in HeLa cells both yielded increased acetylated SMC3 levels, and fibroblasts 
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and lymphoblastoid cells expressing mutant forms of HDAC8 exhibit decreased levels of 
HDAC8 protein and increased levels of acetylated SMC3 (47). It should be noted that 
while the data implicate acetylated SMC3 as an HDAC8 substrate, HDAC8 mutations only 
account for a small percentage of CdLS occurrence (51). Phenotypes of patients with 
HDAC8 mutations reveal some (though not all) clinical characteristics consistent with 
CdLS as well as features unique to HDAC8 patients (non-canonical CdLS characteristics) 
(51). Despite the ambiguity of HDAC8’s role in disease, SMC3 appears to be a probable 
HDAC8 target. 
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Figure 1-3: The proposed model of HDAC8 and SMC3 in cohesin dissassembly 
This figure is adapted from (87). The cohesin complex consists of SMC3 (light green), 
SMC1 (dark green), RAD21 (red), and stromalin (SA) (yellow). Acetylation is depicted in 
white. During anaphase, the cohesin is cleaved and following telophase the complex is 
reassembled. The prerequisite for reassembly is deacetylation of SMC3 by HDAC8. Not 
shown: Deacetylation facilitates removal of RAD21 fragments bound to SMC3 after 
cleavage by separase (47). 
 
A second proposed HDAC8 substrate is the ERRα. This orphan receptor is 
expressed in a number of organs, including the heart, kidney, and muscle, where it 
controls processes that are essential for maintaining energy homeostasis (reviewed in 
88). ERRα can be acetylated at four positions (K129, K138, K160, and K162), where 
these posttranslational modifications inhibit DNA binding (46). A role for HDAC8 in 
catalyzing the deacetylation of ERRα was suggested by the demonstration that the 
acetylation state of ERRα was altered by simultaneous incubation with HDAC8, the 
histone acetyltransferase PCAF, and 14C-acetyl-CoA (46). Furthermore, incubation of 
purified acetylated-ERRα with HDAC8 enhances the affinity of ERRα for DNA, which is 
consistent with HDAC8-catalyzed deacetylation of ERRα. One caveat to these 
experiments is that this assay included metal chelators and low salt, conditions where 
HDAC8 has limited catalytic activity (67, 89). An alternative explanation of these data is 
that HDAC8 binds to ERRα to increase the DNA affinity and/or decrease acetylation 
catalyzed by PCAF. However, addition of the non-homologous deacetylase Sirt1, to these 
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in vitro assays also decreases acetylation of ERRα, suggesting that both enzymes 
recognize ERRα as a deacetylase substrate. Finally, RNAi-dependent decreases in 
cellular HDAC8 or Sirt1 levels are accompanied by increases in ERRα acetylation in vivo 
(46). Taken together, these results suggest that HDAC8 catalyzes deacetylation of ERRα 
in vivo. Consistent with this, the acetylation site K129ac in ERRα has Arg in the -1 position 
(the amino acid on the N-terminal side of the acetyl-lysine), and RKac motifs have been 
demonstrated to be favorable for HDAC8 catalysis (60, 71). Additional analysis, such as 
directly measuring ERRα acetylation patterns by mass spectrometry in the presence and 
absence of HDAC inhibitors would further validate ERRα as an in vivo substrate of 
HDAC8. 
The third proposed HDAC8 substrate is the aberrant inv(16) fusion protein found 
in a significant portion of patients with acute myeloid leukemia (90). This fusion protein 
combines the N-terminus of the transcription factor domain core binding factor β, with the 
C-terminus of the smooth muscle myosin heavy chain (91). In COS7 cells, co-
immunoprecipitation experiments demonstrated that overexpressed HDAC8 associates 
with inv(16) (45). Furthermore, HDAC8 co-localizes and immunoprecipitates with smooth 
muscle myosin heavy chain (83) suggesting that HDAC8 may interact with this domain 
within the inv(16) fusion protein. Other HDAC isozymes do not immunoprecipitate with 
inv(16) under similar conditions, which suggests that HDAC8 may be the main HDAC that 
interacts with inv(16) in vivo. The addition of the HDAC inhibitor TSA inhibits the 
transcriptional repression activity of inv(16) (45), suggesting that HDAC8 activity is 
important for inv(16) regulation. An alternative explanation of these data is that inv(16) is 
a binding partner with HDAC8 rather than a substrate, as HDAC inhibitors have been 
shown to disrupt the association of HDACs with non-substrate binding partners (92). The 
acetylation site in the core binding factor β is RSKacFE (9). Peptide library studies have 
demonstrated that Phe in the +1 position is favorable for HDAC8 catalysis (60, 71) 
although Ser at the -1 position attenuates deacetylation (71). While the core binding factor 
β is acetylated in vivo (9), there is not yet direct evidence that inv(16) is acetylated (93). 
Taken together, these data indicate that inv(16) is either an HDAC8 substrate or forms a 
functionally important complex with HDAC8. 
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The transcription factor CREB is also a potential HDAC8 substrate. Acetylation at 
three CREB sites (Lys91, Lys96, and Lys136) helps to activate this protein (94). HDAC8 
and CREB overexpressed in HEK293 cells co-immunoprecipitate, demonstrating that 
these two proteins associate. When HDAC8 is overexpressed in cells, phosphorylation of 
CREB decreases, which in turn inhibits CREB transcriptional activation (95). Likewise, 
treatment of cells with the pan-HDAC inhibitor TSA (96) or HDAC8-specific BMX (97) 
increased CREB phosphorylation levels, suggesting that HDAC8 activity is important for 
CREB phosphorylation. Specific inhibition of HDAC8 in neuroblastoma mouse models 
had anticancer effects which were postulated to occur through a CREB-mediated effect 
on transcription (50). However, pulldown experiments demonstrate that CREB can 
interact with a number of HDAC isozymes (95), complicating identification of CREB as an 
HDAC8 substrate in vivo. Due to the high amino acid identity between class I HDACs 
(>30%) (98), overexpression and pulldown experiments may not yield results that are 
representative of in vivo situations. Therefore, these experiments suggest, but do not 
confirm, a direct connection between HDAC8 deacetylase activity, the phosphorylation 
status of CREB, and the regulation of CREB activation. Alternatively, HDACs may 
function as protein scaffolds to mediate the inhibitory interaction between CREB and 
protein phosphatase 1 (PP1) (reviewed in 99) (95, 100, 101), leading to a decrease in 
CREB phosphorylation and activity.  
Additional substrates have been suggested over the years, and more continue to 
be reported. The transcription factor p53 remains a classical candidate substrate. 
Knockdown of HDAC8 has been shown to increase the acetylation observed on Lys382 
of p53 while the acetylation state of Lys373 did not change, suggesting that the former 
site may be an HDAC8 substrate (82). A more recently identified target is ARID1A. 
ARID1A was identified as an HDAC8 substrate by Stable Isotope Labeling of Amino Acids 
in Cell Culture (SILAC) followed by mass spectrometry to analyze changes in global 
protein acetylation upon inhibition of HDAC8 (80). HDAC8-catalyzed deacetylation of a 
representative ARID1A peptide lacking a methylcoumarin moiety exhibits a kcat/KM value 
of 740 ± 36 M-1s-1, which is similar to that of the p53-methylcoumarin peptide                     
(800 ± 50 M-1s-1) (67, 72, 80). The fluorophore enhances HDAC8 activity toward the p53 
peptide (71), so among unlabeled peptides HDAC8 is more active toward ARID1A. 
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Therefore, HDAC8 is more specific toward catalyzing deacetylation of the ARID1A 
peptide, which may indicate that this protein is an in vivo substrate. HDAC8 also co-
immunoprecipitates with Hsp20 and HDAC8 inhibition is correlated to increased Hsp20 
acetylation, suggestion another possible substrate (83).  
The current cellular methods for identifying substrates of HDAC isozymes in vivo 
have limitations. Since HDAC selectivity depends on the relative concentrations of the 
HDAC isozymes and the concentrations of all of the acetylated lysine substrates, 
overexpression of HDAC and/or HDAC substrates can alter the normal pattern of 
deacetylase activity. Therefore, experiments using overexpressed proteins suggest that 
a particular interaction can occur in vivo, but does not prove that this contact occurs under 
physiological conditions. Additionally, the distinction between substrates and binding 
partners is ambiguous in pulldown experiments. For example, the Cristea group mapped 
an interactome network for the 11 metal-dependent HDACs using pulldowns and mass 
spectrometry (81). These data provide information regarding biological processes and 
proteins but do not identify substrates versus binding partners. It is possible that are some 
HDAC-substrate interactions are too transient and/or weak to withstand pulldown 
experiments and that these experiments identify non-substrate binding partners. The 
interactome study did, however, report association of HDAC8 with the cohesin complex 
proteins, which is consistent with SMC3 being a substrate (81). Alternate techniques, 
such as crosslinking, may be necessary to increase the detectable lifetime of an HDAC-
substrate complex and increase the likelihood of identifying substrate-HDAC8 
interactions. Importantly, the observation of enhanced protein acetylation after 
knockdown of an HDAC isozyme does not necessarily mean that the HDAC isozyme 
directly catalyzes deacetylation of that site. Therefore alternative methodologies such as 
crosslinking in the presence of HDAC8 inhibitors and in vitro deacetylation assays on 
target proteins need to be explored to enhance the future identification of HDAC8 
substrates. 
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HDAC8 complex formation 
The other class I HDACs, HDAC1, 2, and 3, are observed in complexes in the cell 
and their substrate specificity largely depends on the combination of proteins incorporated 
into their complexes (reviewed in 102). HDAC1 and 2 associate with Sin3 scaffolded 
complexes which serve a range of functions within the cell. The substrate specificity and 
function of these HDAC isozymes can change by altering the protein composition of the 
complex (reviewed in 103). Although HDAC8 is phylogenetically similar to the other class 
I HDACs, divergent evolution (14) may have altered how HDAC8 interacts with protein 
cofactors, possibly allowing this isozyme to function independent of other proteins. 
Recombinant HDAC8 catalyzes deacetylation and displays substrate specificity in the 
absence of additional protein cofactors (18, 56, 57, 59-61, 67, 71, 74, 76, 89, 104, 105), 
suggesting that HDAC8 can catalyze deacetylation in vivo in the absence of a protein 
complex. In the HDAC protein interactome, HDACs 1, 2, and 3 are grouped in large 
networks with significant overlap, partially due to shared functional complexes such as 
NuRD and CoREST (81). HDAC8, however, does not share in this linked network. This 
suggests HDAC8 has a unique cellular function. Nonetheless, HDAC8 does associate 
with other proteins (81), and these interactions likely affect the biological function and 
selectivity of this enzyme.  
Identifying HDAC8 binding partners and distinguishing between binding partners 
and substrates are difficult tasks. Furthermore, binding partner data is somewhat 
inconsistent. 17 HDAC8 interaction partners were identified by pulldowns and subsequent 
SAINT mass spectrometry analysis (Significance Analysis of INTeractions), yet all but two 
of these have been absent in other pulldown studies (81). Differences in binding partner 
determinations may result from experimental differences such as cell line, HDAC8 
overexpression (HDAC8-EGFP was used in (81)), or experimental and analytical 
methods. Some interactions may not withstand pulldown washing conditions, and mass 
spectrometry may not identify low abundance proteins or peptides that are not amenable 
to ionization. Additionally, different binding partners are likely to be observed at different 
points in the cell cycle, and under different cellular conditions (e.g. stress). Nevertheless, 
the interaction partners identified in the SAINT screen include cohesin components 
(SMC3, SMC1A, and STAG2), placing HDAC8 within the cell cycle process, protein and 
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ion transport proteins (SEC16A, CPNE3, and NUP98), as well as several proteins of 
other/unknown function (81). At least 14 of the proteins have acetylation sites, which 
means they could be substrates, such as SMC3 (discussed earlier). 
Several binding partners have been identified by other means and illustrate the 
complicated nature of this search. Previous experiments have provided evidence that the 
HDAC1/HDAC2 complex associates with both the PP1 and CREB, leading to decreased 
CREB phosphorylation (101). Because an inactive HDAC1 mutant still affects CREB 
activity, the function of the HDAC1/HDAC2 complex was proposed to co-localize PP1 and 
CREB. However, it is possible that HDAC2 catalyzes deacetylation of CREB under these 
conditions (101). Similarly, both PP1 and CREB co-immunoprecipitate with HDAC8, and 
HDAC8 overexpression decreases CREB activity. These data are consistent with HDAC8 
either acting as a scaffold to enhance the interaction between PP1 and CREB or 
catalyzing deacetylation of CREB.  
HDAC8 also co-localizes with α-actin, as indicated by immunofluorescence 
staining (65, 83). This interaction was confirmed by pulldown experiments using human 
smooth muscle cells, demonstrating an endogenous association between α-actin and 
HDAC8 (66, 83). The function of this interaction was partially elucidated by demonstrating 
that siRNA knockdown of HDAC8 in human smooth muscle cells decreased the ability of 
cells to contract, when exposed to a collagen lattice. Furthermore, the siRNA-treated 
smooth muscle culture cells were smaller and unable to spread. These changes in cell 
morphology occurred without detectable changes to α-actin acetylation (66), suggesting 
that HDAC8 acts as part of a complex which modulates the cell cytoskeleton without α-
actin deacetylation. Furthermore, pulldown experiments demonstrate that HDAC8 
associates with the proteins Hsp20, myosin heavy chain, and cofilin (83) all of which can 
potentially affect actin dynamics (106, 107). It is currently unclear whether Hsp20 or cofilin 
are substrates for HDAC8. Because HDAC8 enhances cell contractility and associates 
with three proteins important for actin function, it is likely that HDAC8 is a component of 
a complex that modulates actin dynamics. 
Additional potential HDAC8 interaction partners have been identified using a 
bacterial two-hybrid system (108). Two of the fifteen identified binding partners have been 
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examined in detail: the human Ever-Shorter Telomeres 1B (hEST1B) protein that 
activates telomerase activity and HOP1, an adaptor protein linking Hsp70 and Hsp90. 
The two-hybrid results were confirmed using co-immunoprecipitation of overexpressed 
hEST1B and HDAC8 in HeLa cells. HDAC8 knockdowns led to decreased telomerase 
activity through diminished levels of hEST1B. As HDAC8 activity does not affect the 
promoter region regulating hEST1B, the hEST1B level is likely not regulated by alteration 
in transcription. However, hEST1B levels are increased by addition of a proteasome-
dependent pathway inhibitor or decreased by overexpression of ubiquitin and rescued by 
phosphorylated HDAC8. These results argue that phosphorylated HDAC8 protects 
hEST1B from polyubiquitination and subsequent degradation by the proteasome. The 
protective effects of phosphorylated HDAC8 on hEST1B levels are independent of 
deacetylase activity, remaining in the presence of the catalytically inactive His143Ala-
HDAC8 mutant or after exposure of cells to TSA. Therefore, HDAC8 interacts with 
hEST1B but deacetylation is not required for the functional effect. To further explore the 
interaction between HDAC8 and HOP1 indicated by the two-hybrid experiment, the 
association of HDAC8 with known HOP1 binding partners was investigated. Pulldown 
experiments demonstrated that endogenous Hsp70 and Hsp90 co-immunoprecipitate 
with overexpressed HDAC8 (108). This result suggests that HDAC8, HOP1, Hsp70, and 
Hsp90 form a complex. One proposed mechanism for the effect of HDAC8 on telomerase 
activity suggests that the Hsp70-HDAC8 complex protects hEST1B from ubiquitination 
catalyzed by the E3 ubiquitin ligase CHIP (108). This in turn raises the levels of hEST1B 
and activates telomerase. Interestingly, interaction of HDAC8 with the Hsp proteins may 
help to elucidate the effect of HDAC8 on α-actin, since Hsp90 has been proposed to 
modulate α-actin dynamics (109, 110). Thus, it is possible that the HDAC8-HOP1-Hsp90 
complex may regulate α-actin function.  
 
Enzyme structure affects substrate specificity  
The structure of HDAC8 yields clues about molecular recognition relevant to 
substrate selectivity. HDAC8 is the second smallest metal-dependent HDAC at ~42 kDa, 
containing little more than the catalytic domain (14, 56-58). This HDAC folds as a single 
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α/β domain with a core eight-stranded β-sheet surrounded by eleven α-helices (Figure 
1-4A). The substrate binding surface, composed of nine loops and an 11Å tunnel leading 
to the active site, is proposed to have conformational flexibility based on the poor 
occupancy and varying positions of the loop residues in crystal structures (18, 44, 105, 
111-116) (Figure 1-4B). Molecular dynamics simulations have demonstrated that 
residues 100 and 101 of loop L2 can flip in and out and that part of L2 can form an α-helix 
(116). These simulations and crystal structures of HDAC8 bound to largazole analogs 
demonstrate salt bridge interactions between the L1 and L2 loops (44, 116). HDAC8 
flexibility is such that different loop L2 conformations are observed for two monomers in 
the same crystal structure (44). Furthermore, one crystal structure illuminates a bound 
TSA molecule interacting with residues in the hydrophobic core of HDAC8 (112) (Figure 
1-5). While this may simply be an artifact, the alternative binding mode suggests that the 
surface of the protein can change conformation enough to allow hydrophobic molecules 
to intercalate between these loops and interact with the interior of the protein. The various 
loops in the HDAC8 structure are highlighted in Figure 1-4C. 
Loops are a common structure in promiscuous enzymes (reviewed in 117) and 
examples of proteins, such as chymotrypsin (reviewed in 118) and carboxypeptidase A 
(reviewed in 119), that use loops to bind a range of substrates are abundant in nature. 
These loops create a number of different conformations that bind ligands through a 
combination of induced fit and select fit mechanisms (reviewed in 69 pp. 369-371, 120). 
The varied conformations and motifs provide a palette of binding sites to accommodate 
a multiplicity of substrates. Furthermore, long-range allosteric movements propagated 
through the loops may affect the active site and surrounding areas, potentially altering 
substrate preferences.  
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Figure 1-4: HDAC8 structures 
HDAC8 structures. A. PDBID: 2V5W (111). Side view of HDAC8 with bound peptide substrate. 
Helices are purple, sheets are yellow, turns are white, the monovalent cations are orange, and 
the active site metal is colored green. The Fluor‐de‐Lys substrate representing the p53 sequence 
is colored cyan for carbon, red for oxygen, and blue for nitrogen. B. Front view of an overlay of 21 
HDAC8 crystal structures in the PDB. PDBID: 2V5X, 2V5W, 1T69, 1T64, 1VKG, 1T67, 1W22, 
3SFH, 3SFF, 3MZ3, 3EZT, 3FO6, 3MZ4, 3MZ6, 3MZ7, 3EW8, 3EZP, 3F07, 3F0R, 3EWF, and 
3RQD (18, 105, 111-115). Structural variations are especially apparent in the L1, L2, and C‐
terminal loops. C. A map of the crystal structure of HDAC8 outlining the loop regions. Structure 
visualizations and overlay were generated with the Visual Molecular Dynamics (VMD) program 
and reproduced from (73) with permission from John Wiley and Sons.
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Figure 1-5: HDAC8 with two bound TSA molecules 
PDBID: 1T64 (112). In this crystal structure, one molecule of TSA binds to the active site tunnel 
to coordinate the divalent metal ion (colored yellow) while a second TSA molecule binds nearby 
in between the L1, L2, and L3 loops. Image was created with the VMD program and is reproduced 
from (73) with permission from John Wiley and Sons. 
 
In at least fourteen of the HDAC8 crystal structures, the enzyme crystallizes as a 
dimer along the substrate binding interface (18, 105, 111-114). As HDAC8 is a monomer 
in solution (115), the dimer interface may provide insight into long-range interactions 
between HDAC8 and its substrates (Figure 1-4A). To date, substrate specificity has 
mainly been evaluated using peptide substrates, therefore only short range interactions 
have emerged as HDAC8 substrate binding motifs (59-61, 71). Based on the crystal 
structure of bound peptides (105, 111) and biochemical measurements, these 
interactions include base stacking, hydrogen bonding, salt bridges, and electrostatic 
interactions. Base stacking between Tyr100 and the methylcoumarin of the Fluor-de-Lys 
peptides is observed in the crystal structure (105, 111). Similarly, base stacking between 
aromatic amino acids in the +1 position and Tyr100 may be important for substrate 
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recognition (60, 71). Additionally, hydrogen bonding between the back-bone amides of 
the substrate and the Asp101 side chain oxygens are important for molecular recognition 
(105). Salt bridges between positively charged arginines in the substrate and negatively 
charged carboxylate side chain oxygens, and general hydrophobic interactions can be 
seen in the peptide-enzyme interface (105, 111). Because of the limited number of 
interactions, the binding affinity may be dominated by a few strong contacts, as observed 
for the interaction between Tyr100 of HDAC8 and the methylcoumarin moiety of short 
Fluor-de-Lys peptides (71). This pi-pi interaction (~2 kcal/mol) (121, 122) is of comparable 
energy with other HDAC8-peptide contacts. In contrast, binding a protein substrate could 
involve many more contacts, including multiple hydrogen bonds (0.5-1.5 kcal/mol), 
hydrophobic (~1 kcal/mol), electrostatic (<1 kcal/mol) (reviewed in 69pp. 325-339), and 
solvent exposed salt bridge (~1-3 kcal/mol) (123) interactions. Therefore, the binding 
affinity could depend on a large number of interactions that together create a promiscuous 
substrate binding profile. Determinants of substrate specificity are still being evaluated for 
HDACs and further identification of binding motifs will be beneficial for understanding the 
biology of these enzymes.  
The loops of the HDAC8 structure differentiate it from other HDACs. There are 
striking differences in loop size and structure between HDAC8 and the homologous 
polyamine deacetylase APAH (124),. These differences in the loops may be important for 
substrate binding, as APAH catalyzes deacetylation of small molecules including 
acetylated spermidine, putrescine, and spermine, while HDAC8 deacetylates 
macromolecules. In APAH, the L1 and L2 loops are much larger and contain many more 
hydrophobic residues than in the corresponding HDAC8 loops (Figure 1-6A,B), while the 
C-terminal loop and helix in HDAC8 are absent in APAH. Similarly, a comparison of the 
L1, L2, and C-terminal loops of different HDACs reveals interesting variations. The L1 
and L2 loops of HDAC2 (125), 4 (126), 7 (127), and 8 (111) are more divergent in size, 
structure, and number of charged residues than other loops within these HDACs (Figure 
1-6). For instance, the size and number of charges within the L1 and L2 loops change 
two-fold between HDAC8 and HDAC4. HDAC8 reportedly has a more substrate-
accessible active site than un-complexed HDAC3, due in part to differences in the L1 and 
L6 loops (128). The substrate binding surface loops may confer isozyme-specific 
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substrate selectivity, as inhibitor selectivity for HDAC1 over HDAC8 has been observed 
and attributed to the decreased flexibility in HDAC1 loop L1 compared to L1 in HDAC8 
(44, 129). Comparison of HDAC8 crystal structures illustrates that the L1 and L2 loops 
have the most structural variability of the loops in the proposed substrate binding surface, 
suggestive of a role in ligand binding. Additionally, the L2 loop interacts with inhibitors, 
suggesting that it may be important for molecular recognition of substrates (105). The L3 
loop, which lies below the L2 loop and flanks the active site, also varies greatly in the 
number of charges in the loop among HDACs 2, 4, 7, and 8, consistent with a role in 
substrate or binding partner selectivity. The C- and N- terminal portions of the HDACs, 
which lie on the outer edge of the substrate binding surface, may also interact with 
ligands. In the HDAC crystal structures, the C-terminal loops vary in position, charge, and 
size and may be responsible for long distance interactions between HDACs and their 
substrates, or used for recognition of binding partners.
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Figure 1-6: Structural comparison of HDACs 
A. Aligned sequences of published HDAC crystal structures (111, 124-127). Residues in the loop 
regions and putative substrate binding region are yellow. Positively charged residues are red and 
negatively charged residues are green. Sequence alignment was performed with the constraint-
based alignment tool for multiple protein sequences, COBALT (130). B. Surface visualizations of 
the crystal structures for HDAC2 (PDBID: 3MAX (125)), HDAC4 (PDBID: 2VQM (126)), HDAC7 
(PDBID: 3C0Y (127)), HDAC8 (PDBID: 2V5W (111)), and APAH (PDBID: 3Q9B (124)). The Fluor-
de-Lys substrate (white), from the HDAC8 structure, is superimposed on the structures. Positively 
charged residues Arg and Lys are red, and negatively charged residues Asp and Glu are blue. 
Structural visualizations were created using VMD and the figures are reproduced from (73) with 
permission from John Wiley and Sons. 
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Along with structural studies, peptide substrates have been useful for evaluating 
substrate motifs recognized by HDAC8. Reister and colleagues measured the activity of 
HDAC8 with a peptide library of the sequence Ac-X-Z-K(ac)-methylcoumarin, where X 
and Z were all amino acids except for cysteine (59). This work indicated that HDAC8 
favors Pro, Met, Ala, Lys, Arg, Gln, Asp, Phe, and Ser at the -2 position and aromatic 
(Phe, Trp, and Tyr) and hydrophobic (Ile, Met, and Val) amino acids at the -1 position. 
However, the activity of HDAC8 in these assays was low, possibly due to the inclusion of 
the metal chelator EDTA in the assay. The Mrksich group developed a mass 
spectrometric assay to profile the local substrate specificities of HDACs (71). The activity 
of HDAC8 toward a peptide array of the sequence, Ac-G-X-K(ac)-Z-G-C-NH2 where X 
and Z were any amino acid other than cysteine, showed that the most efficient substrate 
contains Arg and Phe at the X and Z positions, respectively (71). However, HDAC8 also 
catalyzes deacetylation of peptides containing the sequence X=Arg/Z= variable and X = 
variable/Z = Phe. HDAC8 selectivity was further screened using a peptide library with the 
following sequence: Ac-G-R-K(ac)-X-Z-C-NH2 (60). These data demonstrated a 
preference for Arg or Phe at the X position. Furthermore, when X is Phe the identity of 
the Z position has only a modest effect on activity. These results suggest that specific 
positions and combinations of amino acids contribute significantly to the substrate 
recognition of small peptides, while other positions fine tune recognition.  
The Mrksich group also demonstrated that distal sequences can modulate HDAC8 
substrate specificity (61). Using peptides representing a partial sequence of the histone 
H4 tail acetylated at K12, they showed that adding a KRHR motif to the C-terminus 
(beginning 4 residues downstream of the acetyl-lysine) enhanced activity (61). A method 
for the preparation of singly-acetylated recombinant histone H3 was recently published 
(131), and we have used this to measure HDAC8-catalyzed deacetylation of full-length 
protein substrates. My dissertation demonstrates the importance of long-range 
interactions between HDAC8 and protein substrates in catalytic efficiency and substrate 
specificity. 
Finally, the structure of the active site may also play a role in HDAC substrate 
specificity. HDAC2 and 8 have well defined 11Å channels leading to their active sites that 
easily accommodate an acetyl-lysine side chain, however, this tunnel is lacking in HDAC4 
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and 7 (111, 125-127) where only half of the channel is apparent. This modification in 
active site structure could suggest that HDAC4 and 7 catalyze deacetylation of alternate 
substrates, as proposed by Lombardi et. al. (124). Alternatively, these isozymes might 
need substrates that complement the active site to stabilize the binding of the acetyl-
lysine moiety.  
 
Catalytic mechanism and regulation of HDAC8 activity 
The active site of HDAC8 contains a divalent metal ion coordinated to two 
aspartate and one histidine side chain (Asp178, Asp267, and His180) and one or two 
water molecules (Figure 1-7). The enzyme is proposed to catalyze hydrolysis using a 
metal-coordinated water nucleophile and general acid-base catalysis (GABC) with either 
one or two side chains, similar to typical metallohydrolase mechanisms, although His 
replaces the typical Glu/Asp GABC (Figure 1-7) (15, 105, 132, 133). The substrate binds 
to HDAC8 with the catalytic metal coordinating both the carbonyl oxygen of the acetyl-
lysine substrate and a water molecule. In the first step of the mechanism, His143 functions 
as a general base to abstract a proton from the metal-bound water, as this nucleophile 
reacts with the carbonyl carbon to form a high energy tetrahedral intermediate. The 
oxyanion intermediate is proposed to be stabilized by coordination with the metal ion, 
hydrogen bonding with Tyr306, and electrostatic interactions with positively charged 
groups in the active site. Proton donation from an active site general acid to the amine 
leaving group accompanies breakdown of the tetrahedral intermediate to form acetate 
and deacetylated lysine (105, 132, 133). In the GABC mechanism originally proposed 
from the crystal structure of the homologous HDLP enzyme (132), His142 and protonated 
His143 are proposed to function as the general base and general acid, respectively. In 
the one GABC mechanism, H143 functions as both the general acid and general base 
catalyst and H142 acts as an electrostatic catalyst (105, 133), similar to the mechanism 
proposed for carboxypeptidase A (15). Subsequent studies utilizing mutagenesis and 
molecular dynamics simulations suggest a preference for the one base mechanism (68, 
105, 133). 
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Figure 1-7: Scheme of proposed HDAC8 mechanism 
Schematic of the one base mechanism for HDAC8. Blue is the acetyl-lysine substrate, while the 
nucleophilic water is green and red. For clarity, equilibration of exchangeable protons with solvent 
is not shown. The figure is adapted from (73) and reproduced with permission from John Wiley 
and Sons. 
 
The HDAC8 crystal structure also contains two monovalent cation sites (18, 105, 
111-114), suggesting that the activity of HDAC8 may be modulated by both the 
concentration and type of ions in solution. One monovalent cation site is 7 Å from the 
divalent catalytic metal ion and is coordinated by the side chain oxygens of Asp176 and 
Ser199 and the backbone carbonyl oxygens of Asp176, Asp178, His180, and Leu200. 
The second site is 21 Å from the divalent catalytic metal ion, and is ligated by two water 
molecules and the backbone carbonyl oxygens of Phe189, Thr192, Val195, and Tyr225. 
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The value of kcat/KM for HDAC8-catalyzed deacetylation has a biphasic dependence on 
the concentration of K+ and Na+ ions (89). In the absence of monovalent ions, the activity 
of HDAC8 is very low; addition of monovalent cations to Zn-bound HDAC8 increases 
activity with K1/2, act = 14 mM for K+. At higher K+ concentrations Zn-HDAC8 activity is 
inhibited with K1/2, inhib = 130 mM. Mutagenesis studies indicate a significant decrease in 
potassium inhibition in the His142Aala and Asp176Ala/Gln mutants indicating that the 
monovalent ion site near the active site is inhibitory. Potassium binding next to His142 
has been proposed to lower the pKa of this residue, decreasing the concentration of 
protonated His142, thereby lowering catalytic activity. Similar biphasic regulation has 
been measured for Na+, but activation and inhibition require a five-fold and ten-fold higher 
concentration of Na+ compared to K+, respectively (89). At the 100 mM K+ concentration 
within smooth muscle cells (134), HDAC8 activity is partially inhibited and sensitive to 
changes in the K+ concentration. 
HDAC8 is activated by a number of divalent metal ions, including Co2+, Zn2+, Ni2+, 
and Fe2+ (67). When HDAC8 is purified under aerobic conditions, the bound metal ion is 
primarily Zn2+. However, recombinant HDAC8 purified anaerobically from E. coli contains 
8-fold more iron than zinc. Consistent with this, the recombinant HDAC8 activity in E. coli 
cell lysates is oxygen-sensitive (67). Additionally, although HDAC8 binds Zn2+ nearly 106-
fold more tightly than Fe2+ (18), the affinities for both metal ions are comparable to the 
readily exchangeable metal concentrations estimated in living cells, suggesting that 
HDAC8 can bind either Fe2+ or Zn2+ in vivo. Furthermore, the identity of the bound metal 
ion alters the catalytic properties of HDAC8. When catalyzing deacetylation of the 
methylcoumarin-labeled p53 peptide, the kcat/KM value for Fe2+-bound HDAC8 (2300 ± 
160 M-1s-1) is almost three times larger than that of Zn2+-HDAC8 (800 ± 50 M-1s-1). 
Interestingly, substitution of Fe2+ for Zn2+ also decreases the value of KM for the substrate 
by five-fold and the KI for SAHA by two-fold, suggesting that Fe2+ enhances ligand affinity 
(67). However, a comparison of the crystal structures of the hydroxamate-bound Fe2+-
HDAC8 and Zn2+-HDAC8 shows no significant differences in the active site or the rest of 
the protein (18). These data suggest that either binding of the hydroxamic inhibitor 
stabilizes a common enzyme conformation, or that the bound metal ion affects protein 
dynamics that are not observable by crystallography. In this dissertation I demonstrate 
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that changing the identity of the active site metal ion affects HDAC8 substrate specificity 
toward non-fluorophore-conjugated peptides in vitro. 
Comparison of the Zn2+/Fe2+ metal affinities with the cellular concentrations of 
those metals suggests that HDAC8 could bind a combination of iron and zinc cofactors in 
eukaryotic cells (18). Furthermore, the cellular zinc concentration can change 
dramatically upon oxidative stress (135, 136) and metal toxicity (137) potentially altering 
the levels of readily exchangeable Fe2+-HDAC8 and Zn2+-HDAC8 based on cellular 
conditions. This provides a means by which the cell could couple HDAC8 activity to 
cellular stresses. This model can be expanded to propose that substrate selectivity is 
differentially regulated by stimuli. For example, scaffolding activators could preferentially 
enhance the binding of HDAC8 to a certain set of substrates. Similarly, alteration of the 
active site metal ion or bound monovalent ions could alter ligand specificity. For example, 
Fe2+-HDAC8 binds the inhibitor SAHA 2-fold more tightly than Zn2+-HDAC8 (89) even 
though Zn2+ is a stronger Lewis acid (reviewed in 138 pp. 337-341). This change in 
binding affinity suggests that the active site metal ion may contribute subtly to the 
structure, dynamics, and molecular recognition of HDACs. 
 
HDAC8 localization  
Most simply, protein localization may regulate HDAC8 substrate specificity by 
changing the effective substrate concentration. HDACs have been found to have a range 
of cellular locations. HDAC1 and 2 are exclusively nuclear, while HDAC6 is mostly 
cytoplasmic, and HDAC3, 4, 5, 6, 7, 9, 10, and 11 appear to shuttle in and out of the 
nucleus (139). Initially, HDAC8 was assumed to be nuclear because it has a nuclear 
localization sequence and was observed in the nucleus of NIH3T3 (56) and HEK293 cells 
(57). Upon further characterization, both nuclear and cytosolic HDAC8 have been 
observed. Microscopy demonstrated that HDAC8 localizes to both the cytoplasm and 
nucleus of embryonic smooth muscle cells, skin fibroblasts, NIH3T3 cells, and human 
myometrial cells (65, 83) although there remains some skepticism about this point. 
HDAC3, the closest HDAC8 human homologue (14), exists in both the cytoplasm and 
nucleus, and localization has been linked to the regulation and cellular function of this 
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enzyme. To what extent cellular localization plays a role in regulation of HDAC8 activity 
is currently unknown. 
Determining the cell type-dependent expression of HDAC8 may provide interesting 
insights about its substrate specificity and biological function. In general, class I HDACs 
are ubiquitously expressed among the various cells of an organism, while class II HDACs 
are more cell-type specific (reviewed in 139, 140). HDAC8 (as well as the other class I 
HDACs) has been found in both normal epithelium and cancerous tissues from the 
stomach, esophagus, colon, and prostate, and has been found in breast, ovary, lung, 
pancreas, and thyroid carcinomas (141). 
 
Phosphorylation of HDAC8 
Post-translational modifications such as phosphorylation may also regulate 
HDAC8 activity. Results from a screen of three protein kinases, casein kinase II, protein 
kinase A (PKA) and protein kinase G (PKG), indicated that HDAC8 phosphorylation could 
be catalyzed by both PKA and PKG (142). PKA phosphorylation appeared to be 
predominant and this function was authenticated in vivo by incubation of cells with the 
PKA inhibitor H-89, which lowered HDAC8 phosphorylation levels (143). Based on 
consensus sequences, nineteen potential phosphorylation sites were identified in 
HDAC8. Phosphoamino acid analysis followed by two dimensional thin layer 
chromatography demonstrated modification of a serine residue (143) and, based on this 
information, Ser39 was identified as the only PKA phosphorylation site in the HDAC8 
sequence (56, 143). A Ser39Ala HDAC8 mutant, which cannot be phosphorylated, 
negates phosphorylation of HDAC8 catalyzed by PKA, confirming this location as the 
primary phosphorylation site on HDAC8. Furthermore, phosphorylation of this site 
modulates HDAC8 activity. The specific activity of HDAC8 purified from cells treated with 
forskolin, a PKA activator, decreased by five-fold in an in vitro assay using purified 
histones as substrates (143). Furthermore, the specific activity of Ser39Glu HDAC8, a 
mutation that mimics phosphorylation, decreases to a level comparable to that of 
phosphorylated HDAC8, while the specific activity of the Ser39Ala mutant is similar to 
that of unmodified HDAC8. To examine whether in vivo effects of phosphorylation of 
HDAC8 correlate with the in vitro measurements, HDAC8-transfected HeLa cells were 
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treated with forskolin. These cells showed increased levels of acetylated histones H3 and 
H4, suggesting that the decreased deacetylase activity of phosphorylated HDAC8 led to 
increased histone acetylation in vivo (143).  
Ser39 is located on the backside of the HDAC8 surface, 21Å from the catalytic 
metal ion (18, 105, 111-115) (Figure 1-8). Nonetheless, phosphorylation has the potential 
to affect the subcellular localization, protein-protein interactions, allosteric effects, and 
HDAC8 activity via conformational changes that propagate to the active site or enzyme-
substrate interface. Ser39 lies near the junction with the L1 loop (18, 105, 111-115) that 
has been implicated in substrate recognition, and therefore phosphorylation at that 
position may alter enzyme-substrate interactions. Ser39 is located in a pocket on the 
enzyme surface surrounded by hydrophobic and acidic residues suggesting that 
phosphorylation of Ser39 could induce a drastic structural perturbation due to charge 
repulsion (112). Ser39 also is near the conserved Arg37 residue, which is proposed to be 
important for gating an acetate release channel in HDAC8 (104) (Figure 1-8). The 
Arg37Ala mutation decreases the kcat/KM value for Co2+-HDAC8-catalyzed deacetylation 
of the Fluor-de-Lys substrate (R-H-Kac-Kac-fluorophore) by 530-fold (104). Based on the 
proximity of Ser39 to Arg37, phosphorylation at this position may affect HDAC8 activity. 
. 
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Figure 1-8: Ser39 in the HDAC8 structure 
Phosphorylation of Ser39 may affect the active site structure and/or activity of HDAC8. PDBID: 
2V5W (111). This structure shows that phosphorylation of Ser39 (red) is poised to potentially 
perturb the position and/or electrostatic environment of Arg37 (orange) and in turn, affect the 
active site residues (yellow). The Fluor‐de‐Lys substrate is blue and the active site metal is green. 
The structure was generated using VMD. Reproduced from (73) with permission from John Wiley 
and Sons.
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Phosphorylation may also regulate HDAC8 through the modulation of protein-
protein interactions. In the bacterial two-hybrid assay that identified fifteen HDAC8-
interacting proteins (108) expression of PKA was necessary for the pulldown of six of 
these identified proteins, and suggests that these proteins interact solely with 
phosphorylated HDAC8. Two of these interactions, those between HDAC8 and hEST1B 
and between HDAC8 and Hsp70, were further observed by co-immunoprecipitation, 
showing that treatment of cells with forskolin led to increased amounts of phosphorylated 
HDAC8 and increased interactions (108). These data strongly suggest that HDAC8 
phosphorylation regulates HDAC8 complex formation. Similarly, phosphorylation of 
HDAC1 and HDAC2 regulates association of these proteins with each other and 
complexes such as mSin3A, RbAp48 (NuRD subcomplex), and CoREST (142, 144, 145). 
Phosphorylation-dependent complex formation may also regulate the cellular localization 
of HDAC8. Fluorescence microscopy of myometrial cells shows that HDAC8 and 
phosphorylated HDAC8 both localize primarily to the cytosol, but cell fractionation data 
suggest that phosphorylated HDAC8 has increased association with the cytoskeleton 
compared to wtHDAC8 in this cell type (83). Phosphorylation is important for localization 
of other HDACs observed in both the nucleus and cytosol. HDAC4, HDAC5 and HDAC7 
utilize a nuclear-cytoplasmic shuttle mechanism involving phosphorylation-dependent 
binding to 14-3-3 proteins (29-32). In the case of HDAC5, phosphorylation-dependent 
translocation is also kinase specific (146, 147). HDAC4 and HDAC5 localization is also 
modulated by cysteine oxidation (33-35). The mechanism through which phosphorylation 
potentially mediates HDAC8 localization is not known. 
The Ser39 site is an interesting location for phosphorylation among HDACs. Ser39 
is not conserved among class I HDACs; the residue in the corresponding position of other 
class I HDACs is arginine in HDAC1 and 2, and alanine in HDAC3. Also, HDAC8, HDAC5, 
and HDAC6 contain the only phosphorylation sites that are located within the HDAC 
catalytic domain (25, 35, 148, 149). In general, the effect of phosphorylation on the activity 
of other class I isozymes, HDAC1 and 2, is ambiguous and/or contradictory (142, 144, 
145, 150, 151). For example, phosphorylation of HDAC1 had little to no effect on 
deacetylase activity using a synthetic histone H4 peptide (145, 150) but activity on 
isolated histones decreased using mutants that could not be phosphorylated (144). 
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Recent data demonstrate that HDAC2 is activated by phosphorylation in a residue-
dependent manner (151). Therefore HDAC8 may be the most straightforward isozyme 
for examining the role of phosphorylation in regulating deacetylation. In this dissertation I 
present kinetic, structural, and simulation data for a phosphomimetic HDAC8 mutant. The 
phosphomimetic HDAC8 demonstrates altered substrate binding, decreased HDAC8-
catalyzed deacetylation of peptides, and an increased rate constant for metal dissociation 
from the active site. 
Many HDACs undergo additional post-translational modifications such as 
acetylation, ubiquitination, and sumoylation (reviewed in 25, 35), but additional in vivo 
modifications of HDAC8 have not yet been demonstrated. HDAC8 has a consensus motif 
for glycosylation at Asn136 that could be modified (56, 143); however the NetNGlyc 1.0 
server does not predict N-glycosylation of this site due to the lack of a signal peptide 
(152). HDAC8 can be S-nitrosylated in vitro, and this has an inhibitory effect on catalysis 
(153). Acetylation was recently reported for HDAC2 (154) and has been observed at 
multiple sites on HDAC1 (155). Two of the HDAC1 sites are located in the deacetylase 
domain and four sites are near the C-terminus; acetylation of these sites inhibits HDAC1 
deacetylase activity toward histones in vitro and corepressor function in vivo (155). The 
two sites in the deacetylase domain, Lys218 and Lys220, are located near the activating 
monovalent cation binding site, so decreased activity from acetylation of these residues 
may arise from alteration of monovalent cation binding (155). Sequence alignment by 
COBALT indicates that the Lys218 position in HDAC1 is conserved in the corresponding 
Lys221 position in HDAC8 (130). As this monovalent site activates HDAC8 allosterically 
(89), it is feasible that HDAC8 activity could be regulated by modification at this location. 
However, no modifications at this site have yet been observed and post-translational 
modifications of HDAC8 need to be further examined. 
 
Concluding remarks 
Due to the prevalence and critical functions of acetylation within the cell, enzymes 
that catalyze acetylation and deacetylation are regulated by an ever-growing collection of 
mechanisms. One mode of regulating HDAC activity is alteration of the substrate 
preferences for these enzymes, which in turn affects cellular processes. This regulatory 
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mechanism may allow the cell to finely tune the substrate preference for many HDACs 
simultaneously by allowing the same stimuli to differentially alter the activity, localization, 
and interactions of each HDAC isozyme. Understanding the relationships between 
diverse cellular stimuli and HDAC regulation will provide insight into the intricacies of 
cellular processes and disease formation. Even though HDAC8 has been extensively 
studied, there are vast areas of the field in need of further characterization, such as 
identification of HDAC8 substrates and binding partners, subcellular localization, and 
regulatory mechanisms. In light of the complicated HDAC regulation landscape, there are 
likely many factors affecting substrate recognition that have yet to be discovered. As we 
continue to investigate these factors, we enhance our understanding of the cellular 
function of HDACs as well as inform the broader field of cellular regulation by post-
translational modifications. 
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Chapter 2  
Histone deacetylase 8 recognizes histone substrates via both long and short 
range interactions1,2 
Introduction 
Histone deacetylases (HDACs) are a group of 18 enzymes that catalyze the 
hydrolysis of the acetyl moiety from acetyl-lysine residues in proteins (5, 156). The 
acetylation of proteins, catalyzed by KATs, alters a variety of protein properties (3) such 
as protein-protein and protein-ligand interactions and protein stability. These changes can 
lead to alterations in a number of downstream cellular events (9, 10). Regulation of 
acetylation by the respective activities of KATs and HDACs is important for effective 
cellular signaling and cellular homeostasis, and aberrant acetylation/deacetylation can 
result in diseases ranging from neurological disorders (157, 158) to cancers (8, 159). 
Identifying the specific substrate set for each HDAC isozyme should lead to both an 
enhanced understanding of the role of HDACs in disease progression and better 
treatments of these diseases. 
Elucidating HDAC substrate specificity is challenging, at least partially because 
multiple HDACs may catalyze deacetylation of the same substrate. Additional 
complications for interpretation of the genetic studies are the difficulty in discerning 
whether the observed phenotypes are due to loss of a direct interaction between HDAC 
and another protein, inhibition of deacetylation of a substrate, or a downstream effect 
                                            
1 Reproduced from a manuscript in preparation: Pitcairn, C. A.*; Wolfson, N. A.*; Kuo, Y.-M.; Leng, K. R.; 
Andrews, A. J.; Fierke, C. A., Histone deacetylase 8 recognizes histone substrates via both long and 
short range interactions. *Co-first authors. In preparation.  
2 Noah A. Wolfson and Carol A. Fierke designed the study. Noah A. Wolfson designed the assays and 
performed the peptide and tetramer assays. Noah A. Wolfson, Carol Ann Pitcairn, and Katherine R. Leng 
purified proteins and performed octamer assays. Carol Ann Pitcairn and Katherine R. Leng assembled 
nucleosomes and performed nucleosome assays. Noah A. Wolfson, Carol Ann Pitcairn, and Carol A. 
Fierke analyzed the data. Yin-Ming Kuo performed and Andrew J. Andrews designed the histone mass 
spectrometry analysis. Noah A. Wolfson, Carol Ann Pitcairn, and Carol A. Fierke prepared the 
manuscript. 
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caused by perturbed acetylation of another HDAC substrate. Substrate identification is 
also difficult because HDAC-substrate interactions are weak (the Zn(II)-HDAC8 KM for a 
commercial HDAC8 peptide substrate is 1.1 mM (67)), in contrast to higher affinity protein 
binding partners that frequently form complexes with HDACs, which make pulldown 
experiments to identify substrates difficult. To mitigate these difficulties, the HDAC field 
has sought to identify sequence motifs that define each isozyme’s substrate specificity 
(59-61, 71). To date, most studies have utilized short peptides to determine HDAC 
recognition motifs. However, the validity of using peptides to mimic the recognition of 
proteins has not yet been established. The role of long-range interactions and secondary 
structural elements is still unexplored, as there has been little characterization of HDAC 
activity toward protein substrates. 
Many HDACs are found in complexes where the protein binding partners may 
moderate substrate recognition (160). HDAC8 has historically been considered to act 
independently of a protein complex (18, 59-61, 67, 71, 89, 105), and therefore assays 
with HDAC8 should reflect in vivo activity. HDAC8 is the best understood HDAC, with 
numerous crystal structures (18, 44, 105, 111-115, 161), kinetic studies (67, 89), and 
peptide substrate specificity studies (59-61, 71). This background provides a good 
platform for further investigation of HDAC substrate recognition. 
While a few putative HDAC8 substrates have been identified, such as ERRα (46) and 
SMC3 (47, 51), the protein substrate set for HDAC8 is currently unclear. Proteomic 
studies of HDAC8 have identified tens of substrates and/or binding partners (45-47, 65, 
66, 81, 95, 108), and a combination of HDAC8-specific inhibitors with proteomic studies 
have led to a number of additional proposed substrates, including ARID1A (80). Many of 
the putative HDAC8 substrates are difficult to purify and generation of singly acetylated 
proteins for kinetic study has been challenging, precluding in vitro HDAC8 assays. As a 
result, previous studies of HDAC8 selectivity have assayed non-specifically acetylated 
protein substrates (56, 57). Kinetic parameters measured using these substrates provide 
little information about substrate preference, as these proteins contain multiple acetylation 
sites that are likely deacetylated at different rates.  
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HDAC8 is localized to both the cytosol and nucleus (56, 57, 66, 83, 139), and has 
been suggested to catalyze the deacetylation of histones. In vivo H3 acetylation levels 
differ modestly upon the overexpression of HDAC8 in HEK293 cells (58); and the HDAC8 
inhibitor SAHA conjugated to pyrrole-imidazole polyamide (SAHA-PIP, also called Jδ) 
increased acetylated H3 levels and expression of HDAC8-regulated transcription factors 
in mouse embryonic fibroblasts (MEF) (162). HDAC8 can catalyze deacetylation of core 
histones and H3-based peptides in vitro (76, 143). However, H3 was not identified as a 
substrate in a proteomic study using an HDAC8-specific inhibitor (80). H3 can be 
prepared with singly acetylated lysines (131), and is amenable to mass spectrometric 
assays (163) so it is an interesting and practical target to study HDAC substrate specificity 
toward full-length proteins.  
To elucidate HDAC8 substrate specificity and recognition of protein substrates, we 
present the first detailed kinetic study of HDAC-catalyzed deacetylation of singly 
acetylated full-length substrates. Singly acetylated lysine side chains are incorporated 
into H3 using unnatural amino acid incorporation (131, 164) and we directly compare 
HDAC8 activity toward peptide substrates and protein substrates with the same primary 
sequences. Furthermore, we analyze the effect of large histone complexes (histone core 
octamer and mononucleosome) on HDAC8-catalyzed deacetylation of Ac-H3. We 
demonstrate that deacetylation of acetylated full-length H3 tetramer and octamer 
complexes catalyzed by HDAC8 is significantly (> 10-fold) faster than that of acetylated 
peptides, although the addition of nucleic acid to form mononucleosomes yields activity 
comparable to that of peptides. HDAC8 recognizes H3 peptide tetramer substrates largely 
based on the six amino acids proximal to the acetyl-lysine. These results indicate 
substrate specificity is determined by both long-range contacts and short range contacts 
for H3 substrates.  
 
Materials and methods 
Reagents 
Adenosine triphosphate (ATP), Coenzyme A, nicotinamide adenine dinucleotide 
(NAD+), L-malic acid, citrate synthase, malate dehydrogenase, and propionic anhydride 
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were purchased from Sigma. Peptides were purchased from Peptide 2.0 Inc. Zinc used 
to reconstitute HDAC8 was purchased as an ICP standard (GFS Chemicals) or atomic 
spectroscopy standard (Fluka) and the acetic acid standard was purchased from Ricca 
Chemical Company. Chelex 100 resin was purchased from Bio-Rad. Acetyl-lysine was 
purchased from Chem-Impex Chemical International Inc. All other materials were 
purchased from Fisher or Sigma and were of a purity >95 % unless otherwise noted. 
 
HDAC8 expression and purification 
HDAC8 was expressed and purified using the method described previously (67, 
72) with the following modifications. BL21 (DE3)pHD4-HDAC8-TEV-His6 E. coli were 
used to express HDAC8 in modified autoinduction-TB medium (12 g/L tryptone, 24 g/L 
yeast extract, 8.3g/L Tris-HCl, 4 g/L lactose, 1 g/L glucose, 10 mL/L glycerol, pH 7.4) 
supplemented with 100 µg/mL ampicillin and 200 μM ZnSO4. The cells were grown 
overnight at 30°C and harvested 20 - 24 hours post inoculation (9,000 x g, 10 min, 4°C). 
Alternatively, BL21 (DE3)pHD4-HDAC8-TEV-His6 E. coli cells were grown in 2xYT at 
37°C to an OD600 of 0.5. The temperature was reduced to 20°C and after one hour cells 
were induced with 0.5 mM IPTG and ZnSO4 was added to a final concentration of 200 
μM. Cells were harvested after 16 hours. The cell pellet was resuspended either in low 
salt DEAE buffer (50 mM HEPES, 200 μM ZnSO4, 1 mM TCEP, 50 mM NaCl, 5 mM KCl, 
1 µg/mL tert-Amyl methyl ether (TAME), 10 µg/mL PMSF, pH 7.8) or buffer A (30 mM 
HEPES pH 8, 150 mM NaCl, 5 mM KCl, 1 mM TCEP, 1 mM imidazole) and lysed using 
a microfluidizer (Microfluidics). In some cases, nucleic acids were precipitated by addition 
of 0.1% polyethylenimine (pH 7.9) followed by centrifugation (39,000 x g, 45 min, 4°C) 
and HDAC8 fractionated on a DEAE Sepharose column with a stepwise salt elution (50 
mM HEPES, 200 μM ZnSO4, 1 mM TCEP, 5 - 500 mM NaCl, 5 mM KCl, pH 7.8) and 
dialyzed against 50 mM HEPES, 100 mM NaCl, 25 mM imidazole, pH 7.8. HDAC8 with 
or without DEAE fractionation was further purified by metal affinity chromatography using 
Ni(II)-charged chelating sepharose fast flow (GE) and either a continuous (26 - 250 mM) 
or stepwise (50 mM/250 mM) imidazole gradient. Following TEV protease cleavage of the 
HIS tag during dialysis in Buffer A without imidazole, HDAC8 was separated from TEV 
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protease on a second Ni column. HDAC8 was then dialyzed against metal-free chelation 
buffer (25 mM MOPS pH 7.5, 1 mM EDTA, 1 mM TCEP, 5 mM KCl) overnight, followed 
by metal-free buffer (25 mM MOPS pH 7.5, 1 mM TCEP, 5 mM KCl). In some cases, the 
protein was further purified by size exclusion chromatrography prior to metal-free dialysis 
using a HiPrep 16/60 Sephacryl S200 HR column (GE) (30 mM HEPES pH 8, 150 mM 
NaCl, 1 mM TCEP). Finally, residual EDTA was removed with a PD-10 column (GE) (25 
mM HEPES pH 8, 127 mM NaCl, 3 mM KCl, and 1 mM TCEP) and HDAC8 was 
concentrated, aliquoted, and stored at -80°C. HDAC8 activity was confirmed using the 
Fluor-de-Lys assay as described previously (67, 70, 165). 
 
HDAC assay 
Assays of deacetylation of acetylated peptides catalyzed by HDAC8 were 
performed using an enzyme-coupled assay, as previously described (72) with a few 
modifications. Briefly, depending on their solubility, peptides were dissolved in water, 50% 
acetonitrile, or 10% DMSO. The dissolved peptide solutions were chelated by incubation 
with Chelex resin at 4°C for more than three hours. Peptide concentrations were 
measured using the fluorescamine assay or absorbance at 280 nm, as previously 
described (72, 166). Peptides (0-100 µM) were incubated in HDAC8 assay buffer (50 mM 
HEPES, 137 mM NaCl, 3.7 mM KCl, pH 7.8) for 10 minutes at 30°C before initiating the 
reactions with the addition of 0.5 µM Zn(II)-HDAC8. Acetate formation was coupled to 
NADH formation measured by an increase in fluorescence (Ex = 340 nm, Em = 460 nm). 
Initial rates were fit to the linear portion of the time versus product curve. 
 
Histone expression and purification 
Recombinant H3 histones containing a single acetylated lysine were expressed 
and purified as previously described (131) with a few modifications. The acetyl-lysine is 
incorporated into expressed proteins at an amber codon site (TAG) using a tRNA-cognate 
tRNA synthetase pair encoded on the pAcKRS-3 plasmid (131). Amber codons were 
substituted for the K9, K14, and K56 codons in the His6-tagged histone H3 sequence in 
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the PCDF PyLT-1 plasmid (generous gift from Jason Chin) (131, 164) using Quikchange 
PCR. BL21 (DE3) cells were transformed with the mutant or wild type PCDF PyLT-1 and 
pAcKRS-3 plasmids for H3 expression. Expression plasmids for preparation of 
recombinant H2A, H2B, and H4 Xenopus histones were generous gifts from Geeta 
Narlikar. BL21(DE3) cells were transformed with the respective plasmids and grown in 
LB or 2xYT supplemented with the proper antibiotic (kanamycin and streptomycin for H3, 
or ampicillin for H2A, H2B, and H4) at 37°C until reaching an OD600 of 0.7. To express 
full-length histone H3 proteins with a single acetyl-lysine residue 20 mM nicotinamide and 
10 mM acetyl-lysine were added to the medium follow by induction of protein expression 
by the addition of 0.5 mM IPTG 30 minutes later. For expression of the other histones, 
the cells were induced with 0.5 mM IPTG. The cultures were harvested 3 - 4 hours after 
induction (5,053 - 9,000 x g, 10-15 min, 4°C). The cell pellets were stored at -80°C. 
Histones were purified according to established protocols (167, 168). Cell pellets 
were resuspended in Phosphate Buffered Saline (PBS) supplemented with 20 mM 
nicotinamide and lysed using the M110L Microfluidizer (Microfluidics). The lysate was 
centrifuged (26,892 x g or 39,000 x g, 45 min, 4°C) and the supernatant was discarded. 
The pellets were resuspended and centrifuged twice in PBS with nicotinamide and 1% 
(v/v) Triton X 100 and twice in PBS with nicotinamide. The pellets were then macerated 
in DMSO and incubated at room temperature for 30 - 60 minutes. After incubation, 6 M 
guanidinium chloride, 20 mM Tris, and 2 mM dithiothreitol (DTT), pH 8 was added and 
incubated with shaking at 37°C for at least 1 hour. Subsequent purification of H3 was 
performed under denaturing conditions, as in (131) with the buffer modified to include 7 
M urea and 1 mM TCEP, using two nickel columns as described for HDAC8: a first nickel 
column with elution by an imidazole gradient, followed by cleavage of the His-tag with 
TEV protease, and then a second nickel column to remove the protease (131). If the 
protease precipitated out of solution during dialysis, the second nickel column was 
omitted. For H2A, H2B, and H4 purification, the DMSO mix was centrifuged as above and 
dialyzed against 7 M urea, 100 mM sodium acetate (NaOAc), 20 mM Tris, 100 mM NaCl, 
pH 7.5 overnight at 4°C. The dialyzed protein extract was applied to an SP sepharose 
column, washed (7 M urea, 100 mM NaOAc, pH 5.2) and eluted stepwise with SP buffer 
(7 M urea, 100 mM NaOAc, pH 7.5) supplemented with 300 mM, 500 mM or 1 M NaCl. 
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The fractions containing H2A, H2B, and H4 (confirmed by SDS-PAGE) were collected 
and dialyzed at least twice in ultrapure water (Milli-Q, Millipore) containing 2 mM 2-
mercaptoethanol (BME). After dialysis, the histones were lyophilized and stored at -80°C. 
Tetramer, octamer, and nucleosome were reconstituted as previously described (131, 
167, 168). Tetramer and octamer were purified by size exclusion chromatography. 
Tetramer, octamer, and nucleosome were dialyzed with and without EDTA to remove 
contaminating metals. Octamer and nucleosome were subsequently treated with Chelex 
resin for at least 1 hour at 4°C to ensure metal removal. Nucleosome was stored in 20% 
glycerol, 20 mM HEPES pH 7.5 – 7.8, 1 mM TCEP.  
 
Protein deacetylation assays 
Apo-HDAC8 was reconstituted with stoichiometric Zn(II) for 1 hour on ice in 
HDAC8 assay buffer (50 mM HEPES, 137 mM NaCl, 3.7 mM KCl, pH 7.8) (67). Histone 
complexes were incubated in assay buffer (above) for 10 minutes at 30°C before initiating 
reactions by addition of 0 - 15 μM Zn(II)-HDAC8. The final concentration of NaCl in the 
assays with octamer was 137 or 239 mM NaCl. Reactions were quenched by addition of 
25% trichloroacetic acid at varying times. The samples were incubated for 30 minutes on 
ice and then centrifuged (16,000 x g, 10 min, 4°C). The supernatant was removed and 
the pellet was washed 2 times with acetone and centrifuged after each wash. The pellet 
was dried in a SpeedVac System (Thermo Savant) and frozen at -80°C. The pellets were 
resuspended in 2 µL propionic anhydride and 6 µL ammonium hydroxide (NH4OH) and 
incubated at 51°C for 1 hour. 30 µL of 50 mM NH4HCO3 was added to each tube, and the 
pH of each tube was adjusted to 7 – 9 using NH4OH. Then 0.2 μg sequence grade trypsin 
(Promega) was added and incubated overnight at 37°C. Then 3.5 µL of 10% formic acid 
was added to each tube, and the tubes were centrifuged (16,000 x g, 10 min, 4°C). The 
supernatants were transferred to autosampler mass spectrometry vials and deacetylation 
was quantified by MS/MS mass spectrometry analysis in the lab of Andrew Andrews (Fox 
Chase Cancer Center) as previously described (169). The kinetic data were analyzed 
using a single exponential decay:
 
Substrate
(Substrate+Product)
 = e-kobs × t. Nucleosome reaction initial 
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rate data were fit to a linear equation. Variation of mass spectrometry results between 
days was less than 20%. Data were fit using Prism (GraphPad Software, Inc.). 
A concern with assaying octamer under low salt conditions (HDAC8 assay buffer 
and less than 240 mM NaCl) is that the octamer would disassemble into H3/H4 tetramer 
and H2A/H2B dimers. However the K1/2, inactivation for NaCl-dependent inhibition of HDAC8 
(320 ± 140 mM for Co(II)-HDAC8) precluded higher salt concentrations (89). The 
observed kinetics for the tetramers and octamers are significantly different and suggest 
that the octamers, once assembled, remain intact during our assays. 
 
Results 
Sequence determines peptide specificity of HDAC8 
To date, many papers determining HDAC substrate specificity have utilized 
acetylated peptides (60, 61, 71, 73), predicated on the assumption that HDAC8 uses the 
same interactions to recognize peptide and full-length protein substrates. To test the 
validity of this assumption, we examined the kinetics of deacetylation of peptides 
mimicking three biologically relevant acetylation sites on the putative HDAC8 substrate 
histone H3 for comparison to HDAC8 activity toward full-length proteins (Figure 2-1) and 
Table 2-1). We utilized histone H3 because histone H3 was shown previously to be 
amenable to non-natural acetyl-lysine incorporation (131). Two sites (H3K9ac and 
H3K14ac) are found within close proximity to each other on the N-terminal tail and share 
an unfolded secondary structure. Because these sites differ only in amino acid sequence, 
the role of primary sequence in HDAC8 substrate specificity can be probed. A third site 
(H3K56ac), located on an α-helix in the globular structure of H3 (Figure 2-1), allows the 
role of secondary structure in HDAC8 substrate recognition to be investigated. Peptides 
containing 7 amino acids (7-mer) representing the 3 amino acids upstream (-3) and 
downstream (+3) of the acetyl-lysines were synthesized. This complements the activity of 
HDAC8 with peptides containing 3 to 6 amino acids, which were used previously (60, 61, 
71). The rates of HDAC8-catalyzed deacetylation of the H3K9ac, H3K14ac, and H3K56ac 
peptides were measured under multiple turnover conditions, using an assay coupling 
acetyl-lysine deacetylation to the formation of NADH (72). The initial rates were linearly 
45 
 
dependent on peptide concentration, indicating that the KM values are higher than the 
peptide concentrations used in this assay (> 100 µM). The value of kcat/KM, the specificity 
constant, is the best parameter to compare the activity of HDAC8 toward multiple 
substrates (170-172). HDAC8 has the highest catalytic efficiency for catalyzing hydrolysis 
of the H3K56ac peptide (kcat/KM = 78 ± 8.0 M-1s-1), followed by the H3K9ac                            
(56 ± 6.0 M-1s-1) and H3K14ac (8.0 ± 0.70 M-1s-1) peptide (Table 2-2). 
 
 
 
 
Figure 2-1: Structure of histone H3/H4 tetramer with highlighted acetylation sites 
Structure of histone H3/H4 tetramer (167) with boxes around the sites which were acetylated. H3 
is shown in blue and H4 in yellow. H3 residues 1 to 20 are shown in an extended conformation 
as they have no discrete fold within the crystal structure. The structure was generated from PDB 
ID 1AOI using VMD.
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Table 2-1: Sequences of peptides used in this study 
All peptides contained N-terminal acetylation and C-terminal carboxamide. 
 7-mer peptide 13-mer peptide 
H3K9ac Ac-TARKacSTG-NH2 Ac-TKQTARKacSTGGKA-NH2 
H3K14ac Ac-TGGKacAPR-NH2 Ac-RKSTGGKacAPRKQL-NH2 
H3K56ac Ac-RYQKacSTE-NH2 Ac-EIRRYQKacSTELLI-NH2 
 
 
Table 2-2: Catalytic efficiencies for deacetylation of histone substrates by 
HDAC8a 
Substrate 
7-mer 
Peptide 
13-mer 
peptide 
17-mer 
peptide 
Tetramer Octamer Nucleosome 
kcat/KM
 
(M-1
 
s-1) kmax/K1/2
 
(M-1
 
s-1) 
H3K9ac 56 ± 6 51 ± 3 120 ± 11 >24,000 3700 ± 100 28 ± 3 
H3K14ac 8.0 ± 0.7 21 ± 4 - 2,500 ± 70 1,000 ± 200 - 
H3K56ac 78 ± 8 100 ± 10 - 4,000 ± 600 - - 
a HDAC8 activity was measured and catalytic efficiencies were determined as described 
in the Experimental Procedures and the legend of Figures 2-4. 
 
 
To probe the importance of amino acids further removed from the acetyl-lysine in 
determining substrate selectivity, longer peptides (13 and 17 amino acids) were assayed 
(Table 2-1). H3K9ac was assayed in the context of each peptide length and protein 
complex (tetramer, octamer, and nucleosome). The H3K14ac and H3K56ac sites were 
assayed as 7 and 13 amino acid peptides and select protein complexes for comparison. 
Increasing the length of the peptides from 7 to 13 amino acids had little to modest effects 
on catalytic efficiency (0.9 to 2.6-fold change) and did not affect the substrate specificity 
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trend of K56ac > K9ac > K14ac. A 17 amino acid peptide representing the H3K9ac site 
also showed less than a three-fold increase in kcat/KM compared to the 7-amino acid 
peptide (56 ± 6.0 M-1s-1 vs 120 ± 11 M-1s-1; Table 2-2). The modest differences in activity 
toward the longer peptides indicate that the primary sequence surrounding the acetylated 
lysine residue (+/- 3 of the acetyl-lysine) is the largest determinant of selectivity in peptide 
substrates, consistent with previously published data (59-61, 71). 
 
HDAC8 catalyzes deacetylation of H3/H4 tetramers more efficiently than H3 peptides 
To investigate the importance of long-range HDAC8-substrate interactions in 
substrate recognition, we compared the rates of peptide deacetylation to the rates of full-
length protein deacetylation catalyzed by HDAC8. A major challenge in identifying HDAC 
substrates is determining the rates of deacetylation for individual acetyl-lysine sites, as 
HDAC substrates, such as histones, may have multiple acetylated lysine residues. We 
prepared proteins with single acetyl-lysine sites using the method of recombinant non-
natural amino acid incorporation developed by Jason Chin’s group. (131, 164) Q-TOF 
LC/MS of modified histone H3 demonstrated a mass change corresponding to an added 
acetylated lysine (data not shown). To stabilize H3, it was assembled into a H3/H4 
tetramer. We measured HDAC8 activity toward the singly acetylated H3 proteins 
acetylated at the H3K9, H3K14, and H3K56 sites under single turnover (STO) conditions 
(3-15 µM HDAC8 and 0.5 µM acetylated H3/H4 tetramer) and assayed deacetylation by 
mass spectrometric analysis. STO was used to minimize the amount of singly acetylated 
H3/H4 tetramer. An exponential decay was fit to the reaction progress curves to generate 
the observed rate constants, kobs (Figure 2-2A). The three sites showed differential 
dependence on the concentration of HDAC8. H3K9acH3/H4 tetramer has little 
dependence on HDAC8 concentration indicating that the enzyme concentration is above 
the K1/2 for the reaction, even at the lowest concentration (3 µM). In contrast, 
H3K14acH3/H4 and H3K56acH3/H4 tetramers show hyperbolic and nearly linear 
dependence, respectively, on the HDAC8 concentration. Assuming rapid equilibration of 
the HDAC8-H3/H4 complex, a hyperbolic fit to these data yield values of kmax/K1/2 equal 
to >24,000 M-1s-1, 2500 ± 70 M-1s-1, and 4000 ± 600 M-1s-1 for the H3K9ac, H3K14ac, and 
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H3K56ac tetramers, respectively (Figure 2-2B–D and Table 2-2). Each of these catalytic 
efficiencies is 10- to 100-fold faster than the corresponding peptide kcat/KM values. These 
specificity parameters can be directly compared assuming that product release is not rate 
limiting under multiple turnover conditions. Previous data suggest that the deacetylation 
step is likely the rate-limiting step (see discussion), also suggesting that K1/2 and KM reflect 
KD (67, 76). These data demonstrate that interactions outside of short peptide sequences 
are important for enhancing HDAC8 substrate selectivity. The observed increase in 
catalytic efficiency is mainly due to a decrease in K1/2 in the STO reaction relative to KM 
for the peptides, suggesting enhanced binding of the protein substrates. While H3 
peptides have KM values higher than 100 µM, (data not shown) the H3K9ac/H4 tetramer 
has a K1/2 value < 1 µM and the H3K14ac/H4 tetramer has a K1/2 = 19 ± 1 µM. These 
differences suggest that long-range interactions enhance activity of HDAC8 toward full-
length substrates. 
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Figure 2-2: Single turnover deacetylation of singly acetylated H3/H4 tetramers 
A. Sample data from deacetylation reaction with 7 µM HDAC8 and 0.5 µM H3K9ac/H4 tetramer 
(1 µM acetyl-lysine) measured using mass spectrometry. Data are best described by a single 
exponential. B. Dependence of apparent deacetylation rate constant of H3K9ac/H4 on the 
concentration of HDAC8. The kobs is almost independent of [HDAC8]. Three separate hyperbolic 
fits bracket potential K1/2 values: K1/2 = 0.25 µM (red); K1/2 = 0.5 µM (black); K1/2 = 1 µM (blue). 
These fits demonstrate that the K1/2 is < 1 µM and kmax/K1/2 is > 24,000 M-1s-1. The data points are 
from multiple measurements in a single reaction at each HDAC8 concentration. C. Dependence 
of deacetylation rate of H3K14ac/H4 on the concentration of HDAC8. The data points are from 
multiple measurements in a single reaction at each HDAC8 concentration. A hyperbolic fit 
indicates that the kmax/K1/2 is 2,500 ± 70 M-1s-1. D. Dependence of deacetylation rate of 
H3K56ac/H4 on the concentration of HDAC8. The data points are from multiple measurements in 
a single reaction at each HDAC8 concentration. A linear fit indicates that the kmax/K1/2 is 4,000 ± 
600 M-1s-1.
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While the increased substrate length enhances substrate recognition in all three 
cases, the ratio of HDAC8 catalytic efficiency toward the protein versus peptide 
substrates is different for each acetylation site. The largest observed enhancement in 
catalytic efficiency is for the H3K9ac substrates (>400-fold increase with the tetramer 
substrate), followed by H3K14ac (~300-fold) and then H3K56ac (~50-fold). In particular, 
the modest selectivity of HDAC8 for catalyzing cleavage of H3K56ac peptide compared 
to H3K9ac peptides is not maintained in the tetramer substrates, as would be expected if 
sequence was the only determinant of substrate recognition. In the context of a full-length 
protein, the H3K9ac site on the H3 tail is more accessible than the H3K56ac site, which 
is within a helix, likely explaining the reversed preference of these two sites. The fact that 
H3K14ac is the least favorable substrate may be dictated by the amino acid sequence, 
since structurally it is expected to be similar to H3K9ac. Another explanation of decreased 
HDAC8 activity toward the H3K56/H4 site is that the binding surface of an α-helix is better 
characterized by the -3, 0, and +3 residues and therefore a linear peptide may not be a 
good representative of this site.  
 
Octamer substrates fall between peptides and tetramers in substrate specificity profile 
To further examine substrate selectivity, we measured the deacetylase activity of 
HDAC8 toward histone octamer complexes containing single acetylation sites at either 
H3K9ac or H3K14ac. Histone octamers were reconstituted with two copies of each core 
histone (H2A, H2B, H3Kac, and H4). The deacetylation rate catalyzed by HDAC8 was 
measured under single turnover conditions and analyzed as described above. The 
resulting kobs values for H3K9ac octamer are linearly dependent on the HDAC8 
concentration (Figure 2-3), yielding a kmax/K1/2 value of 3700 ± 100 M-1s-1. Deacetylation 
of the H3K14ac octamer has a hyperbolic dependence on HDAC8 concentration leading 
to a value of kmax/K1/2 of 1,000 ± 200 M-1s-1. This catalytic efficiency is decreased 3-fold 
compared to the H3K14ac/H4 tetramer and is ~45-fold faster than the deacetylation of 
H3K14ac peptides. These data suggest that the K14ac site is recognized similarly in the 
octamer and the tetramer by HDAC8. The catalytic efficiency for the H3K9ac octamer 
site, however, is decreased 12-fold compared to that of H3K9ac tetramer. 
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Figure 2-3: Single turnover deacetylation of singly acetylated H3 octamers 
A. Reaction progress curves for deacetylation of H3K9ac octamer catalyzed by 2.5 µM (■), 5 µM 
(▲), and 7.5 µM (▼) HDAC8. Data points are from multiple measurements in a single reaction at 
each HDAC8 concentration, and a single exponential was fit to the data. B. Dependence of 
apparent deacetylation rate constant of H3K9ac octamer on the concentration of HDAC8. Data 
points are from multiple measurements in a single reaction at each HDAC8 concentration, and 
error bars on kobs values represent errors calculated from the exponential fits. A linear fit of the 
data indicates that the kmax/K1/2 is 3700 ± 100 M-1s-1. C. Dependence of apparent deacetylation 
rate constant of H3K14ac octamer on the concentration of HDAC8. The data points are from 
multiple measurements in a single reaction at each HDAC8 concentration. A hyperbolic fit 
indicates that the kmax/K1/2 is 1,000 ± 200 M-1s-1. 
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 HDAC8-catalyzed deacetylation of acetylated nucleosome is slow 
HDACs involved in transcriptional regulation are likely to encounter nucleic acid-
bound substrate proteins. To test the specificity for HDAC-catalyzed deacetylation of a 
larger substrate complex containing nucleic acid, we incorporated H3K9ac into 
recombinant mononucleosomes. These were assayed in the same manner as the 
tetramer and octamer substrates (Figure 2-4). Surprisingly, the addition of nucleic acid to 
the octamer to assemble nucleosomal substrates significantly decreased HDAC8 
catalytic efficiency at this site, kmax/K1/2 = 28 ± 3 M-1s-1. This is two-fold lower than the 
kcat/KM for the H3K9ac 7-mer peptide and ~900 fold slower than deacetylation of this site 
in the H3/H4 tetramer. Adding the DNA component of the nucleosome to an assay with 
the Fluor-de-Lys peptide resulted in only a 25% decrease in HDAC8 activity (data not 
shown); thus the 130-fold decrease in HDAC8 activity observed between octamer and 
nucleosome substrates is unlikely to be due to DNA inhibition of the enzyme. 
 
 
Figure 2-4: Single turnover deacetylation of singly acetylated H3 nucleosome 
Progress curves for deacetylation H3K9ac nucleosome catalyzed by 0 – 7.5 µM HDAC8 were fit 
linearly to calculate initial rates. The data points are from multiple measurements in a single 
reaction at each HDAC8 concentration, and error bars represent errors calculated from the initial 
rate fits. A linear fit of the data indicates that kmax/K1/2 28 ± 3 M-1s-1. 
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Discussion 
To understand the role of HDACs in cellular regulation, it is important to determine 
the substrate specificity and the molecular determinants of substrate recognition for each 
isozyme. Until now, HDAC recognition of protein substrates has largely been tackled by 
studying activity toward peptide substrates, which typically interact with less than an 8 Å 
x 20 Å area of an approximately 2025 Å2 binding surface (111). Within this larger binding 
interface there may be many more HDAC8-protein substrate contacts, including potential 
recognition hotspots and negative interaction sites. With a peptide, a single interaction of 
0.5 - 2 kcal/mol can alter the catalytic efficiency by 50-fold (72). With a larger substrate, 
the increased number of interaction sites could overcome the 2 kcal/mol of energy 
obtained from local interactions. There is a precedent for distal HDAC8-substrate 
interactions in recognition of a long peptide substrate; an upstream KRHR motif (based 
on histone H4) increases HDAC8-catalyzed deacetylation of an acetylated peptide (61). 
To investigate the role of long-range interactions on HDAC8 substrate recognition, we 
measured HDAC8-catalyzed deacetylation of substrates of increasing complexity, from 
peptide to full-length protein to protein-nucleic acid complex.  
To analyze HDAC8-catalyzed deacetylation of peptide and protein substrates, we 
compared multiple turnover reactions (kcat/KM) of peptide substrates to single turnover 
(kmax/K1/2) reactions of the protein substrates. This was due mainly to the challenge of 
preparing singly acetylated substrates. The apparent second order rate constants 
measured under these two conditions measure comparable reactions since a variety of 
data suggest that the hydrolytic step is the slowest step for peptide substrates preceded 
by rapid, equilibrium substrate binding. For example, HDAC8 catalyzes deacetylation of 
trifluoroacetate peptide substrates faster than non-fluorinated peptides (kcat), ruling out 
product release as the rate-limiting step (76). Furthermore, the kcat/KM values for peptides 
are significantly slower than diffusion control (102-103 M-1s-1 vs 107-108 M-1s-1) and the KM 
values are large (> 100 µM), suggesting that substrate association is also not rate-limiting. 
However, additional experiments will be done to further demonstrate that the single 
turnover and multiple turnover data are comparable. 
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The protein substrates have remarkably enhanced catalytic efficiency in 
comparison to the comparable peptide. Previous analysis of activity toward acetylated 
peptide substrates has shown that HDAC8 prefers substrates with aromatic amino acids 
on the C-terminal side of the acetyl-lysine (+1 position) (60, 71). Based on these empirical 
data, the mediocre catalytic efficiency of the histone H3-based peptides                                 
(10 to 102 M-1s-1) (Table 2-2) was predicted. The interactions between the 7-mer peptides 
and HDAC8 occur within a ~10 Å radius of the active site. HDAC8 catalyzed hydrolysis 
of the acetylated H3/H4 tetramers, which still lack an aromatic residue in the +1 position, 
is 50 - 400 times faster than the corresponding peptides. Thus, HDAC8-tetramer 
interactions that are absent with the peptide substrates enhance HDAC8 substrate 
recognition. The catalytic efficiency of the acetylated H3/H4 tetramer increased by 2-4 
kcal/mol, lowering the activation energy1 and demonstrating the importance of longer 
range interactions for protein substrate recognition by HDAC8. The H3K9ac/H4 tetramer 
has both the highest value of kmax/K1/2 and the largest increase in activity compared to the 
corresponding peptide (>400-fold) that may be due to one or a few strong interactions or 
a number of weak interactions. However, the lower tetramer-induced enhancement 
values for deacetylation of H3K14ac (300-fold) and H3K56ac (50-fold) tetramers indicate 
that this is not a nonspecific protein-protein-interaction. The Mrksich group previously 
demonstrated that distal HDAC8-substrate interactions can have a significant effect on 
peptide deacetylation and proposed an exosite model which involves binding at the active 
site and at a second location elsewhere on the HDAC8 surface (61). Perhaps the slightly 
shifted interaction of HDAC8 with the K14ac and K56ac sites on the tetramer offers less 
rate enhancement due to a decrease in additional, non-active site binding interactions, 
and therefore these sites have limited full-length protein rate enhancement. Additionally, 
the different HDAC8 catalytic efficiencies likely reflect both variations in the interactions 
between HDAC8 and substrate residues surrounding the acetyl-lysine, as previously 
demonstrated (61) and differences in accessibility of the acetyl-lysine to the active site. 
The crystal structure of HDAC8 is useful in visualizing the potential protein-protein 
interactions involved in full-length substrate recognition. In many crystal structures 
                                            
1 Δ Δ G = RT*ln((kcat/KM1)/ (kcat/KM2)) 
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HDAC8 forms a dimer at the substrate binding interface, as part of the fundamental crystal 
unit. The HDAC8 substrate binding interface is a flexible 45 Å x 45 Å surface containing 
multiple interaction sites, including 10 van der Waals interactions and 6 hydrogen bonds 
between the HDAC8 dimers (112, 115). The interactions observed between these two 
HDAC8 units provide a framework for explaining the differences in catalytic efficiency 
observed for peptide and full-length substrates. The 2-4 kcal/mol difference between the 
peptide and tetramer affinity could be explained by the van der Waals interactions and/or 
hydrogen bonds that are observed in the dimeric crystal structures. The dimer also 
visualizes repulsive charge-charge interactions. The attractive and repulsive protein-
protein interactions likely work in concert to determine the HDAC8 substrate specificity. 
The HDAC8-substrate binding interface is mainly composed of flexible loops. Recent 
crystal structures have shown conformational changes in HDAC8 loops L1 and L2 upon 
binding of largazole analogs, as well as different L1 and L2 loop conformations between 
two monomers of the same crystal structure, demonstrating the adaptability and 
importance of these loops in HDAC8 inhibitor and substrate binding (44). These loops 
likely are important for conferring structural selectivity for large protein substrates.  
Further increasing the size and complexity of the substrate protein complex in the 
histone octamer did not further enhance the catalytic efficiency. The H3K14ac histone 
octamer was deacetylated with a similar catalytic efficiency to the corresponding 
tetrameric substrate, suggesting that interactions with the tetramer are sufficient to 
explain HDAC8 substrate interactions in that case. In contrast, the H3K9ac octamer was 
deacetylated at least 12 fold slower than the tetrameric substrate. This is likely due to 
decreased accessibility of the acetyl-lysine to the HDAC8 active site, although other 
effects including protein-protein interaction, and allosteric effects could be involved in the 
recognition of these proteins. Addition of the nucleic acid component to form a 
nucleosome converted the most efficient substrate, the H3K9ac/H4 tetramer, to a 
substrate that is less efficiently deacetylated by HDAC8 than the corresponding peptide. 
The drastic decrease in kmax/K1/2 for nucleosomal H3K9ac likely reflects decreased 
substrate accessibility due to precluded binding of the substrate to the distal HDAC8 
binding interface, blocking the HDAC8 active site tunnel, or direct binding of the acetyl-
lysine on the H3 tail by the nucleosome. One possibility is that the positively charged 
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histone H3 tail interacts with the negatively charged DNA in the nucleosome and is no 
longer accessible to HDAC8. The data are consistent with proteomic studies suggesting 
that histones are not physiological substrates for HDAC8 (80). However, the low activity 
observed for nucleosomal acH3K9ac does not completely preclude deacetylation by 
HDAC8 under all conditions. The chromatin structure can be altered by transcription 
factors, DNA binding proteins, chromatin remodeling factors and other proteins, possibly 
complexed with HDAC, to alter the accessibility of the acetylated lysines in the tail of H3.  
This work presents a study of HDAC8 substrate recognition and the first report of 
detailed kinetics for HDAC8-catalyzed deacetylation of singly acetylated full-length 
protein substrates. HDAC8 catalyzes deacetylation of tetrameric protein substrates with 
catalytic efficiencies >10-fold greater than corresponding peptide substrates. Larger 
protein complex substrates have decreased catalytic efficiencies. The differences in 
catalytic efficiency represent the effects of HDAC8-protein substrate interactions which 
are absent in HDAC8-peptide interactions. This work provides a foundation for the study 
of full-length protein substrate specificity of HDACs.  
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Chapter 3  
Metal switching specificity: A novel regulatory mechanism for HDAC81,2 
 
Introduction 
Protein lysine acetylation is an enzymatically reversible post-translational 
modification. Acetylation is catalyzed by twenty lysine acetyl transferases (KATs) while 
hydrolysis of the acetyl moiety is catalyzed by eighteen lysine deacetylases, including the 
metal-dependent histone deacetylases (HDACs) and the NAD(+)-dependent sirtuins 
(SIRTs). The balance of the enzymatic activities of HDACs and KATs is involved in many 
cellular processes (173). These enzyme families control the acetylation state of the >3800 
acetylated sites in the mammalian proteome (1), and it is therefore important to 
understand the mechanisms by which the enzyme specificities are regulated (11, 174). 
Elucidating the determinants of HDAC substrate specificity is important for understanding 
the regulatory mechanisms of acetylation/deacetylation in the cell and for engineering 
selectivity in therapeutics.  
HDAC8 is a member of the class I metal-dependent HDACs. HDAC8 is well 
understood biochemically, but its cellular role and regulation are still under investigation. 
It is primarily expressed in human smooth muscle cells and is found in both the nucleus 
and the cytoplasm (56, 65). The precise HDAC isozyme substrate sets remain largely 
undefined, but the list of putative HDAC8 substrates includes nuclear proteins, such as 
structural maintenance of chromosomes protein 3 (SMC3) (47, 51, 80, 175) and histone 
proteins (57), and several cytosolic substrates such as estrogen-related receptor alpha 
                                            
1 Reproduced in part from manuscript in preparation: Joseph, C. G.*; Pitcairn, C. A.*; Scholle, M. D.; 
Mrksich, M.; Fierke, C. A., Metal switching specificity: A novel regulatory mechanism for HDAC8. *Co-first 
authors. In preparation. 
2 Caleb G. Joseph performed the SAMDI high-throughput screen, Carol Ann Pitcairn performed the peptide 
assays in solution, Michael D. Scholle performed the MALDI mass spectrometry, and Milan Mrksich 
designed the SAMDI experiments. Caleb G. Joseph and Carol Ann Pitcairn analyzed the data, and Carol 
Ann Pitcairn, Caleb G. Joseph, and Carol A. Fierke wrote the manuscript.  
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(ERRα) (46, 73). HDAC8 is also sensitive to monovalent cation concentrations. The 
structure demonstrates two monovalent ion binding sites (18, 44, 105, 111-115); the site 
farther from the active site is activating, while the site near the catalytic metal is inhibitory 
(89). HDAC8 was originally proposed to be a zinc-dependent enzyme since zinc co-
purified with the enzyme and was observed in the first HDAC8 crystal structure (115, 
132), however several metal ions activate the enzyme and substrate specificity and 
inhibitor efficacy in vitro are dependent on the metal identity (67). The trend for kcat/KM 
values catalyzed by metal-substituted HDAC8 is Co(II) > Fe(II) > Zn(II) > Ni(II) > Mn(II) 
(67). Furthermore, the inhibition constant, Ki, of the T-cell lymphoma drug suberoylanilide 
hydroxamic acid (SAHA) follows a similar dependence on the identity of the metal bound 
to HDAC8 (Co(II) < Fe(II) < Zn(II)) (18). 
Crystal structures of metal-substituted HDAC8 have not explained the differential 
activation and inhibition. Structures of HDAC8 bound to Fe(II), Co(II), Mn(II), and Zn(II) 
and hydroxamic acid inhibitors demonstrate a common penta-coordinate, square 
pyramidal geometry for the metal-substituted enzyme forms (18). These structures are a 
snapshot and do not show conformational changes or dynamic interactions that may 
occur when substrate is bound to the enzyme. Additionally, the hydroxamic acid inhibitor 
likely forces the active site into the metal coordination state observed in the crystal 
structure regardless of the identity of the bound metal ion.  
Based on cellular metal concentrations and the affinity of HDAC8 for each metal, 
either Zn(II) or Fe(II) could activate the enzyme in vivo. Exchangeable Zn(II) is less 
available than Fe(II) in cells; although concentrations differ with cell type and subcellular 
location, the ranges are 5 pM – 2 nM exchangeable zinc and 0.2-12 μM exchangeable 
iron (136, 176-181). HDAC8 has a 106-fold higher affinity for Zn(II), at 5 ± 1 pM, compared 
to Fe(II) and is not activated by Fe(III) (18, 67, 182). Lysine deacetylase activity in both 
bacterial and mammalian cell lysates is oxygen sensitive, suggesting Fe(II)-dependent 
activity (67, 183). Moreover, immunopurified HDAC8 overexpressed in human tissue 
culture cells demonstrates oxygen-sensitive activity (183). Taken together, these data 
suggest that iron may play a role in cellular HDAC8 activation and regulation and 
demonstrate the importance of determining which metal/s activate HDAC8 in vivo.  
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Because cellular metal concentrations are dynamic, sometimes changing very 
rapidly (184), metalloproteins could be equipped to adapt to altered metal levels by either 
recognizing metal flux as a trigger for an alternate activity level or substrate set or by not 
exchanging metal ions rapidly and thus retaining the original metal. In bacteria there is a 
precedent for metal switching in UDP-3-O-((R)-3-hydroxymyristoyl)-N-acetylglucosamine 
deacetylase (LpxC) and N-acetyl-1-D-myo-inosityl-2-amino-2-deoxy-alpha-D-
glucopyranoside deacetylase (MshB), which switch between Fe(II) or Zn(II)(185, 186), 
and a precedent for metal-dependent substrate and inhibitor specificity for the E. coli 
methionine aminopeptidase (EcMetAP), which is activated by Co(II), Mn(II), Fe(II), or 
Zn(II) in vitro (187, 188). Similarly metal alteration in human HDAC8 may be a novel 
regulatory mechanism for this and other eukaryotic metalloenzymes. 
Prompted by the enhanced activity of Fe(II)-HDAC8 and the oxygen sensitivity of 
this enzyme in cell extracts, we further investigated the role of the identity of the catalytic 
metal ion in regulating HDAC8 activity and substrate specificity in vitro. Here we show 
that the activity and substrate selectivity of HDAC8 is dependent on the metal ion in the 
active site; the specificity toward peptide substrates changes when the active-site metal 
ion is switched between Fe(II) and Zn(II). In cells, HDAC8 may switch metals with 
changing cellular availability of Fe(II) and Zn(II), potentially initiated by oxidative stress 
(18, 189). In our proposed model, HDAC8 is Fe(II)-bound in cells until a change in metal 
homeostasis increases the exchangeable Zn(II) concentration, yielding Zn(II)-HDAC8. 
This work suggests a new mechanism by which the specificity and activity of HDAC8 may 
be regulated. 
 
Materials and methods  
Metal free HEPES, NaCl, KCl, and NaOH are from Sigma, and TCEP is from 
GoldBio. All other reagents were purchased from Fisher unless otherwise specified.  
 
 
 
61 
 
HDAC8 purification 
HDAC8 was prepared using the following method, modified from (67). 
HDAC8TEVHis6 was transformed into BL21DE3 Z competent cells and grown in 2xYT 
supplemented with 100 µg/mL ampicillin at 37°C and 170 rpm until OD600 0.4 – 0.7. The 
temperature was decreased to 20°C for 45 – 60 minutes, followed by induction with IPTG 
(0.5 mM) and addition of ZnSO4 (0.2 mM). Cells were harvested 15-16 hours post-
induction by centrifugation (5,000 rpm, 15-20 minutes, 4°C) and resuspended in HDAC8 
resuspension buffer (30 mM HEPES pH 7.8-8, 100-150 mM NaCl, 5 mM KCl, 1 – 16 mM 
imidazole, and 1 mM TCEP) supplemented with a cOmpleteTM protease inhibitor cocktail 
tablet (Roche). Cells were lysed by microfluidizer, in some cases followed by nucleic acid 
precipitation with polyethyleneimine (pH 7.9). After centrifugation (26,000 – 27,000 x g, 
45 min, 4°C), HDAC8 was loaded onto a Ni(II)-charged chelating sepharose (GE 
Healthcare) gravity column equilibrated with HDAC8 purification buffer (30 mM HEPES 
pH 8, 150 mM NaCl, 5 mM KCl, 1 mM TCEP) supplemented with 1 mM imidazole. The 
column was washed with 20 mM imidizole purification buffer and HDAC8 was eluted in a 
linear gradient (25 – 250 mM imidazole). The His6 tag was cleaved by His6-tagged TEV 
protease during overnight dialysis HDAC8 purification buffer to remove imidazole. A 
second, stepwise nickel column separated HDAC8 from the protease. HDAC8 was eluted 
in the flow through and 20 mM imidazole steps. HDAC8 was concentrated in 10k or 30k 
MWCO Amicon Ultra centrifugal concentrators at 2,800 – 3,2000 rpm and subjected to 
metal-free dialysis in metal-free buffer A (1 mM EDTA, 25 mM MOPS pH 7.5, 1 mM TCEP, 
5 mM KCl) followed by metal-free buffer B (25 mM MOPS pH 7.5, 1 mM TCEP, 5 mM 
KCl). In some cases a PD-10 column (GE Healthcare) in either PD-10 buffer A (25 mM 
HEPES pH 7.4 - 7.8, 150 mM NaCl, 3 mM KCl, 1 mM TCEP) or PD-10 buffer B (25 mM 
MOPS pH 7.5, 1 mM TCEP) was used to remove residual EDTA. HDAC8 was aliquoted, 
flash frozen in liquid nitrogen, and stored at -80°C. Concentration was measured by 
absorbance at 280 nm using the extinction coefficient 52,120 M-1cm-1, which was 
determined empirically in (68). 
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High-throughput SAMDI mass spectrometric deacetylation assay 
The specificity screens were performed using Self-Assembled Monolayers for 
MALDI-TOF Mass Spectrometry (SAMDI). The SAMDI assays were performed as 
previously published (60, 61, 71, 190). Peptides were transferred to an array plate having 
384 gold islands, each having a monolayer presenting a maleimide group at a density of 
10% against a background of tri(ethylene glycol) groups. In this way, the peptides 
underwent immobilization through the side chain of the terminal cysteine residue while 
the glycol groups play the important role of preventing non-specific adsorption of proteins 
to the monolayer. The array was treated with HDAC8 by distributing 3 µL portions of a 
solution (0.5 µM enzyme, 25 mM Tris pH 8.0, 147 mM KCl, 3 mM NaCl) using a 12-
channel pipette. The solutions were kept at 37°C for 30 min and the reactions were then 
stopped by rinsing the array plate with ethanol. Separate controls were performed using 
ICP-MS to measure metal contamination in HDAC8 reactions from several SAMDI plates. 
Zn(II) was found at 0.5- to 1-fold the HDAC8 concentration, not including Zn(II) added for 
reconstitution.  
 
Enzyme-coupled assay for in-solution peptide assays 
Peptides (Peptide 2.0) had acetylated N-termini and carboxamide C-termini. Zn(II)- 
and Fe(II)-HDAC8 were reconstituted as described in (67, 182). Apo-HDAC8 (10 µM) was 
reconstituted with stoichiometric Zn(II) (Fluka) in peptide assay buffer (20-25 mM HEPES 
pH 8, 137 mM NaCl, 3 mM KCl) and incubated for 1 hour on ice. For Fe(II)-HDAC8, apo-
HDAC8 was equilibrated in an anaerobic glove bag (Coy Laboratory Products) for one 
hour prior to reconstitution. Solid iron(II) chloride (Sigma), L(+)-ascorbic acid (Fluka), and 
peptide assay buffer were equilibrated in the anaerobic chamber at least overnight. Fe(II) 
(100 µM) in 5 mM ascorbate and assay buffer was prepared daily. Fe(II)-HDAC8 (10 µM) 
was reconstituted anaerobically with 5-fold excess Fe(II) in assay buffer and 2.5 mM 
ascorbate for 1 hour in a 0-4°C CoolBox (Biocision). Assays were performed aerobically 
within 2 hours, the effective working time for ascorbic acid to maintain Fe(II) (data not 
shown). The enzyme-coupled assay was performed as in (72). Fe(II)- and Zn(II)-HDAC8 
and peptides in assay buffer were equilibrated to 30°C and reactions were initiated with 
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enzyme (1 µM HDAC8, 50 – 1200 µM substrate). Time points were quenched with 
hydrochloric acid, flash frozen in liquid nitrogen, and stored at -80°C. Assay workup was 
performed as in (72). Standards were prepared from acetic acid (Ricca Chemical 
Company). Time points were neutralized with sodium bicarbonate, and centrifuged 
(16,000 x g, 1 minute), and added to equilibrated coupled enzyme solution (50 mM 
HEPES pH 8, 0.4 to 9.4 mM ATP, 0.01 – 2.1 mM NAD+, 30 – 730 μM CoA, 0.07 U/μL CS, 
0.04 – 0.08 U/μL MDH, 50 μM ACS, 8 - 100 mM NaCl, 2.4 - 3 mM KCl, 33 - 100 mM 
MgCl, 2.5 - 46 mM L-malic acid, pH 8) in a 96-well plate (Corning #3686). The 
fluorescence of the resulting NADH was measured using a POLARstar fluorescence 
microplate reader (ex. filter = 340 nm, em. filter = 460 nm) and a linear equation was fit 
to the data to calculate initial rates.  
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Results and discussion 
Mass spectrometry screen 
As an initial screen to identify potential differences in specificity with different active 
site metals, we performed a high-throughput SAMDI screen of a 361-peptide array and 
showed that the substrate selectivity of HDAC8 is metal ion-dependent (71). The peptides 
were of the form GXKAcZGC, where the flanking residues X and Z were varied across 
nineteen amino acids (all natural residues excluding cysteine). The monolayers were 
analyzed by matrix-assisted laser desorption-ionization mass spectrometry using the 
SAMDI method to observe the substrate and product of the reaction (Figure 3-1). The 
extent of deacetylation for each peptide was determined by the ratio of the deacetylated 
peak area to the sum of the peak areas for the substrate and product. 
We prepared HDAC8 reconstituted with Fe(II) or Zn(II) and applied each of these 
enzyme forms to the peptide array. In both cases we observed deacetylation of multiple 
substrates. For Zn(II)-HDAC8, 172 of the peptides were non-substrates (< 3% 
deacetylation), 72 peptides were hydrolyzed with moderate activity (3-15% conversion) 
and 117 peptides showed high activity (> 15% conversion). Similarly, for Fe(II)-HDAC8 
139 of the peptides were non-substrates, 62 peptides showed moderate activity and 160 
peptides showed high activity. In total more peptides were substrates for Fe(II)-HDAC8 
(222 peptides) than for Zn(II)-HDAC8 (189 peptides). The data are presented in heat 
maps for each Me(II)-HDAC8 (Figure 3-1A, B). The 0.5- to 1-fold Zn(II) contamination 
above the concentration of reconstituted HDAC8 concentrations could result in inhibition 
of Zn(II)-HDAC8 activity by up to 50% and Zn(II) displacement of Fe(II) in reconstituted 
Fe(II)-HDAC8 (18, 67), suggesting that these data are a lower limit for the alterations in 
metal-dependent selectivity. However, the significant specificity differences that were 
observed in this screen suggest that the plates used in these experiments likely contained 
less Zn(II) contamination. 
To better visualize differences in relative activity of the two metal forms of the 
enzyme, we generated a specificity map with the ratios of Fe(II)-HDAC8 product 
conversion to Zn(II)-HDAC8 product conversion (Figure 3-1C). This heat map 
demonstrates that the peptide substrate selectivity of HDAC8 is dependent on the bound 
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metal ion. In the screen, Zn(II)-HDAC8 had higher activity (where the relative conversion 
was greater than seven-fold), than Fe(II)-HDAC8 for 11% of the peptides while 15% of 
the peptides were better substrates for the Fe(II) enzyme (by a factor of seven or more). 
Additionally, 34% of the peptides were comparably deacetylated (within a factor of two), 
and 40% of the peptides were non-substrates or demonstrated negligible deacetylation 
for both metal-substituted forms of HDAC8. In addition to Zn(II)/Fe(II) differences, the 
arrays suggest general peptide sequence specificity trends for HDAC8. For example, all 
but three of the peptides containing phenylalanine at the Z position were metal-insensitive 
substrates (deacetylated by both Me(II)-HDAC8), while methionine in the Z position was 
largely unfavorable to both enzyme forms and resulted in many non-substrate peptides. 
These data clearly demonstrate that the substrate selectivity varies with the identity of the 
active site metal ion. 
 .
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Figure 3-1: HDAC8 metal specificity screen 
The specificities of Fe(II) and Zn(II)-bound HDAC8 were determined using an array of 361 
peptides (GXKAcZGC). A. The extent of peptide deacetylation by Zn(II)-HDAC8 is shown in a grey 
scale heat map. X and Z residues are on the axes. B. The extent of peptide deacetylation by 
Fe(II)-HDAC8 is shown in a grey scale heat map. X and Z residues are on the axes. C. A metal 
specificity heat map displaying the ratio of conversions for the Zn(II) and Fe(II) enzyme. Peptides 
having a greater than seven-fold activity for the Fe(II)-form are shown in blue and a Zn(II)-
preference is shown in red. Non-substrates and metal-insensitive peptides are shown in white 
and gray, respectively.
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Putative substrate peptides in solution 
To further investigate these compelling metal-dependent specificity differences, 
we selected peptide substrates (listed in ) based on putative in vivo substrates, as 
identified by proteomic and computational methods (80, 191), and measured HDAC8-
catalyzed deacetylation under steady-state conditions. We obtained apparent kcat/KM 
(catalytic efficiency) values that were used to compare the Fe(II) and Zn(II)-substituted 
enzymes.  
To measure deacetylation we used an acetate-NADH coupled assay that 
measures the conversion of acetate product to NADH by fluorescence (72, 192). 
The stopped assay was performed using Zn(II)- or Fe(II)-HDAC8 under multiple 
turnover conditions and initial rates of peptide deacetylation were used to 
calculate catalytic efficiencies. Representative peptide reaction data are 
presented in ( 
 
Figure 3-2). The catalytic efficiencies for the peptides ranged from 1.4 to 300 M-1s-
1 for Zn(II)-HDAC8 and 8.3 to 1700 M-1s-1 for Fe(II)-HDAC8. In contrast to the array data, 
Fe(II)-HDAC8 exhibited greater catalytic efficiency toward deacetylation of all of the 
peptides tested in solution. Nonetheless, the ratio of kcat/KM values for the two metal-
substituted enzymes varied widely, as predicted by the initial library screen. The ratios of 
Fe(II)- to Zn(II)-HDAC8 kcat/KM values ranged from 2 to 15 (Figure 3-3 and Table 3-1).
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Figure 3-2: Metal-dependence of HDAC8 catalytic efficiency  
A. The dependence of the initial rate on the substrate concentration for incubation of 1 – 1.5 µM 
Fe(II)-HDAC8 (●) or Zn(II)-HDAC8 (■) with 50 – 500 µM SMC3 10 amino acid acetyl-lysine peptide 
in 20-25 mM HEPES pH 8, 137 mM NaCl, 3 mM KCl at 30°C determined measuring production 
of acetate using an enzyme-coupled assay (72). The value of kcat/KM was calculated from a linear 
fit of the data. B. The dependence of the initial rate on the substrate concentration for incubation 
of 1 – 1.5 µM Fe(II)-HDAC8 (◯) or Zn(II)-HDAC8 (☐) with 0 – 200 µM CSRP2BP acetyl-lysine 
peptide. The Michaelis-Menten equation was fit to these data.  
A 
 
 
 
 
 
 
B 
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Figure 3-3: Fe(II)/Zn(II) HDAC8 substrate specificity ratios 
The ratios of apparent catalytic efficiency for Fe(II)- and Zn(II)-bound HDAC8 are presented as a 
bar graph. Errors were propagated from the errors in kcat/KM, apparent.
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The observed differences in Fe(II)- and Zn(II)-HDAC8 suggest several potential 
metal-dependent determinants of HDAC8 substrate specificity. The first is substrate 
length. For the H3K9ac peptides, increasing the peptide length from a 7-mer to a 13-mer 
had little effect on the catalytic efficiency on Zn(II)-HDAC8 but increased the Fe(II) activity 
3.5-fold, resulting in an increase in the Fe/Zn specificity ratio. These data suggest that 
additional HDAC8-substrate interactions occur in the Fe(II)-bound enzyme. Length may 
not be the main determinant of metal selectivity, however, as three shorter peptides 
demonstrate higher Fe(II)/Zn(II) activity ratios than the 13mer H3K9ac peptide: CAD 
protein (6-mer), THRAP3 (8-mer) and SMC3 (9-mer). Furthermore, the SMC3 10-mer 
peptide exhibits a 3-fold decrease in Fe(II)/Zn(II) activity as compared to the 9-mer 
peptide. 
A second substrate selectivity determinant is the sequence downstream of the 
acetyl-lysine. For example, a methylcoumarin fluorophore on the C-terminal side of the 
acetyl-lysine in the commercial Fluor-de-Lys substrates enhances HDAC8 activity (71, 
72). The SMC3 peptides differ by the presence or absence of a tyrosine at the +3 position 
and this change leads to a 2-fold decrease in Fe(II)-HDAC8 catalytic efficiency with little 
effect on the Zn(II)-HDAC8 efficiency, therefore the Fe(II)/Zn(II) ratio decreases. This 
result suggests that the Fe(II)-HDAC8 may make enhanced interactions with the amino 
acid in the +3 position of peptides, conferring increased Fe(II)/Zn(II) selectivity, or that the 
kcat for this substrate may be affected in a metal-dependent manner. Fe(II)-HDAC8 is also 
more active with the CREB94 peptide, which has a Phe at the +3 position, compared to 
Zn(II), although this peptide has low activity with both enzymes. These data suggest that 
+3 position aromaticity enhances the activity of Fe(II)-HDAC8.  
The third factor affecting specificity is the overall peptide sequence where the 
entire sequence alters the Fe/Zn activity ratios. Peptides in the solution-based assay with 
Phe at the +1 position (Z-position) relative to the acetylated lysine (CAD, LARP1, ARID1A, 
CSRP2BP; ) were predicted by the screen to have < 7-fold Fe(II)/Zn(II) HDAC8 activity 
preference. In general, the solution assays are consistent with this, although all four 
peptides have preference for Fe(II)-HDAC8 with Fe(II)/Zn(II) ratios of 3.2 ± 0.6 to 10 ± 2. 
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Interestingly, La-related protein 1 (LARP1) and CAD protein differ only at the -1 and +2 
positions (both have a +1 Phe, -3 Leu, and +3 Arg), and while Fe(II)-dependent catalytic 
efficiency is nearly identical (and higher than for Zn(II)), the Zn(II) catalytic efficiency is 3-
fold lower for the CAD peptide. Therefore, the Fe/Zn activity ratio for the CAD peptide of 
10 ± 2 is increased compared to the LARP1 peptide. Based on the +1 (Z) and -1 (X) 
positions, the H3K9ac 7-mer was predicted as a zinc-specific substrate, however kinetic 
analysis using the solution assay indicates a slight preference for Fe(II)-HDAC8 
(Fe(II)/Zn(II) = 2.0 ± 0.9). The H3K9ac 7mer data also show that characteristics of peptide 
sequence can switch HDAC8 substrate specificity in a metal-dependent manner, since 
placing a zinc-specific X and Y sequence [RK(ac)S] in the context of additional residues 
[TARK(ac)STG] in the H3K9 7mer peptide increased Fe(II) specificity. These data 
demonstrate that while the individual amino acids surrounding the acetyl-lysine alter the 
metal-dependent peptide specificity, the overall sequence of the peptide affects both 
specificity and metal-dependent selectivity which is difficult to discern from this data set.  
Taken together, the data presented here demonstrate metal-dependent substrate 
specificity for HDAC8-catalyzed deacetylation. The Fe(II)/Zn(II) specificity varies with 
peptide substrate sequence. Residues throughout the substrate peptide sequence are 
synergistic in determining metal-dependent and sequence-dependent specificity for 
HDAC8. We suggest that either metallated form of HDAC8 could be a relevant 
deacetylase in vivo, and that manipulating the Me(II)-HDAC8 identity could regulate the 
pool of recognized substrates. This presents an intriguing link between cellular metal 
homeostasis and the acetylation/deacetylation process. 
Remarkably, the difference between iron and zinc-HDAC8 activities varies greatly 
depending on the sequence of the substrate peptide. We showed previously that Fe(II)-
HDAC8 had a higher kcatKM than Zn(II)-HDAC8 for a commercial peptide (67), however it 
was not determined whether the difference in metal-dependent activation was substrate-
dependent. Here we show that even among the short 6 amino acid peptides, which 
interact only with the active site and local substrate binding surface, there are significant 
differences in both catalytic efficiency and Fe(II)/Zn(II) specificity. If the ratio of 
Fe(II)/Zn(II) catalytic efficiency remained constant, it would suggest that the metal ion 
identity is a way to modulate level of HDAC8-catalyzed deacetylation in the cell. The 
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variability of the Fe(II)/Zn(II) specificity ratio lends itself to a more complicated hypothesis 
where the catalytic metal ion regulates the substrate specificity of HDAC8 toward its 
cellular targets. 
The structural basis for the metal-dependent substrate specificity is unclear. 
Crystal structures of HDAC8 indicate that the substrate binding site is primarily composed 
of flexible loops which accommodate a range of substrates and also influence the 
enzyme’s specificity (18, 44, 73, 105, 111, 112, 114, 115). The active site metal ligands 
may be oriented in part by these loops and their substrate-dependent interactions. 
Intrinsic properties of the metal ion, including Lewis acidity, size and geometric 
preferences, could influence the structure of the hydrophobic amino acids surrounding 
the metal ligands (193). These alterations could be propagated to alter the structure and 
dynamics of the loop regions thereby altering the binding interface presented to 
substrates and influencing substrate selectivity. 
The range of catalytic efficiencies for Fe(II)-HDAC8 is much greater than that of 
Zn(II)-HDAC8 among the peptides tested, demonstrating that molecular recognition of 
Fe(II)-bound HDAC8 is more sensitive to the peptide sequence than Zn(II)-HDAC8. The 
ranges of activity may be even greater among full-length protein substrates, as it is known 
that moving from peptide to protein increased the range of Zn(II)-HDAC8 specificity in the 
context of histone H3 (Chapter 2; Fe not tested). Thus, in a cellular context, binding Zn(II) 
versus Fe(II) could have drastic effects on the selectivity for deacetylation of HDAC8 
substrates. Compared to Fe(II)-HDAC8 (8.3 to 1700 M-1s-1), the Zn(II)-enzyme loses 
nearly an order of magnitude in efficiency (1 to 300 M-1s-1). This result suggests that 
switching from the Fe(II)-dependent HDAC8 to a Zn(II)-enzyme in the cell would 
significantly decrease the HDAC8-catalyzed deacetylation. Furthermore, the observed 
deacetylation would likely be less substrate-specific since the Zn(II)-enzyme does exhibits 
a narrower range of sequence-dependent substrate specificity.  
The changes in HDAC8 catalytic efficiency may be due to changes in either KM or 
kcat. It was not possible to make these measurements for a majority of the peptide 
substrates as the value of KM is too large, likely reflecting weak binding affinity. However, 
we anticipate changes in both parameters upon substituting the metal ion, as observed 
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for catalysis of coumarin-labeled peptides (67). Because the metal ion is directly involved 
in catalysis, the kcat values are likely to reflect metal-dependent differences in activity. The 
hydrophobic shell around the active site is important for metal affinity and metal-specificity 
(193). These residues interact with the substrate, and may mediate specificity changes 
via the KM as well.  
These results suggest that HDAC8’s metal-dependent specificity may be important 
for regulating deacetylation in the cell in response to changing metal homeostasis. This 
is plausible, given the dynamic nature of metal concentrations. For example, zinc is tightly 
buffered, but cellular zinc concentrations can change rapidly and drastically (184, 194). 
For example, zinc can be transported to the nucleus by metallothioneins when cells are 
stimulated by cytokines and nitric oxide (195), and zinc concentrations have been shown 
to increase in both the nucleus and cytoplasm under oxidative stress (196). The 
concentration of exchangeable Zn(II) is increased under redox stress as cellular zinc 
ligands are oxidized and release Zn(II) (reviewed in 189, 197). The dependence of Fe(II) 
concentration on the redox state of the cell is unclear, however Fe(II) and Fe(III) are likely 
involved in the cellular oxidative response as Fe(II) can generate free radicals via the 
Fenton reaction and the concentration of labile iron pools in mouse cancer cells correlates 
with increased DNA damage from hydrogen peroxide (reviewed in 198). We have shown 
previously that the metal-dependent bacterial deacetylase LpxC purifies with Zn or Fe 
based on the relative abundance of these metals in the growth conditions, and that the 
metal cofactor bound to LpxC metal switches from Fe(II) to Zn(II) under aerobic conditions 
in vitro (186). We propose a similar model for metal-dependent HDACs; Fe(II)-HDAC8 
(KD for Fe(II) = 0.2 – 1 µM) (18, 182) may exist in a resting state, but upon increased 
exchangeable Zn(II) concentration HDAC8 would exchange the Fe(II) cofactor for Zn(II), 
which has a picomolar KD for Zn(II) (18, 182), maintaining HDAC8 activation but altering 
the activity level and substrate specificity.  
Although peptides that react more readily with Zn-HDAC8 were observed in the 
high-throughput screen, the universal trend among the longer, more physiologically 
relevant peptides was higher Fe(II)-dependent catalytic efficiency (kcat/KM) and therefore 
greater Fe(II) specificity for the enzyme. One possible explanation for these differential 
results is that the two screens reflect different kinetic parameters; the high-throughput 
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screen may reflect values for kcat rather than kcat/KM since the substrate is on a solid 
surface rather than in solution. The higher Fe(II)-dependent HDAC8 activity suggests that 
the enzyme is activated, at least in part, by Fe(II) in the cell. A complementary hypothesis 
is that peptides with a high ratio of iron to zinc activity may represent in vivo substrates 
while peptides with a ratio nearer to 1 may not be HDAC8-specific substrates in vivo. This 
is bolstered by the fact that peptides corresponding to proteins recently identified as 
potential HDAC8 substrates in a proteomics screen (80) have Fe/Zn substrate specificity 
ratios of 5 – 10, however this conclusion is complicated by the drastic effects of sequence-
dependent specificity (for example SMC3 Fe/Zn ratio drops from 15 to 5 upon the addition 
of 1 residue at the C-terminus). Likewise, despite in vitro activity, cellular inhibitor studies 
are beginning to suggest that histones may not be in vivo HDAC8 substrates (80, 199, 
200) and the H3K9ac 13-mer had an Fe/Zn ratio of 10, although the shorter peptide has 
a ratio of 2. Thus the metal-dependent specificity of peptide substrates is too sensitive to 
length and local sequence to be a strong indicator of in vivo substrates at this point. An 
alternative model is that the metal-dependent substrate specificity ratio is not a predictor 
of substrates versus non-substrates, but rather distinguishes substrates by cellular 
priority. The proteins that are not highly affected by metal switching may be constitutively 
deacetylated substrates acted upon at a basal level regardless of the bound metal ion, 
while substrates that are highly activated by Fe(II) binding to HDAC8 would be 
deacetylated under specific, iron-favored cellular conditions. 
Another possibility is that the metal-dependence is related to subcellular HDAC8 
location, particularly due to the wide range of metal concentrations reported for cytosol, 
nuclei, and organelles. Analysis of acetylated proteins identified experimentally and 
computationally in 2009 parsed some localization-dependent sequence specificity 
surrounding the acetylation sites (9, 174, 201). Nuclear, cytosolic, and non-histone 
acetylated lysine sites had similarities among their sequences, while mitochondrial and 
histone sites differed. Glycine in the -1 position of nuclear substrates was prevalent in 
both the experimental and computational studies and tyrosine at the +1 position was the 
most common amino acids among the mitochondrial, nuclear, and cytosolic sites 
identified by Choudhary et al. (9). My data demonstrate a range of Fe/Zn selectivity for 
peptides with small aliphatic amino acids at the -1 position, however these ratios tend not 
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to be as large as the ratios that are observed for lysine and serine at that position. As 
most of the substrates examined are nuclear and the Fe/Zn selectivity ranges from 2 - 15, 
our data does not provide support for localization-dependent selectivity at this point. 
In conclusion, this study is the first to demonstrate that the sequence-dependent 
substrate specificity of HDAC is dependent on the identity of the active site metal ion. The 
SAMDI peptide screen enabled a broad survey of enzyme specificity, and the enzyme 
assays in solution demonstrate a range of Fe/Zn specificities toward substrates of 
physiological relevance. In vivo evidence consistent with the hypothesis of metal 
switching regulation is still needed, however the data presented here allude to the 
possibility that cellular conditions dictate the active site metal ion as a means of 
modulating the deacetylation of specific target proteins. 
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Chapter 4  
Investigation of the effect of HDAC8 phosphorylation on activity, metal 
dissociation, and substrate specificity1 
 
Introduction 
Phosphorylation, acetylation, and methylation are general cellular regulatory 
mechanisms of increasing interest (2). These ubiquitous PTMs are enzymatically 
appended to and removed from proteins throughout the cell and are part of the larger 
cellular phenomenon known as post-translational modification crosstalk, which has been 
observed among histone and non-histone proteins (reviewed in 6, 202, 203). In the 
complicated system of cellular function, post-translational modifying enzymes can also 
be modified themselves. HDACs can undergo post-translational modification, with 
modifications including phosphorylation, acetylation, and ubiquitination affecting enzyme 
activation, protein-protein interactions, and localization (5, 25). Understanding the ways 
that PTMs regulate enzymatic function and signal transduction is important for 
characterizing normal and diseased cellular processes.  
Phosphorylation is common among HDACs; HDACs 1 through 9 are 
phosphorylated on at least one site, and the modifications regulate their protein-protein 
interactions, protein complex formation, and subcellular localization (25, 35). Of these, 
only HDAC5, HDAC6, and HDAC8 have a phosphorylation site within the deacetylase 
domain of their protein structure. HDAC8 is phosphorylated at S39 (142, 143). This site 
is not conserved among the closely related class I HDACs (arginine in HDAC1 and 
HDAC2, alanine in HDAC3). HDAC4, 5, 7, and 9 have a nearby serine based on 
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sequence alignment, though the local sequence environment is different (126). Ser39 is 
conserved among HDAC8 homologs in several species, but is not conserved in HDAC8 
from Schistosome, a parasite for which HDAC8 is a druggable target. The uniqueness of 
this HDAC8 phosphorylation site makes it an interesting target of investigation as it may 
be an isozyme-specific regulatory mechanism.  
S39 phosphorylation on HDAC8 was first reported in 2004 (143). The site was 
identified by phosphoamino acid analysis, thin layer chromatography, immunoblotting, 
and mutagenesis (143). HDAC8 was identified as a substrate of cyclic AMP dependent 
protein kinase A (PKA) by process of elimination (CK2 and PKC do not generate 
radiolabeled HDAC8 (142)), and by the observed changes in phospho-HDAC8 levels 
upon activation or inhibition of PKA (143). Phosphorylation of HDAC8 by other kinases 
and/or at other sites in vivo has not been determined; however PKG can catalyze 
formation of radiolabeled phospho-HDAC8 (142). Additionally, a phosphorylation 
prediction server (Group-based Prediction Server ver 3.0) predicts additional kinase 
recognition motifs in the HDAC8 sequence and suggests that other kinases may catalyze 
phosphorylation at S39 (204).  
Ser39 is ~20 Å from the active site metal (18, 105, 111-115) yet phosphorylation 
affects catalysis. Immunopurified Flag-HDAC8 from PKA-activated cells, producing 
phosphorylated HDAC8, was inhibited in its ability to catalyze deacetylation of core 
histones H3 and H4 (143). Additionally, histones isolated from forskolin-treated HeLa cells 
(adenylyl cyclase activator to stimulate PKA) expressing Flag-HDAC8 demonstrated 
increased acetylation over controls with either no HDAC8 overexpression, no forskolin, 
or expression of S39A-HDAC8, indicative of PKA-mediated HDAC8 inhibition (143). The 
mechanism by which this inhibition occurs has not been studied, but one hypothesis is 
that perturbation of the position of R37, located near S39 (Figure 4-1), distorts hydrogen 
bonding in the HDAC8 internal channel (104). R37 is critical for high catalytic efficiency 
of HDAC8 (104). Additionally, S39 is at the base of the L1 loop, which is important for 
HDAC8-substrate interactions, and structural perturbations upon adding a phosphate at 
this site are predicted (112).  
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HDAC8 phosphorylation affects both protein-protein interactions (108) and 
subcellular localization (83). Phosphorylation increases association with Human Est1p-
like protein B (hEST1B) and Hsp70 (108). Phosphorylation may affect HDAC8 subcellular 
localization, or HDAC8 may be phosphorylated to different extents depending on the cell 
type or cellular location. There is a precedent for this, as class II HDACs demonstrate 
phosphorylation-dependent mechanisms of translocation between the nucleus and 
cytosol (29-32, 146, 147). HDAC8 is observed in both the nucleus and the cytoplasm (65, 
66, 83). In myometrial cells, phosphorylated HDAC8 co-localizes almost entirely with the 
cytoskeleton while unmodified HDAC8 is observed in the cytoplasmic, cytoskeletal, and 
nuclear fractions (83). Intriguingly, phosphorylated HDAC8 levels (but not overall HDAC8 
expression) are increased in the myometrial cells of pregnant women (83). This suggests 
there is a functional relationship between phosphorylation, HDAC8 localization, and 
HDAC8 protein interactions that needs to be explored further. 
 
 
Figure 4-1: Ser39 and HDAC8 structure 
HDAC8 structure (PDBID: 2V5W) (73, 111) showing Ser39 (red) in relationship to Arg37 (orange) 
and the active site residues (yellow). The Fluor‐de‐Lys substrate is blue and the active site metal 
is green. The structure was generated using VMD and the figure is reproduced (73)from with the 
permission of John Wiley and Sons.  
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Structurally, phosphorylation is poised to have a significant impact on the substrate 
binding site and on the active site. The L2 loop of HDAC8 is very flexible, and typically 
the electron density for this loop is less resolved than the rest of the crystal structure (44). 
These structures show that the L1 and L2 loops of HDAC8 interact via residues K33 and 
D101 and this is likely important for substrate recognition and/or binding affinity (44). 
D101 has been reported as a critical residue for positioning peptide substrates (105). S39 
is located such that perturbing its size and charge would distort the α2 helix and could 
impact K33 positioning and the K33-D101 interaction, thereby affecting substrate binding 
affinity or specificity.  
Phosphorylation on HDAC8 is unique regarding residue location and catalytic 
effect, compared to other class I HDACs. HDAC1 and HDAC2 phosphorylation has been 
suggested to activate these enzymes (142, 144, 145, 150, 151), while decreased activity 
was observed for phospho-HDAC8 (143). Phosphorylation also plays a role in complex 
formation for HDAC1 and HDAC2, but the evidence is conflicting (142, 144, 145). HDAC8 
is the most amenable HDAC to study in vitro because activity does not depend on 
formation of a protein complex and it is well-characterized biochemically. Phosphorylation 
of HDAC8 presents a distinctive mode of HDAC regulation. Here we provide, using the 
S39E phosphomimetic mutant, a combination of structural and kinetic data demonstrating 
that phosphorylation of HDAC8, although on the surface of the protein, modulates its 
function via changes in catalytic activity, metal binding, and substrate specificity. 
 
Materials and methods 
Reagents 
Most reagents used for buffers or crystallization were purchased from Fisher or 
Sigma, unless otherwise specified. The HDAC inhibitor 4-(4-chloro-2-methylphenoxy)-N-
hydroxybutanamide (Droxinostat) was obtained from Sigma Aldrich and was used without 
further purification. 
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Expression and purification of S39E HDAC8 for crystallization 
The S39E mutation was introduced into the HDAC8-6His-pET20b construct (105) 
using Quickchange site directed-mutagenesis kit protocols (Agilent Technologies, Inc.). 
Primers used for PCR mutagenesis are as follows: forward, 5’-GCT AAA ATC CCG AAA 
CGT GCA gag ATG GTG CAT TCT TTG ATT GAA G-3’; and reverse, 5’-C TTC AAT CAA 
AGA ATG CAC CAT ctc TGC ACG TTT CGG GAT TTT AGC-3’. Incorporation of desired 
mutations was confirmed by DNA sequencing at the University of Pennsylvania Perelman 
School of Medicine. Recombinant S39E HDAC8 was expressed in BL21(DE3) 
Escherichia coli cells and purified according to a previously published procedure (86). 
 
Expression and purification of wild type and S39E-HDAC8 for assays2  
The S39E mutation was introduced into the pHD4 (HDAC8-TEV-His) plasmid 
using custom primers (Integrated DNA Technologies) via Quikchange site directed 
mutagenesis. The primer sequences were: forward, 5’-CCC GAA ACG TGC Aga GAT 
GGT GCA TTC TTT GAT TGA AGC ATA TG-3’; and reverse, 5’-CAT ATG CTT CAA TCA 
AAG AAT GCA CCA TCt cTG CAC GTT TCG GG-3’. Incorporation of the mutation was 
confirmed by DNA sequencing performed by the University of Michigan DNA Sequencing 
Core and the corresponding mass of the purified S39E-HDAC8 was confirmed via Q-TOF 
HPLC-MS (Agilent). WT and S39E-HDAC8 were expressed and purified as in (67, 191). 
BL21(DE3) cells were grown in Tris auto-TB media (12 g/L tryptone, 24 g/L yeast extract, 
8.3g/L Tris-HCl, 4 g/L lactose, 1 g/L glucose, 10 mL/L glycerol, pH 8.3) supplemented 
with 0.2 mM ZnSO4 and 100 µg/mL ampicillin at 30°C overnight with shaking at 170 rpm. 
Alternatively, 2xYT media was used and cells were grown at 30-37°C until OD600 of at 
least 0.4, followed by a temperature decrease to 20°C for 45-60 minutes and induction 
with IPTG (0.5 mM) and supplementation with 0.2 mM ZnSO4. At 15-17 hours post-
induction, cells were harvested by centrifugation at least 5000 rpm for at least 15 min at 
4°C. Cells pellets were resuspended in either DEAE low salt buffer (30 mM HEPES pH 
8, 10 µM ZnSO4, 1 mM TCEP, 100 mM NaCl, 10 µg/mL PMSF, and 1 µg/mL TAME) or 
                                            
2 Several batches of enzyme were used for these experiments. One preparation of S39E-HDAC8 was 
performed by rotation student Oleta Johnson. 
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Nickel buffer A (30 mM HEPES pH 8, 100-150 mM NaCl, 1 mM imidazole, 1 mM TCEP, 
5 mM KCl) which in some cases included cOmpleteTM protease inhibitor cocktail tablets 
(Roche), and lysed using a microfluidizer (microfluidics). In some cases, nucleic acids 
were precipitated by PEI pH 7.9 for 10-15 minutes stirring on ice. Lysate was cleared by 
centrifugation (26,900 – 38,700 x g, 4°C, for at least 40 min). Cleared lysate was loaded 
onto a 100 mL DEAE column and purified as in (191) or a 15 mL Ni(II)-charged chelating 
sepharose fast flow (GE Healthcare) column and purified as in (67). Following the nickel 
column, HDAC8 was incubated with 6His-TEV protease during overnight dialysis in 25-
30 mM HEPES pH 8, 100-150 mM NaCl, 1 mM TCEP, and 5 mM KCl at 4°C. In one case 
TEV protease was added following dialysis and incubated for 4 hours. HDAC8 was 
purified from 6His-TEV on a second nickel column, concentrated in 30k MWCO Amicon 
centrifuge filters at 3200 rpm, and dialyzed against metal-free chelation buffer (25 mM 
MOPS pH 7.5, 5 mM KCl, 1 mM EDTA, 1 mM TCEP) at least overnight, If necessary, the 
enzyme was further purified by size exclusion chromatography on an S200 column in 
chelation buffer. The enzyme was then dialyzed in metal-free buffer (25 mM MOPS pH 
7.5, 1 mM TCEP, 5 mM KCl) at 4°C at least overnight. Residual EDTA was removed using 
a PD-10 column (GE Healthcare) in metal-free buffer or assay buffer. 
 
Fluor-de-Lys assay 
The Fluor-de-Lys assay (70, 165) (Enzo Life Sciences) was performed as in (67). 
Enzyme was reconstituted for 1 hour on ice with stoichiometric Zn(II) (Fluka Zinc Atomic 
Spectroscopy standard #96457) or Fe(II) (iron(II)chloride, Sigma). Reactions were 
performed at 30°C using the Fluor-de-Lys HDAC8 substrate (Enzo Life Sciences). 
Enzyme was used to initiate reactions in 0.5 or 1X HDAC8 assay buffer (1X assay buffer: 
20-25 mM HEPES or Tris pH 8.0, 137 mM NaCl, 3 mM KCl) with p53-based commercial 
fluorophore-conjugated peptide substrate. Enzyme and substrate were equilibrated for at 
least 5 min at 30°C prior to the assay. For iron assays, solid iron(II)chloride (Sigma), solid 
ascorbic acid (Fluka), and HDAC8 assay buffer were equilibrated overnight in an 
anaerobic chamber (Coy Laboratory Products). The enzyme was equilibrated in the 
anaerobic chamber for 1 hour prior to reconstitution and substrate was equilibrated 1 hour 
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prior to the assay. Iron assays which were performed outside the anaerobic chamber 
were completed within 2 hours, the effective working timespan for ascorbic acid to 
maintain Fe(II) (data not shown). Enzyme concentrations were 0.5 to 1 µM and substrate 
concentrations were 10 to 500 µM. Time points were quenched using a combination of 
trypsin developer and trichostatin A (TSA) solution. After at least fifteen minutes of 
incubation at room temperature, fluorescence of product (ex. 340 nm, em. 450 nm) and 
substrate (ex. 340 nm, em. 380 nm) were measured using a PolarStar fluorescence plate 
reader. The ratio of product to substrate fluorescence was used to calculate HDAC8 
activity using a standard curve. Kcat/KM values were generated by fitting v0/[E] versus [S] 
to the Michaelis-Menten equation (equation 1). 
Equation 1: 
v0
[E]
=
kcat
KM
(
[S]
(
[S]
KM
+1)
). 
 
Enzyme-coupled HDAC8 assay 
Non-fluorophore conjugated peptides were assayed by coupling deacetylation of 
acetyl-lysine residues to the formation of NADH. Hydrolysis of acetyl-lysine forms acetate, 
which is converted to NADH via acetyl-CoA synthetase, citrate synthase, and malate 
dehydrogenase, and NADH is measured by fluorescence, as described in (72, 192). 
Peptides (Peptide 2.0) were N-terminally acetylated (N-terminal acetylation is not 
hydrolysable by HDAC8) with C-terminal amides. The enzyme-coupled HDAC8 assay 
was performed as in (72). The concentration of substrate was 120 µM and the 
concentration of HDAC8 was 2.4 µM. Reaction time points were quenched into 
hydrochloric acid. Coupled enzyme solution reagents were purchased from Sigma, with 
the exception of HEPES (Fisher) and acetyl-CoA synthetase, which was expressed and 
purified as in (72). Neutralized time points (60 µL) were loaded into wells of a black 96-
well plate (Corning #3686) containing coupled enzyme solution (10 µL) and allowed to 
equilibrate protected from light. The fluorescence of the resulting NADH was measured 
(ex. = 340 nm, em. = 460 nm) and converted to product concentration using an acetate 
standard curve. Initial rates of reaction were used to calculate the apparent catalytic 
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efficiency using equation 1 under the assumption that the substrate concentration was 
well below the KM. 
 
Determination of metal ion dissociation rate constants (koff) 
The divalent metal off rate constants for HDAC8 were determined by measuring 
the time-dependent decrease in activity upon incubation with EDTA as described in (182). 
HDAC8 was reconstituted with stoichiometric Zn(II) or Fe(II) for activity assays. Fe(II)-
HDAC8 was reconstituted in the glove bag in the presence of ascorbic acid. A stock of 
500 µM Fe(II) in 5 mM ascorbic acid was prepared and used for a final enzyme 
reconstitution of 100 µM Fe(II)-S39E-HDAC8 in 1 mM ascorbic acid and 1X assay buffer. 
After at least one hour on ice or coolbox in the glove bag, the enzyme was diluted into 
assay buffer containing 1 mM EDTA at 30°C. At each time point (0–60 min), the enzyme 
in EDTA was diluted 4-fold into 1X assay buffer containing 250 µM Fluor-de-Lys HDAC8 
substrate, and initial rates of deacetylation were measured using the Fluor-de-Lys assay 
(70, 165). Reaction time points were quenched by adding them to TSA and trypsin 
developer as described above. The initial rate for product formation was determined for 
reactions at each EDTA incubation time. Control reactions without EDTA were incubated 
for the same times at 30°C and the initial rate of the EDTA reaction was divided by the 
non-EDTA reaction for each incubation time to yield the activity retained. The koff was 
determined by fitting the normalized activity retained (fraction activity/y-intercept of single 
exponential) to a single exponential (Equation 2). In the equation, ∆A is the normalized 
fraction activity, A is the normalized fraction activity at time zero, t is time, and koff is the 
dissociation rate constant. 
Equation 2: ∆A = A × exp(-koff × t) 
 
Determination of Zn(II) affinity (KD) 
The KD values were measured using the anisotropy of fluorescein suberoylanilide 
hydroxamic acid (flSAHA), synthesized as in (182). The flSAHA assay was performed as 
described (182). HDAC8 was reconstituted with NTA-buffered Zn(II) and incubated at 
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25°C for 30 minutes. The NTA buffer (1 mM nitrilotriacetic acid (NTA), 137 mM NaCl, 3 
mM KCl, 10 mM MOPS, pH 7) maintained concentrations of free Zn(II). The concentration 
of free metal ion was calculated from the total metal content using the software program 
MINEQL (Environmental Research Software). Final concentrations were [Zn(II)]free = 0 - 
4.5 nM ([Zn(II)]total = 0 – 1 mM) and 1 μM S39E-HDAC8. Zn(II)-HDAC8 was added to a 
96-well half-area black plate (Corning) and mixed with flSAHA (50 nM). Anisotropy of 
flSAHA (ex = 485 nm, em = 535 nm) was measured using a TECAN plate reader. The KD 
values were obtained by fitting the data (GraphPad Prism) to a binding isotherm (Equation 
3), where r is anisotropy, ∆r is the change in anisotropy, X is the Zn(II)free concentration, 
KD is the metal affinity equilibrium constant, and C is the amplitude (fit by the software). 
Equation 3: 
r
∆r
= (
X
X+KD
)+C 
 
Molecular dynamics simulations 
The coordinates for the HDAC8-substrate complex for the simulations were taken 
from PDB ID: 2V5W (111). The spatial positions of K+ ions and Zn+2 were retained in the 
simulation from the original PDB. Three sets of simulations were carried out. (a) WT 
HDAC, (b) HDAC8 with phosphorylated S39 and (c) HDAC8 with S39E mutation.  
The modified phosphorylated protein was made using the Forcefield PTM server 
(www.selene.princeton.edu/FFPTM). The AMBER forcefield parameters for post-
translations modifications were taken from Khoury et al. (205, 206). The S39E mutant 
was obtained from the crystal structure. The missing loops were constructed using 2V5W 
structure as the template. The substrate was introduced in the HDAC enzyme after 
superimposition with 2V5W structure. A total of six simulations were carried out, with and 
without substrate.  
The parameters for substrate were generated via the Antechamber module of the 
AMBER software using Generalized AMBER force field (207, 208). The charges were 
assigned to the substrate using the AM1-BCC method (209). The systems were set up 
using xleap module of AMBER14 (210). K+ ions were used for neutralization and TIP3P 
water molecules were used for solvation. AMBER-adapted Joung and Cheatham 
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parameters specific for TIP3P waters and K+ ions (radius 1.593 Å and well depth 
0.4297054 kcal mol-1) were used (211). The system was solvated in a periodic box whose 
boundaries extended at least 10 Å from any solute atom. The periodic boundary 
conditions were defined by the PME algorithm and non-bonded cut-off was set to 10 Å 
(212). All chemical bonds involving hydrogen atoms were restrained using SHAKE, 
allowing for stable simulations with a 2 fs time step (213). Simulations were carried out 
using an NPT ensemble, using the Berendsen algorithm to control temperature and 
pressure (214). Standard equilibration protocols were used for initial minimization of the 
structure (215). The final MD simulations were carried out for 400 ns using ACEMD and 
the frames were collected every 10 ps using a timestep of 4fs (216). Analyses of the 
trajectory were performed using the GROMACS 4.5 tools (217, 218). The programs ICM, 
VMD and PyMOL were used for visualization (219-221).  
 
Crystallization and data collection.  
Crystals of the S39E HDAC8-Droxinostat complex were prepared by 
cocrystallization at 21°C in sitting drops using the vapor diffusion method. A 500 nL drop 
containing 5.0 mg/mL S39E HDAC8, 50 mM Tris (pH 8.0), 150 mM KCl, 5% glycerol, 1 
mM dithiothreitol, 2 mM Droxinostat, and 0.03 M glycylglycylglycine was added to a 500 
nL drop of precipitant solution and equilibrated against a 100 L reservoir of precipitant 
solution. The precipitant solution consisted of 100 mM BisTris (pH 6.5), 6% (w/v) PEG 
8,000 (Hampton Research), and 4 mM tris-(2-carboxyethyl)phosphine.  
Crystals typically appeared within 1 day. Crystals were flash-cooled in liquid 
nitrogen after transfer to a cryoprotectant solution consisting of precipitant solution 
supplemented with 25% glycerol. X-ray diffraction data were collected on beamline X29 
at the National Synchrotron Light Source (NSLS, Brookhaven National Laboratory, New 
York). Data collection statistics are recorded in Table 4-1. Data were indexed, integrated 
and scaled using HKL2000 (222). 
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Phasing, model building, and structure refinement  
Crystals belonged to space group P21, with 2 molecules in the asymmetric unit. 
The crystal structure was solved by molecular replacement using PHENIX (223) with the 
atomic coordinates of the H143A HDAC8–tetrapeptide substrate complex (PDB 
accession code 3EWF) (105) less substrate, metal ions, and solvent molecules used as 
a search probe for rotation and translation function calculations. The model was refined 
with iterative cycles of refinement in PHENIX (223) and manual model rebuilding in COOT 
(224). Solvent molecules and inhibitors were added after initial rounds of refinement. 
Translation Libration Screw (TLS) refinement was performed in the late stages of 
refinement. TLS groups were automatically determined using PHENIX. Final refinement 
statistics are recorded in Table 4-1. 
Portions of the N-terminus, the C-terminus, and the L1 and L2 loops were 
characterized by missing or broken electron density. These segments appeared to be 
disordered and were excluded from the final model as follows: M1-S13 (monomers A and 
B), A32-I34 (monomer B), G86-D89 (monomer A) G86-E95 (monomer B), I378-H389 
(monomer B), and E379-H389 (monomer A). Likewise, side chains of residues that were 
partially or completely disordered were excluded from the model as follows: L14 
(monomers A and B), K33 (monomer A), I34 (monmer A), K52 (monomer B), K58 
(monomer B), K60 (monomers A and B), K81 (monomers A and B), Q84 (monomer A), 
E85 (monomer A), I94 (monomer A), E95 (monomer A), Y100 (monomer B), E106 
(monomer B), K132 (monomers A and B), K221 (monomer B), E238 (monomer B), Q253 
(monomers A and B), E358 (monomer B), K370 (monomer A), V377 (monomer A), and 
I378 (monomer A). 
Occasional ambiguous electron density peaks were observed in the structure. 
These peaks were usually elongated and potentially corresponded to disordered PEG 
fragments or other molecules present in the crystallization buffer. However, since these 
electron density peaks were not confidently interpretable, they were left unmodeled. 
Similarly, ambiguous electron density was observed around W141 in monomer A, 
possibly corresponding to alternative conformations. However, since such conformations 
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were not confidently interpretable, the W141 side chain was modeled in only one primary 
conformation. 
 
Results 
Crystal structure of S39E HDAC8  
Because the phosphorylated enzyme is difficult to obtain in large quantities and 
purity for crystalization, we used the S39E-HDAC8 mutant, which mimicks 
phosphorylation at this site. The mutant was crystalized in an inhibitor-bound state. This 
is the first crystal structure of an HDAC isozyme complexed with Droxinostat, a selective 
HDAC3, HDAC6, and HDAC8 inhibitor (225). The structure of the S39E HDAC8-
Droxinostat complex shows how the phosphorylation of S39, as mimicked by the S39E 
substitution, might influence inhibitor binding in the enzyme active site. Residue S39 is 
located in helix A2, 20 Å away from the catalytic Zn2+ ion. The structure of the S39E 
HDAC8–Droxinostat is similar to that of the wild-type HDAC8–M344 complex (PDB 
accession code 1T67) (112) with an r.m.s. deviation of 0.49 Å for 356 C atoms and 0.47 
Å for 350 C atoms, for monomer A and B, respectively. Although the S39E substitution 
does not cause any large-scale change in the HDAC8 structure (Figure 4-2), local 
structural changes are observed in the vicinity of S39E that propagate through to the 
active site via changes in the structure of Loop 1. These structural changes may similarly 
be triggered by phosphorylation of S39 in the wild-type enzyme.  
In the wild-type HDAC8 structure, the hydroxyl group of S39 donates a hydrogen 
bond to the carboxylate group of D29, which is located in the adjacent helix A1. In S39E-
HDAC8, the E39 side chain is oriented toward solvent and does not interact with any 
surrounding residues, including positively charged K36. Similarly, E39 does not perturb 
the nearby residue R37, the “gatekeeper” for the internal channel (104). However, the 
S39E mutation induces a slight shift of D29 (0.6 Å for the C atom). The carboxylate side 
chain of D29 undergoes a conformational change away from E39, presumably to 
minimize electrostatic repulsion with the carboxylate side chain of E39 (Figure 4-2).  
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The conformational change of D29 causes the L1 loop to reorganize. The L1 loop 
(L31-P35) connects helices A1 and A2 and is adjacent to the active site. The L1 loop is 
important, along with the L2 loop, for substrate and inhibitor binding (73). Alternative 
conformations are often observed for these loops in HDAC8 structures as they 
accommodate the binding of different ligands. Although more data is needed to 
definitively state that the mutation of S39 significantly alters loop L1 beyond the normal 
flexibility, there is evidence that the L1 loop in the S39E-HDAC8 structure is more 
disordered than usually observed in HDAC8 complexes. These observations are the 
higher thermal B factors, along with missing electron density for the side chains of K33 
and I34 in monomer A, and weak electron density in monomer B that did not allow 
modeling of the A32-I34 segment.
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Figure 4-2:  
Stereoview of Superimposition of S39E-HDAC8-Droxinostat and WT-HDAC8-M344 
Stereo view superimposition of the S39E HDAC8-Droxinostat complex (monomer A: C = wheat, 
N = blue, O = red, Zn2+ = magenta sphere) and the wild-type HDAC8-M344 complex (PDB 1T67, 
color-coded as above except C = light blue). In the wild-type structure, S39 donates a hydrogen 
bond (black dashed line) to D29. Upon substitution to a glutamate (simulated omit map contoured 
at 4.0 showing the E39 side chain), this interaction is not conserved and causes local 
rearrangement. The L1 loop adopts a different conformation as highlighted in red and blue for the 
S39E HDAC8-Droxinostat complex and the wild-type HDAC8-M344 complex, respectively. 
 
 
Figure 4-3:  
Stereoview of simulated annealing omit map of S39E-HDAC8-Droxinostat 
Simulated annealing omit map of Droxinostat bound in the active site of S39E HDAC8 (monomer 
A, contoured at 3.0). Atomic color codes are as follows: C = wheat (protein, monomer A), or 
green (inhibitor), N = blue, O = red, Zn2+ = magenta sphere. Metal coordination and selected 
hydrogen bond interactions are shown as solid black or dashed black lines, respectively. As in 
Figure 4-2, the L1 loop of S39E-HDAC8 is highlighted in red.  
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Table 4-1: Data collection and refinement statistics for the S39E-HDAC8-
Droxinostat complex 
  
Unit cell  
  space group 
symmetry 
P21 
    a, b, c (Å) 53.4, 84.4, 94.6 
    α, β, γ (deg) 90, 99.4, 90 
  
Data collection  
  wavelength (Å) 1.075 
  resolution limits (Å) 43.0-1.59 
  total/unique 
reflections 
819616/110604 
  Rmergea,b 0.080 (0.605) 
  I/σ(I)a 19.3 (4.7) 
  redundancy a 7.4 (7.1) 
  completeness (%)a 100 (100) 
  
Refinement  
  reflections used in 
refinement/test set 
110567/5539 
  Rcrystc 0.142 
  Rfreed 0.160 
  protein atomse 5648 
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a Values in parentheses refer to the highest shell of data. b Rmerge = Ih - Ih/Ih, where Ih is 
the average intensity for reflection h calculated from replicate reflections. c Rcryst = |Fo| - 
|Fc|/|Fo| for reflections contained in the working set. Fo and Fc are the observed and 
calculated structure factor amplitudes, respectively. d Rfree = |Fo| - |Fc|/|Fo| for reflections 
contained in the test set held aside during refinement. e Per asymmetric unit. f Calculated with 
PROCHECK version 3.4.4.  
  water moleculese 777 
  ligand moleculese 2 
  Zn2+ ionse 2 
  K+ ionse 4 
  glycerol moleculese 2 
  
R.m.s. deviations 
from ideal geometry 
 
  bonds (Å) 0.010 
  angles (°) 1.3 
  dihedral angles (°) 12 
  
Ramachandran plot 
(%)f 
 
  allowed 91.1 
  additionally allowed 8.9 
  
PDB accession code 5BWZ 
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This disorder appears to propagate through to the active site; the 4-chloro-2-
methylphenoxyl capping group of the hydroxamate inhibitor Droxinostat is characterized 
by somewhat weaker electron density and higher thermal B factors. The hydroxamate 
moiety of Droxinostat coordinates to the active site Zn2+ ion, forming a five-membered 
ring chelate, as typically observed in all HDAC8-hydroxamate crystal structures (18, 86, 
105, 111, 112, 115). The coordination distances to the Zn2+ ion are 2.0 Å and 2.2 Å for 
the hydroxamate hydroxyl and carbonyl groups, respectively. The Zn2+-bound 
hydroxamate is also stabilized by hydrogen bond interactions with Y306, H142, and H143 
(Figure 4-3). The capping group of Droxinostat does not make significant interactions with 
residues at the mouth of the active site. A contact is made between the chlorine atom of 
Droxinostat and the hydroxyl group of Y100 in the L2 loop (the Cl---O distance in 
monomer A is 3.2 Å; the side chain of Y100 is disordered in monomer B). However, Y100 
is poorly oriented to consider this interaction as a hydrogen bond. The interaction may be 
a halogen bond. 
 
S39E mutation decreases Co(II)- Fe(II)- and Zn(II)-dependent catalytic efficiency 
 While inhibition of HDAC8 activity by phosphorylation or the S39E-HDAC8 
phosphomimetic mutant had been observed for core histone deacetylation, detailed 
kinetic parameters for either of these enzymes had not been determined (143). Using the 
Fluor-de-Lys assay, S39E-HDAC8 was assayed with Zn(II), Fe(II), and Co(II) bound to 
the active site to compare the catalytic efficiency to that of wild type HDAC8. Consistent 
with previous reports, S39E-HDAC8 activity was decreased compared to WT-HDAC8 in 
all cases tested (Table 4-2, Figure 4-4). Fe(II)-dependent catalytic efficiency (kcat/KM) was 
6-fold lower for the mutant, Zn(II)-dependent catalytic efficiency was 12-fold decreased, 
and Co(II)-dependent catalytic efficiency was 7-fold decreased. The KM and kcat values 
can also be compared for the Fe(II) enzymes, and they reveal that the decrease in kcat/KM 
is due to both a 2-fold increase in KM and a 3-fold reduction in kcat. This indicates that 
mutation of S39 to E39 minimally affects both substrate recognition and hydrolysis. 
Phosphorylation on HDAC8 may be a modulator of HDAC8 activity.
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Table 4-2: Kinetics of S39E-HDAC8 toward Fluor-de-Lys peptidea 
HDAC8 kcat/KM (M-1s-1) KM (µM) kcat (s-1) 
Fe(II)-S39E 440 ± 60 170 ± 30 0.077 ± 0.005 
Fe(II)-WT 2800 ± 700 90 ± 30 0.25 ± 0.02 
Zn(II)-S39E  50 ± 40 > 400b > 0.05b 
Zn(II)-WT 580 ± 90  1100 ± 50c  0.90 ± 0.03c 
Co(II)-S39E 1100 ± 400 > 1700b > 2b 
Co(II)-WT  7500 ± 300c 160 ± 6c 1.2 ± 0.2c 
a Reactions consisting of 0.5 to 1 µM HDAC8 and 10 to 500 µM 
substrate in 20-25 mM HEPES or Tris pH 8.0, 137 mM NaCl, 3 mM 
KCl at 30°C. 
b KM and kcat are poorly defined by this data set. More data is needed. 
c Values reported in (67). 
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Figure 4-4: S39E-HDAC8 catalytic activity toward Fluor-de-Lys peptide substrate 
A. Dependence of initial rates for deacetylation of the Fluor-de-Lys peptide substrate on the 
substrate concentration catalyzed by Fe(II)-S39E-HDAC8 (open blue circles) and Fe(II)-WT-
HDAC8 (closed blue circles). The Michaelis-Menten equation was fit to the data. B. Substrate 
concentration dependence of the initial rate for deacetylation catalyzed by Zn(II)-WT-HDAC8 (■), 
Zn(II)-S39E-HDAC8 (□), and Co(II)-S39E-HDAC8 (♦). The data are a combination of three 
experiments, with error bars (colored to match the symbols) representing errors calculated from 
fits of initial rates, and the Michaelis-Menten equation (S39E-HDAC8) or a linear slope (Zn(II)-
WT-HDAC8) was fit globally to the data.  
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S39E-HDAC8 activity is decreased toward unlabeled peptide substrates 
 To investigate whether S39 alteration affects substrate specificity of the enzyme 
or simply reduces activity towards all substrates, we measured the apparent catalytic 
efficiency of Zn(II)-S39E-HDAC8 and Zn(II)-WT-HDAC8 toward two peptides that do not 
contain a fluorophore. The methylcoumarin fluorophore on the Fluor-de-Lys peptide 
enhances activity and substrate affinity to HDAC8 (71, 72). The two peptides tested were 
a 13 amino acid peptide representing the H3K9ac acetylation site on histone H3, Ac-
TKQTARKacSTGGKA-NH2, and a peptide representing an acetylation site on SMC3, a 
putative in vivo HDAC8 substrate, of the sequence Ac-RVIGAKKacDQY-NH2. An assay 
which couples the formation of acetate to a fluorescent NADH readout was used (72). 
The decrease in activity observed for S39E-HDAC8 was comparable to the decrease 
observed for S39E-HDAC8 toward the methycoumarin-conjugated Fluor-de-Lys peptide 
substrate (12-fold decrease), at 13- and 16-fold lower apparent catalytic efficiency for 
H3K9ac and SMC3, respectively (Figure 4-5 and Table 4-3). These data suggest that the 
S39E mutation mainly decreases activity and not substrate selectivity. More data is 
needed, however, as the fits of three time points may underestimate the initial rates for 
WT-Zn(II)-HDAC8. 
 
 
 
97 
 
 
Figure 4-5: S39E-HDAC8 catalytic activity toward unlabeled peptides 
Dependence of HDAC8-catalyzed product formation on time for deacetylation of SMC3 (red 
circles) and H3K9ac (black squares) peptides by WT-Zn(II)-HDAC8 (● for SMC3, ■ for H3K9ac) 
and S39E-Zn(II)-HDAC8 (○ for SMC3, □ for H3K9ac). A linear slope was fit to the data to measure 
initial rates of reaction (3 time points) over 1800 seconds for 120 µM peptide and 2.4 µM Zn(II)-
HDAC8, using the NADH-coupled acetate assay. Data points are from single measurements and 
data was fit using GraphPad Prism. 
 
 
Table 4-3: S39E-HDAC8 apparent catalytic efficiency for unlabeled peptides 
HDAC8 
H3K9ac peptide 
kcat/KM, app (M-1s-1) 
SMC3 peptide 
kcat/KM, app (M-1s-1) 
WT-Zn(II)-HDAC8 92 ± 5 60 ± 30 
S39E-Zn(II)-HDAC8  7 ± 3 4 ± 2 
fold decrease 13 16 
The kcat/KM, apparent values were calculated from the linear initial rates of 
reaction (3 time points) over 1800 seconds for 120 µM peptide and 2.4 
µM Zn(II)-HDAC8, using the NADH-coupled acetate assay. 
 
 
 
 
 
98 
 
S39E-HDAC8 metal dissociation is faster than wild type 
To explore the effect of phosphorylation on the active site metal ion, the 
dissociation rate constants for the catalytic metal (Fe(II) or Zn(II)) were determined. The 
dissociation rate constants for both Fe(II)- and Zn(II)-S39E HDAC8 increased more than 
10-fold (Figure 4-6), indicating that metal dissociation is much more rapid for this mutant 
compared to WT-HDAC8. However, similar to wild type, the dissociation rate constants 
for the two metal ions are comparable. This dramatic increase in metal koff indicates that 
an alteration within the S39E structure facilitates rapid metal dissociation.  
 
Table 4-4: Metal ion dissociation rate constants for S39E and WT HDAC8 
Enzyme Fe(II) koff (min-1) Zn(II) koff (min-1) 
S39E-HDAC8 0.48 ± 0.05 0.57 ± 0.07 
WT-HDAC8 0.03 ± 0.004a 0.04 ± 0.003a 
The koff values are calculated by a global fit of an exponential 
decay equation to data from replicates on different days. 
aValues reported in (182). 
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Figure 4-6: Metal ion off rates for Fe(II)- and Zn(II)-S39E HDAC8 
A and B. Initial rates for Zn(II)-S39E-HDAC8 (A, red squares) and Fe(II)-S39E-HDAC8 (B, blue 
circles) deacetylation activity as a function of time as measured using the Fluor-de-Lys assay 
after addition of 1 mM EDTA. The fraction activity is determined by dividing this activity by the 
activity of HDAC8 incubated in the absence of EDTA. The exponential equation, Y=Amp*exp(-
koff*time, was fit to all of the data, and replicates from multiple days are shown. C. Graphical 
representation of koff values demonstrates the significant difference between WT and S39E metal 
ion off rates. aValues reported in (182).
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Zn(II) affinity of S39E-HDAC8  
Intrigued by the effect of S39E on the dissociation rate constants for the catalytic 
metal ion bound to HDAC8, we measured the metal affinity equilibrium constant using a 
fluorescein-SAHA anisotropy assay (182). The resulting KD value for the S39E mutant 
was 2 ± 2 pM, which is comparable to the WT value of 6 ± 1 pM (182), however more 
data is needed to precisely determine the KD and draw conclusions comparing mutant 
and wild type HDAC8 Zn(II) binding. A complicating factor for these data is that in addition 
to the expected increase in anisotropy at low metal concentrations due to binding of 
fluorescein-SAHA to the enzyme, there is a decrease in anisotropy at the highest zinc 
concentrations. One possible explanation for this result is that at higher zinc 
concentrations the mutant binds multiple zinc ions that complete with fl-SAHA binding at 
the active site and as a result the observed anisotropy decreases. 
 
 
Figure 4-7: Zinc affinity for S39E-HDAC8 
Global fit of two replicate KD experiments. Different symbols represent different days. Equation 3 
was fit to the data. 
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Molecular dynamics simulations suggest possible phospho-HDAC8 structural changes 
The crystal structure provides a snapshot of inhibitor-bound S39E-HDAC8. To 
investigate the effects of phosphorylation on substrate-HDAC8 interactions, molecular 
dynamics simulations were used, starting with an HDAC8-peptide substrate complex 
crystal structure (PDBID: 2V5W (111)). We compared the substrate binding dynamics of 
phosphorylated HDAC8 (pS39-HDAC8, modeled), S39E-HDAC8 (with substrate 
modeled), and WT-HDAC8. By simulating phosphorylation on the WT structure, we were 
able to predict the structure and dynamics of residues in the L1 loop that were not 
resolved in the S39E crystal structure and validate the S39E mutation as a mimic of 
phospho-HDAC8. While the mutant was crystalized in complex with an inhibitor, the 
simulations predict the structure of pS39-HDAC8 with and without peptide substrate 
bound. In the first set of simulations (Figure 4-8), WT-HDAC8 is modeled with and without 
the Fluor-de-Lys p53-based peptide substrate, to compare with the pS39 simulations. 
Relevant residue conformations surrounding S39 are highlighted in Figure 4-8, with the 
most important being that of substrate, Y306, and K33. Figure 4-9 shows the results of 
simulation of pS39-HDAC8, and Figure 4-10 shows a comparison of pS39- and S39E-
HDAC8 with and without bound substrate. These simulations indicate that modification of 
S39 leads to a disruption of the interaction between Y306 and K33, which perturbs 
substrate binding. The interaction between S39 and D29 is also disrupted by the addition 
of negative charge at position 39; D29 instead interacts with K36. The K36-D29 
interaction and altered Y306-K33 interaction preclude binding of substrate at the wild-
type position, instead the peptide binds in a channel between K33 and Y306 where it is 
not optimally positioned for deacetylation by the active site metal-water nucleophile. 
These simulations provide insight into the basis for decreased pS39- and S39E-HDAC8 
activity, and although the D29-K36 contact is not noticeable in the S39E crystal structure, 
the altered orientation of D29 is consistent with the 0.6 Å shift for D29 that was observed 
in the crystal structure.  
102 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-8: Simulations of WT-HDAC8 binding to substrate 
The top panel shows the orientation of key residues in WT-HDAC8 at the (a) start, (b) 204 ns and 
(c) 400 ns of the substrate binding simulation. S39 is solvent-exposed. Y306 bends at 90° toward 
K33, and the Hε of Y306 forms a hydrogen bond with the carbonyl of K33 (b). This opens the 
tunnel for substrate interaction with the active site, which is otherwise blocked by Y306. Yellow 
and purple spheres represent Zn+2 and K+ ions respectively. The bottom panel shows a 
representation of the key residues and loops with (d) and without (e) substrate. The K33 side 
chain interacts with a substrate oxygen. Spheres represent metal ions as above.  
(d)      (e) 
D29 
D29 
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Figure 4-9: Simulation of substrate binding to pS39-HDAC8 
Representation of key residues in HDAC with phosphorylated S39 (A) without and (B) with 
substrate. RMSF of K33 is equivalent in both the simulations. As the –OH group of pS39 is 
unavailable, in (B) K36 interacts with D29 directly. The substrate does not gain full access to 
catalytic site and instead goes into the channel between K33 and Y306. Yellow and purple 
spheres represent Zn(II) and potassium ions respectively.
D29 
D29 
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Figure 4-10: Simulations of pS39 and S39E bound to substrate 
In simulations, the S39E mutant behaves similarly to the pS39-HDAC8, validating this 
phosphomimic. In the top panel (pS39 modeled on WT-HDAC8), two snapshots (start (a) and 400 
ns (b)) during the simulation demonstrate that the substrate is shifted in the active site between 
K33 and Y306 compared to WT-HDAC8 (Figure 4-8A–C). Y306 interacts with substrate but does 
not interact with K33. The bottom panel (S39E-HDAC8 with modeled substrate) is a 
representation at the start (a) and 400 ns (b) of the simulation of key residues in S39E-HDAC8 
and demonstrates that the enzyme behaves similarly to pS39-HDAC8. The L1 loop is distorted, 
Y306 and K33 do not interact (unlike in WT-HDAC8 (Figure 4-8B) where Y306 forms a hydrogen 
bond with the carbonyl oxygen of K33), and Y306 does not interact with substrate in this 
simulation. Substrate access to the active site is altered.
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Discussion 
 The mechanistic and functional roles of phosphorylation on HDAC8 are important 
facets of HDAC8 regulation that have not been well studied up to this point. To examine 
the effect of addition of a bulky negative charge at S39, the S39E mutant HDAC8 was 
used as a phosphomimic. The validity of the mimic was bolstered by the fact that the 
S39E- and phospho-HDAC8 behave similarly in assays while the S39A-HDAC8 behaves 
like the wild type enzyme (143). Previously, crystal structures of the S39D-HDAC8 has 
been solved, and the structure of this mutant is reported to be essentially the same as the 
wild type (44, 111). The S39E mutant, however, is a more appropriate mimic of 
phosphorylation (143) and the S39E-HDAC8-Droxinostat structure visualizes noticeable 
differences from the wild type structure. The structure of S39E-HDAC8-Droxinostat 
reveals that the L1 loop is distorted and the interaction between S39 and D29 is disrupted 
by the glutamate substitution. Loop L1 is important for HDAC8 substrate and inhibitor 
interactions (44), so this structural perturbation likely contributes to the decreased 
catalytic efficiency. It is important to note that a structure of WT-HDAC8 complexed with 
Droxinostat has not been solved. Comparing S39E-HDAC8-Droxinostat directly to WT-
HDAC8-Droxinostat would be useful to eliminate the possibility of structural changes 
induced by the identity of the inhibitor. 
Interestingly, the position of R37 is not altered in either the inhibitor-bound crystal 
structure or the phosphorylation simulation. R37 is critical for activity (104) and, due to its 
proximity to S39E, distortion of this residue would not have been surprising. Additionally, 
an electrostatic interaction between K36 and E39 had been anticipated but was not 
evident in the structure. Instead the relevant changes are in the perturbed interactions 
between Y306, substrate, and K33, the loss of a hydrogen bond between the hydroxyl of 
S39 and the carboxylate of D29 (which bridges the α1 and α2 helices) and the gain of an 
interaction between D29 and K36. Regarding the lost D29-S39 hydrogen bond, the 
inhibitor bound structure shows that this change is correlated with a distortion of the L1 
loop. The pS39 HDAC8 simulation reveals that this lost interaction alters the position of 
the bound substrate. In this simulation, K36 interacts with D29 and the side chain of K33 
is shifted (part of the L1 loop). Substrate binding is typically oriented in part by Y306 and 
K33, however in the absence of the hydrogen bond interaction between Y306 and the 
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K33 backbone carbonyl, the substrate is shifted in the active site between these residues. 
This was the most significant difference observed in the simulations. The inhibitor-bound 
crystal structure does not show this altered Y306/K33 interaction and the inhibitor is 
positioned in the typical Zn(II)-bound orientation such that the carbonyl forms a hydrogen 
bond with Y306 (Figure 4-3). The fact that the crystal structure and the simulation provide 
somewhat different visualizations of ligand-bound S39E-HDAC8 may be due to several 
factors. Mainly, the inhibitor is small and interacts primarily with the active site, limiting 
interactions with the HDAC8 peptide binding groove outside of the active site tunnel. The 
interaction between Droxinostat and Y100 is not even close enough to be characterized 
as a hydrogen or halogen bond. Additionally, some residues (e.g. K33) cannot be directly 
compared to the simulated structure because they were not resolved in the crystal, 
suggesting significant mobility. Finally, while the S39E structure demonstrates structural 
difference and mimics phosphorylation, glutamate is not identical to phosphoserine and 
thus some differences between E39 and pS39 are expected.  
S39E-HDAC8 exhibits a decrease of 6- to 16-fold in catalytic efficiency compared 
to WT. The simulations and crystal structure suggest that the decrease in catalytic activity 
that accompanies the mutation and phosphorylation arise from the consequent reordering 
of and/or disorder in the L1 loop flanking the active site cleft. Structural differences in this 
loop presumably influence its affinity for substrates and inhibitors binding to the active 
site. The increase in KM observed for Fe(II)-S39E-HDAC8 over WT-HDAC8 is consistent 
with perturbation in the L1 loop affecting substrate affinity, since KM is proposed to reflect 
KD for peptide deacetylation (67). Assuming that the mutation does not change the kinetic 
mechanism of this enzyme, the kcat effect indicates that hydrolysis of the acetyl-lysine is 
decreases. This may be due to a direct effect on the reactivity of the metal-water 
nucleophile via structural changes propagated by the altered D29-S39 interaction, but it 
is more likely due to the altered site of the bound peptide that leads to incorrect positioning 
of the acetyl-lysine amide bond relative to the metal-water. However, the kcat value was 
only accurately determined for the Fe(II)-bound enzyme while the structure and 
simulations used Zn(II)-HDAC8; and activity data demonstrate that both S39E-HDAC8 
and WT HDAC8 (67) are activated to different extents depending on the identity of the 
catalytic metal ion. Additionally, we have shown that the substrate specificity of Zn(II)-
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S39E-HDAC8 toward three peptides was comparable to wild type activity (i.e. the 
mutation decreased activity by the same fold difference in each case). Further study using 
a larger library of peptides is needed to further evaluate substrate specificity effects.  
The dissociation rate constants for the catalytic metal surprisingly reveal a greater 
than 10-fold increase in koff for the catalytic metal ion which is 21 Å away from the 
mutation. The structural and simulation data do not readily explain the significant effect 
of the S39E mutation on metal dissociation. The effect on metal dissociation may be 
indicative of decreased protein stability, partially due to the loss of D29-S39 hydrogen 
bonding between the α1 and α2 helices. Monovalent cation stability of HDAC8 may also 
be affected, however it is not clear how modification at S39 would propagate an effect to 
the monovalent sites. Since no perturbation of R37 was observed, that residue and the 
internal HDAC8 channel are not likely to be involved in the metal dissociation difference.  
The significant increase in the dissociation rate constant means that there should 
also be either a significant increase in the KD values (decreased metal affinity), a 
significant increase in the kon values, or changes in both KD and kon. Preliminary KD 
measurements indicate a Zn(II) KD of approximately 2 pM, comparable to the wild-type 
enzyme. Assuming a single step metal binding, the apparent kon should be at the diffusion 
controlled limit (5 x 109 M-1s-1). However, the comparable values measured for koff for 
Zn(II) and Fe(II) despite the large differences in KD values argue for at least a two-step 
metal binding mechanism, possibly consisting of a rapid metal binding association step 
followed by a unimolecular rearrangement step. In the case of the wild type enzyme, the 
koff values and the affinities for Fe(II) (KD = 0.2 ± 0.1 µM) and Zn(II) (KD = 6 ± 1 pM) are 
such that the metal association was predicted to be a one-step mechanism for Zn(II) 
(konapp = 1 x 108 M-1s-1) and a two-step mechanism for Fe(II) (konapp = 3 x 103 M-1s-1) (182). 
A similar metal association scheme is predicted for S39E- (and phospho-) HDAC8.  
Taken together, these data provide insight into the residue interactions (i.e. 
S39/D29) that lead to perturbation of the kinetic properties by S39 phosphorylation. 
Further study is needed to parse how the metal-dependence, phosphorylation, and 
substrate specificity of HDAC8 are interconnected. The role and regulation of phospho-
HDAC8 in the cell is unclear, and elucidating some of these factors will help us to 
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understand the regulation of deacetylation and will inform drug discovery, as 
phosphorylation-dependent protein-protein interactions may present druggable targets 
for small molecule therapeutics. 
 
Accession Code  
The atomic coordinates and the crystallographic structure factors of S39E HDAC8 
in complex with Droxinostat have been deposited in the Protein Data Bank 
(www.rcsb.org) with accession code 5BWZ. 
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Chapter 5  
Conclusions and future directions 
 
Overview 
This dissertation presents an investigation into several facets of the inherently 
complex system of HDAC regulation. HDAC8 is part of a large family of enzymes that 
catalyze the same chemical reaction, hydrolysis of acetate from acetyl-lysine, but which 
serve in distinct and diverse roles throughout the cell. Because HDACs are involved in an 
elaborate web of critical cellular processes, it is not surprising that their regulatory modes 
are proving to be equally intricate. Narrowing the focus to 6% (1 out of 18) acetyl-lysine 
deacetylase enzymes still offers several avenues of HDAC regulation that require further 
elucidation, including metal switching, substrate recognition determinants, and 
phosphorylation, which I have discussed here. Despite over a decade of kinetic and cell-
based research, including recent studies aimed at revealing endogenous HDAC8 
substrates (80), parsing HDAC8-inhibitor interactions (44), and illuminating HDAC8’s role 
in disease (51), there is still much to be uncovered regarding how this metallo-hydrolase 
contributes to normal and disease-related cellular function. 
In the HDAC field, very little is known about the kinetics of deacetylation on 
biological substrates. We have performed the first detailed kinetic study of HDAC-
catalyzed deacetylation of a full-length protein acetylated at a single site, and provides 
new information regarding determinants of HDAC8 substrate recognition. For the first 
time, HDAC8 substrate specificity toward peptides is compared directly to the substrate 
specificity for protein substrates. This method would be useful for assaying other HDACs 
as well, to glean more information about how HDACs recognize physiological substrates.  
The metal-dependent substrate specificity findings I have presented here suggest 
a potential regulatory mechanism for HDAC8, as well as other metal-dependent 
deacetylases. In particular, HDACs 1, 2, and 3 (class I), which are the most similar to 
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HDAC8 (14), may be activated by Fe(II) and may also be regulated by metal switching in 
the cell. Metal-dependent HDACs are currently described in the literature as Zn(II)-
dependent, but our Fe(II)-HDAC8 data challenges this paradigm. Additionally, there is 
some data to suggest iron-related HDAC1 behavior in cells. In the rat hippocampus, iron 
deficiency was recently linked to an increase in HDAC1 binding to the bdnf-IV (brain-
derived neurotrophic factor) promotor, and iron deficiency was correlated to decreased 
H4 acetylation levels (226). The altered acetylation was linked to the interdependence of 
histone methylation and acetylation (226), but iron-dependent HDAC1 activity could be 
involved. Thus, investigating the relationship between HDAC8 metal-dependence and 
substrate specificity is important to enhance our understanding of HDAC8 regulation as 
well as to further our understanding of the metal-dependent regulation of other HDACs in 
the cell. 
Post-translational modifications on HDACs, phosphorylation in particular, are 
important for the cellular regulation of HDACs, modulating protein-protein interactions, 
localization, and activity (25, 35). HDAC1 and HDAC2 may be activated by 
phosphorylation (142, 144, 145, 150, 151), and they exhibit phosphorylation-dependent 
protein-protein interactions (142, 144, 145). HDAC4, 5, and 7 exhibit phosphorylation-
dependent localization and translocation (29-32, 146, 147). Studies of HDAC8 
phosphorylation demonstrate effects on localization, protein-protein interactions, and 
activity inhibition, but do not make clear conclusions regarding the physiological role of 
phosphorylation on HDAC8 nor the mechanism by which this modification regulates 
HDAC8 function (83, 108, 143). The investigation I have presented here, studying the 
effect of phosphorylation on HDAC8 kinetic properties and substrate interactions, is 
important for elucidating how HDAC8 is regulated by phosphorylation and how this 
regulatory mode may differ from that of phosphorylation on other HDACs. 
 
Substrate recognition: peptide and protein substrates 
Considerable data have been amassed regarding HDAC8 peptide substrate 
specificity, and recently full-length proteins have been investigated as well (191). The 
work presented here measures the kinetics for deacetylation of singly acetylated full-
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length protein substrates in multi-protein complexes and a protein-nucleic acid complex, 
which is a significant jump for the field in terms of biologically relevant substrate 
recognition. Remarkably, full-length proteins demonstrate significantly greater catalytic 
efficiency than corresponding peptides, and show that peptide substrate specificity does 
not fully represent HDAC8 specificity toward physiological (full-length) substrates. The 
determinants of HDAC8 substrate recognition include local substrate sequence and long-
range contacts, as demonstrated and discussed in the previous chapters and in (61). 
Interestingly, HDAC8 exhibits varied selectivity among acetylation sites in the same 
protein and protein complex, suggesting that increased activity toward proteins over 
substrates is not due mainly to non-specific interactions. As in vivo HDAC8 substrates 
continue to be identified, they are typically characterized using representative peptides in 
vitro (80). While this does provide a prediction of HDAC8 activity and substrate specificity, 
our work suggests that these measurements may not provide the best representation of 
HDAC8 selectivity in vivo. To accurately capture HDAC substrate specificity, the kinetics 
of full-length substrates must be measured. Additionally, Zn(II)-HDAC8 activity toward 
histone substrates was examined here; Fe(II)-HDAC8 substrate specificity may be 
different as well, and a next step is to compare the full-length substrate specificity of the 
two Me(II)-bound HDAC8 enzymes. 
To further elucidate the determinants of HDAC8 substrate selectivity as it pertains 
to full-length proteins, substrates with in vivo validation such as SMC3 (47, 51, 80) should 
be examined. The challenges of purifying and assaying physiologically relevant proteins 
in vitro (such as SMC3 in the cohesin complex) point toward a need for in vivo deacetylase 
assays such as the mass spectrometry-based substrate identification assay described in 
Olson et al (80). HDAC8 substrate recognition in the cell is likely to be more complicated 
than simply HDAC8-substrate contacts. Binding partners and chaperones may be 
involved in this process, as suggested by pull-down experiments (81). Using a more 
global approach can also tackle substrate specificity determinants such as metal 
switching and HDAC8 phosphorylation.  
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Metal switching 
HDAC8 is curiously poised within cellular metal homeostasis such that it could be 
activated by iron(II) or zinc(II) in vivo. Previous work has shown that the enzyme is 
activated by both metals and exhibits metal dependent inhibitor efficacy in vitro (67). 
Mammalian and E. coli lysates, and immunopurified HDAC8 overexpressed in HeLa cells 
have demonstrated oxygen-sensitive deacetylase activity, suggesting iron(II)-dependent 
catalysis (67, 183). The data presented here add to this evidence by demonstrating metal-
dependent substrate specificity toward a high throughput library of short peptides as well 
as a library of peptides based on putative physiological substrates. Here I have presented 
three key concepts regarding HDAC8, metal-dependence, and metal switching. The first 
is that HDAC8 is more active with Fe(II) than with Zn(II) toward all substrates tested in 
solution. The second is that the range of catalytic efficiencies observed for iron is an order 
of magnitude greater than the range of activity observed for the zinc-activated enzyme. 
The third observation is that the ratio of Fe/Zn catalytic efficiency varies in a range of 2 to 
15. This demonstrates that not only is Fe(II)-HDAC8 is more active than Zn(II)-HDAC8 
under the conditions tested, the substrate specificities of Fe(II)- and Zn(II)-HDAC8 are 
different. These results lead to several questions which will guide future study.  
 The first question is: do the peptide substrate specificities and the preference for 
Fe(II) remain true for protein substrates of HDAC8? In light of the histone data presented 
in chapter 2, which shows that full-length protein substrates contain additional contacts 
that enhance binding affinity relative to peptides, it is likely that the peptide substrate 
specificities for Fe(II)- and Zn(II)-HDAC8 do not directly correlate to that of proteins. The 
relative ratios of Fe/Zn substrate specificity may change for full-length protein substrates, 
but this does not undermine the fact that these distinct metal-dependent differences in 
specificity exist. We have shown that the sequence, length, and complex of protein 
substrates are indeed important for determining substrate specificity, but we then add to 
that the identity of the HDAC8 catalytic metal ion. The important next step is to examine 
iron- and zinc-dependent substrate specificity using full-length protein substrates, to 
investigate how the different metal-bound forms of HDAC8 behave and further elucidate 
the determinants of substrate specificity in the cell.  
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Another lingering question is which metal binds to HDAC8 in vivo. HDAC8’s metal 
affinities combined with cellular metal concentrations present conditions where HDAC8 
could modulate its activity and specificity by switching metal ion cofactors. We propose 
that the Fe(II)-enzyme would switch to a Zn(II)-enzyme under cellular stimuli that increase 
highly regulated exchangeable zinc concentrations. If endogenous cellular HDAC8 is 
indeed sensitive to the flux of iron and zinc metal ions in the cell, this adds a layer of 
complexity to an enzyme that is involved in both nuclear and cytosolic processes, such 
as regeneration of the cohesin complex during the cell cycle (47) and cellular contractility 
(66). We have been working to develop an assay to quantify the metals bound to cellular 
HDAC8. We use pull downs from mammalian tissue culture cells combined with 
inductively coupled plasma mass spectrometry (ICP-MS) to measure the metal content 
of HDAC8. This method is currently being optimized and will be a novel and versatile way 
of identifying metal(s) bound to cellular metalloenzymes. An additional method we have 
sought to optimize is that of top-down mass spectrometry to identify metals bound to 
HDAC8. The goal of this method would be its potential application to human tissues. Mass 
spectrometry has been used previously to identify metallated species of superoxide 
dismutase (227), however HDAC8 is more than 2-fold larger than SOD, which is 
prohibitory for current mass spectrometry methods. Using high resolution mass 
spectrometry such as Fourier transform ion cyclotron resonance (FT-ICR) MS, the top 
down identification of Me(II)-HDAC8 from cells and tissues may be attainable. 
Third, as I have discussed, is the question of the in vivo plausibility of metal 
switching. Metal concentrations and cellular metal homeostasis are dynamic and the 
metal switching hypothesis depends on this fluctuating cellular landscape, but this makes 
identifying HDAC8’s role in vivo challenging. An area that remains to be studied is to pull 
down HDAC8 from human cells following manipulation of cellular metal concentrations 
and redox state to assay metal content. To investigate metal switching, tissue culture cells 
expressing HDAC8 will be exposed to conditions such as supplemental Fe2+ and Zn2+, 
nitric oxide-generating compounds to induce oxidative stress, and iron chelators to alter 
metal homeostasis. The role of iron chaperone proteins is an additional avenue we can 
pursue in this manner, by expressing the iron chaperone human poly (rC) binding protein 
1 (PCBP1) (228, 229). HDAC8-bound metals will be analyzed using the pull down/ICP-
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MS method we are optimizing. Comparing these data to HDAC8-bound metals under 
resting cellular conditions will provide a clear picture of what metal(s) HDAC8 utilizes in 
vivo. 
 Finally, the direction in which this project will go is toward simultaneous 
identification of substrates, substrate specificity, and metal-dependent specificity in vivo. 
The recent proteomic work of our collaborators has demonstrated a method for 
identification of specific HDAC8 substrates in the cell (80), and further proteomic study 
can be applied to the question of metal-dependent specificity. This versatile method can 
be used to probe other HDACs for metal-dependent specificity and activity as well, using 
several HDAC-specific inhibitors. In addition to broad substrate identification, we can use 
proteomics to look at target proteins, such as those which had large Fe/Zn ratios here, 
under the various cellular conditions stated above. A proteomic study of the acetylation 
state of specific substrates following induction of metal switching in cells would elucidate 
this regulatory HDAC mechanism and is within the scope of current technologies. 
 
Phosphorylation and HDAC8 
HDAC8 is positioned within the network of post-translational modifications as both 
a modifying enzyme and a substrate protein. Elucidating how phosphorylation regulates 
HDAC8 is important for determining how HDAC8 fits into normal and diseased cellular 
function. I have demonstrated here, using a phosphorylation mimicking mutant, that 
phosphorylation of HDAC8 decreases HDAC8 activity toward non-histone peptide 
substrates in vitro and that phosphorylation changes the metal dissociation properties of 
HDAC8. We have shown with crystal structure and molecular dynamics data that 
phosphorylation at S39 perturbs substrate binding to HDAC8, decreases catalytic 
efficiency toward non-histone as well as histone substrates in vitro, and increases the 
catalytic metal dissociation rate constant. However, there is still more to uncover 
regarding how phosphorylation of HDAC8 affects substrate specificity, metal-binding, 
protein-protein interactions, and ultimately, the role of HDAC8 in disease.  
I am investigating the effect of phosphorylation on HDAC8 substrate specificity 
using a peptide library representing putative and predicted in vivo substrates (80, 191). 
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Structural data predicts that pS39 will affect substrate recognition. I expected to observe 
differences for phosphorylation-dependent specificity as were observed for metal-
dependent specificity, although this was not observed for the small peptide library 
examined. HDAC8 is promiscuous, ubiquitous, and localizes to both the nucleus and 
cytosol, so the fact that we are uncovering complicated modes of regulating substrate 
specificity is not surprising. In addition to in vitro substrate specificity, it is imperative to 
understand the effect of phosphorylation on HDAC8 substrate recognition in vivo.  
Alteration of acetylated histone levels in HeLa cells upon activation of PKA to 
phosphorylate HDAC8 were observed by Lee et al (143). In light of the ambiguity of 
histones as HDAC8 substrates, and the recent availability of high-quality proteomic 
techniques (80), I propose subsequent studies to analyze global cellular acetylation states 
of proteins (particularly the set of new putative in vivo HDAC8 substrates, such as SMC3 
and ARID1A) to monitor changes upon phosphorylation of HDAC8 using proteomics. 
Additionally, I expect that controlling for the phosphorylation state of HDAC8 during in 
vivo substrate identification experiments will effectively add to the growing list of 
physiological HDAC8 substrates. For example, we know that HDAC8 associates with 
actin (65, 83), but the actin structure-related proteins that were identified in a proteomic 
substrate screen did not demonstrate sufficient changes in acetylation levels to be 
considered above the experimental threshold (80) and no HDAC8-specific actin 
interactions were observed in recent binding partner pulldowns (81). One imaging study 
demonstrates that HDAC8 is increasingly associated with actin upon phosphorylation 
(83). Thus, using the pulldown and mass spectrometry methods to look for phospho-
HDAC8 substrates may explain why some predicted substrates have not been observed 
above background in global analyses.  
Phospho-HDAC8 specific binding partners also failed to appear in a proteomic 
interactome study (81). Phosphorylation is known to affect protein-protein interactions 
and HDAC complex formation (reviewed in 25, 35). Based on this precedent and the 
location of S39 on the surface of HDAC8, away from the active site, a role in protein-
protein interactions is expected. Consistent with this, Hsp70 has been demonstrated to 
co-immunoprecipitate only with phospho-HDAC8 (108), and, as discussed above, actin-
HDAC8 co-localization is increased upon phosphorylation of HDAC8 (83). Despite this 
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evidence, recent identification of the HDAC “interactome” did not report HDAC8-specific 
interactions with these proteins (81). The absence of these interactions in the pulldown 
may be due to the pulldown method or cell line-specific complexes. Lysis disrupts the 
cytoskeleton, and actin was observed as a non-specific interaction (81). The GFP fusion 
protein increases the effective size of HDAC8 and may alter HDAC8-protein binding. 
Another possibility is that the proteins are not observed due to the fact that these pS39-
specific interactions account for only a small population of HDAC8 and are thus 
overshadowed by the other binding partners. There is a need for proteomic studies that 
select for phospho-HDAC8 or use cells that contain significant levels of phospho-HDAC8. 
These experiments may confirm binding partners and/or substrates such as actin and 
Hsp70.  
The effect of phosphorylation on HDAC8 metal affinity is intriguing and had not 
been studied prior to the work presented here. There is a possibility that phosphorylation 
facilitates the metal switching proposed in the previous section. The hypothesis is that 
upon a cellular stimulus, HDAC8 is phosphorylated and the bound metal ion dissociates 
rapidly. Because both Fe(II) and Zn(II) dissociation rate constants are approximately the 
same, phosphorylation may be a way for Zn(II)-HDAC8 to switch to Fe(II)-HDAC8 despite 
the much stronger affinity for Zn(II). Further study of phospho-HDAC8 metal affinity is 
needed. 
Finally, phosphorylation of HDAC8, as it relates to disease states, is of great 
importance. For example, I have shown that phospho-HDAC8 activity toward an SMC3 
peptide is decreased significantly from that of WT-HDAC8. If this disparity is maintained 
in vivo, then phosphorylation of HDAC8 would affect the function and dissociation of 
cohesin in the cell cycle. A percentage of CdLS cases display mutations in HDAC8, and 
it is possible that abnormal regulation of the PKA pathway is responsible in some cases 
as well. We need to investigate the effect of HDAC8 phosphorylation in cellular processes 
such as the cohesin cycle and cytoskeleton dynamics in normal and disease states.  
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Concluding remarks 
The HDAC field is at an exciting stage, moving increasingly toward in vivo assays 
and an informed picture of HDACs in healthy cells as well as cells and patients of clinical 
pathologies. In a fascinatingly unfortunate paradox, the more we learn about HDACs, and 
HDAC8 in particular, the more complicated the study becomes. For example, consider 
the status of HDAC8 in a given cell. If the regulatory mechanisms of HDAC8 are limited 
to the determinants we currently know, then HDAC8 can be Fe(II)-bound, Zn(II)-bound, 
or apo; saturated with monovalent metal ions at either or both the activating or inhibitory 
sites (described in (89)); and unmodified or phosphorylated. From a purely mathematical 
standpoint, that yields 12 possible HDAC8 states, each potentially with a different level of 
catalytic activity and specificity, and capable of changing upon cellular stimulus. That 
does not include the potential (and likely) effects of phosphorylation-dependent binding 
partners or subcellular localization. Thus, future HDAC8 studies need to be very specific 
and elucidate HDAC8 behavior under various defined cellular conditions/states. I look 
forward to the developments the next decade will uncover, and I have a feeling the story 
of human HDAC8 is going to become more intricate before it becomes truly clear.
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